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Abstract 
Pneumococcal disease is preceded by nasopharyngeal colonization, which is also the source 
of transmission. Current pneumococcal conjugate vaccines protect against invasive disease 
and reduce carriage in children, but are less effective against mucosal disease and have 
limited serotype coverage. There is an urgent need for new vaccines and colonization has 
been suggested as an alternative endpoint in vaccine licensure. Experimental human 
pneumococcal carriage, although potentially risky, offers a way to examine colonization in 
the context of vaccination. Experimental carriage also allows the investigation of the 
impact of a pathogen on the immunological complexity and normal microbiota of humans, 
both of which cannot be done using animal models. We developed a safe and reproducible 
method of experimental human pneumococcal carriage, described bacteriological and 
immune factors associated with carriage, and examined the density and duration of 
experimental carriage.   
The data presented in this thesis show that experimental human pneumococcal carriage 
was safe and reproducible. There were important bacteriological differences between 
pneumococcal strains that affected carriage. Asymptomatic upper respiratory tract viral 
infection increased both the risk of pneumococcal colonization and the levels of mucosal 
Factor H, leading to increased colonization density. This model will be useful in further 
studies of pneumococcal pathogenicity and host protection against carriage and disease. 
The model may also be used to select vaccine candidates by protective efficacy in blocking 
experimental carriage.  
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Introduction 
 
1.1 Streptococcus pneumoniae  
Streptococcus pneumoniae (pneumococcus) is an encapsulated Gram positive diplococcus 
with more than 90 structurally and serologically distinct pneumococcal serotypes (Figure 
1.1). The serotype is determined by the polysaccharide capsule which is the outermost 
layer of the cell and is made of repeating units of simple sugars. Of the more than 90 
described polysaccharide capsular types, all but four are negatively charged due to acidic 
sugars, phosphate, or pyruvate, with the remainder being neutral [1].  
Approximately 20 serotypes are associated with 70% of invasive pneumococcal disease 
(IPD) worldwide and around 10 of these serotypes account for most paediatric infections 
[2]. However, disease only occurs following colonization of the nasopharynx. The 
asymptomatic carriage state, therefore, is the most important interaction between 
bacterium and host as it is both the reservoir for spreading the bacteria within the 
community and the source of disease.  
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Figure 1.1: Photomicrograph of S. pneumoniae grown from blood culture (taken from CDC 
Public Health Image Library, image ID# 2896). 
 
1.1.1 Epidemiology of pneumococcal carriage 
Pneumococcal carriage rates are dependent on an individual’s age and vary by geographic 
area. In children, carriage rates range from 27% in developed countries to 85% in 
developing countries [3]. In developing countries, children can become colonized within 
days of birth. In The Gambia >80% of children have acquired pneumococcus within 33 days 
of birth [4]. In contrast, less than 50% of children from developed nations are likely to 
become colonized within the first year of life [5]. After the first year, carriage incidence 
rises steadily until around 4 years of age and then decreases to around 10% in adults [6].  
 
Not only does carriage incidence decrease with age, but so also does the duration of 
carriage. Large variations in the duration of carriage have been observed in different 
cohorts. In a study done in neonates from Alabama in the 1970s, duration of carriage 
ranged from one to 17 months and, on average, the younger the infant was at the time of 
acquisition, the longer a strain was likely to be carried [7]. This trend was also observed in 
Sweden where the mean carriage duration of penicillin-resistant pneumococci in children 
under five was 43 days as compared to 25 days in those over the age of five [8].  
Pneumococcal serogroup is also important to carriage duration. Both the Alabama study 
and the Swedish study, as well as others [9,10], have found that duration of carriage is 
longer for common serotypes such as 6 and 23. In the Swedish study there was no longer a 
difference in duration for either age or serogroup beyond the age of five.  
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1.1.1.1 Risk factors associated with carriage 
Risk factors for pneumococcal carriage and disease are multi-factorial and can include 
crowding, the environment, and socio-economic factors [11-13].  
1.1.1.1.2 Crowding 
Crowding is very important in the spread of pneumococcus and particularly so in young 
children who are both in close contact with other young children and have a poorly 
developed immune system. In The Netherlands, children attending day care centres have 
been found to be at a 1.6- to 3.4-fold increased risk of nasopharyngeal colonization than 
those not attending [14].  
1.1.1.1.2 Environment 
Exposure to smoke increases the risk of pneumococcal carriage. Smoking, both passive and 
active, increases carriage in the smoking parent and the child exposed to the smoke [15-
17]. In Australian Aboriginal adults, carriage is also associated with the frequency of sitting 
at an outside fire [18].  
1.1.1.1.3 Socioeconomics 
Socioeconomic factors can influence transmission. Overcrowded housing combined with 
inferior hygiene facilitates transmission, allowing pneumococcus to sustain in the 
community [18,19]. Aerosol transmission has been demonstrated in a ferret model where 
ferrets carrying S. pneumoniae were able to transmit the bacteria to other ferrets in the 
same cage or up to 1m away [20]. This could be comparable to the conditions people face 
in overcrowded, unsanitary housing.  
In rural Alaskan communities, a lack of in-home running water has been associated with 
increased carriage in children under 10 [21]. It is suggested that conserving water for 
cooking and dish washing decreases handwashing, especially in children who need 
assistance. Hand contamination in Australian Indigenous children also correlates with 
carriage; Aboriginal children living in remote areas were 2 times more likely to be carrying 
pneumococcus and 8 times more likely to have hand contamination than children 
attending urban child-care centers [22].  
Sharing beverages could also increase carriage rates. In a study of Israeli army recruits, 
frequent sharing of a drinking bottle was shown to be a strong risk factor for pneumococcal 
carriage [23].  
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1.1.2 Epidemiology of pneumococcal disease  
Similar to the pattern observed with carriage, IPD rates also correlate with age (Figure 1.2) 
and disease rates and mortality vary geographically, with the majority of deaths occurring 
in Asia and Africa.   
 
 
Figure 1.2: Invasive pneumococcal disease (IPD) incidence rate per 100,000 in England 
and Wales. Reproduced with permission from Public Health England, July 2012. 
 
Prior to the introduction of the conjugate vaccine, the incidence of IPD in children less than 
2 years of age was 44.4/100,000 (range 11.3-104.4) per year in Europe and 167/100,000 in 
the United States [3,24]. In comparison, the incidence in the same population in 
Mozambique was 797/100,000. However, following the introduction of the conjugate 
vaccine IPD incidence dropped drastically in some countries. In the United States the 
overall incidence of IPD in children under 5 dropped to 23.6/100,000 by 2007 [25]. And in 
South Africa, the overall incidence of IPD in children under 2 declined from 54.8 cases per 
100,000 to 17.0 cases in 2012 [26]. 
In adults, pneumonia is also one of the leading causes of infectious death [27]. In American 
and European adults, S. pneumoniae causes approximately 30-50% of community-acquired 
bacterial pneumonia (CAP) [3]. In the United States alone, CAP accounts for more than 
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600,000 hospitalizations and 59,000 deaths [28]. As more and more of the general 
population reaches the age of 65, the burden of disease in this age group will only increase.  
1.1.3 The association of pneumococcal carriage with disease 
The spectrum of disease caused by S. pneumoniae is wide and varied. Following 
colonization, the pneumococcus can spread and cause non-invasive illness, such as otitis 
media or sinusitis, or it can spread to the lungs, blood or meninges, causing pneumonia, 
bacteraemia, or meningitis. Disease does not occur without an initial colonization step 
(Figure 1.3).  
 
Figure 1.3: Pathogenesis of pneumococcal disease. 
 
1.1.3.1 Association between carriage and disease in animal models 
The first proof of the association between carriage and disease comes from animal models. 
Using a chinchilla model, Linder et al. demonstrated that intranasal inoculation of 
pneumococci leads to otitis media [29]. Similar results were seen in rats and then in ferrets 
that were first infected with influenza virus and then challenged with pneumococci [30,31]. 
Colonization was also shown to lead to invasive disease in mice [32,33]. 
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1.1.3.2 Association between carriage and disease in humans 
The first study in humans to show a link between recent acquisition of pneumococci and 
pneumococcal disease was done by Gray et al. who followed 82 infants from birth up to 2 
years of age [7]. In these infants, serotypes causing disease were similar to commonly 
carried serotypes but disease was mainly associated with a newly acquired serotype; 74% 
of infections were caused by serotypes carried less than a month before disease. In a larger 
study of 329 children followed from 2 months to 2 years of age, pneumococcal acute otitis 
media was also associated with the newly acquired disease-causing serotype [34].  
1.1.3.3 Association of serotype with the incidence of carriage and disease  
The difference in disease virulence between serotypes is best illustrated by serotype 1 as it 
is a major cause of IPD and has been associated with outbreaks yet it is rarely found in 
healthy carriers [35]. This is in comparison to serotypes 6B and 23F which are frequently 
carried and have low invasive potential [36]. Sleeman et al. demonstrated that attack rate 
varies by capsule and an inverse relationship exists between attack rate and carriage 
duration [9].  
One explanation for the differences in attack rate between serotypes is the capsular 
structure. Serotypes that are more heavily encapsulated are more resistant to neutrophil-
mediated killing and persist for longer in the nasopharynx [37]. Pneumococcal surface 
charge has been shown to be one of the mechanisms behind this, with a more negative 
surface charge correlated with increased resistance to nonopsonic killing and increased 
carriage prevalence [38].  
1.2 Mechanisms of S. pneumoniae carriage  
For S. pneumoniae to access epithelial surfaces and establish carriage it must first reduce 
entrapment in the nasal cavity mucus secretions. This is achieved through expression of the 
polysaccharide capsule [39,40].  
1.2.1 Expression of capsule during colonization 
The polysaccharide capsule is differentially controlled based on the host niche. 
Pneumococcal isolates lacking capsule rarely cause disease and, in a mouse model, 
nonencapsulated derivatives are unable to colonize when compared to an encapsulated 
parent strain [41,42].  
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While sufficient capsule is needed to evade clearance mechanisms, excessive capsule has 
been shown to inhibit adherence to the epithelium [43,44]. To achieve a balance, the 
pneumococcus spontaneously switches its expression between two phenotypes - opaque 
and transparent - which are distinguished by differences in colony opacity [45].   
Differences in colony opacity are due to the production of capsular polysaccharide; in the 
opaque form there is a 1.2- to 5.6-fold greater amount of capsular polysaccharide as 
compared to the transparent form [46]. The thinner capsule of the transparent phenotype 
provides better access to the epithelium and, compared to the opaque variant, enhances 
adherence to buccal epithelial cells [47]. This difference in colonization capability was 
demonstrated in infant rats where rats that received the transparent phenotype had higher 
rates of carriage than those that received the opaque phenotype [45]. In the rats that 
received the opaque inoculum, all colonies were transparent by 7 days post-inoculation.  
Hammerschmidt et al. used electron microscopy to visualize pneumococci during contact 
with epithelial cells and found that pneumococci in contact with, and starting to enter, cells 
lacked capsule [48]. Once pneumococcus has accessed the epithelial surface it uses surface 
proteins to bind to host cell-surface carbohydrates and proteins and initiate colonization. 
1.2.2 Pneumococcal surface proteins involved in carriage  
Underneath the capsule lies the cell wall which acts as an anchor for cell-wall-associated 
surface proteins responsible for assisting with pneumococcal adherence to cell-surface 
carbohydrates [49-51]. Adherence to the nasal epithelium is initiated when the 
pneumococci bind to cell-surface carbohydrates such as N-acetylglucosamine-β-(1,4)-
galactose [52,53]. This initial binding is mediated by a number of bacterial structures, 
including phosphorylcholine (ChoP), choline-binding protein A (CbpA), and adhesins. 
1.2.2.1 Choline-binding proteins mediate adherence 
ChoP, a component of both cell-wall associated and lipotechoic acids, mediates adherence 
to the receptor for platelet-activating factor (rPAF) and is the anchor for a number of 
choline-binding proteins [49]. ChoP and these choline-binding proteins, including CbpA, are 
found in larger amounts on transparent pneumococci due to the increased amount of 
techoic acid in this phenotype [46,54]. This may account for the increased adherence and 
better colonization of the transparent phenotype.  
CbpA, also known as pneumococcal surface protein C (PspC), binds to the polymeric Ig 
receptor which mediates adherence and aids in the migration of pneumococci through the 
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mucosal barrier [55]. A PspC knockout mutant has shown reduced epithelial cell binding 
and decreased nasopharyngeal colonization when compared to wild-type [54]. In addition, 
PspC binds factor H (FH), a regulator of the alternative complement pathway, enabling the 
pneumococci to evade the host immune response and aiding adherence to epithelial cells 
[56-58].  
Another choline-binding protein, pneumococcal choline-binding protein A (PcpA), is also 
able to facilitate pneumococcal adherence to nasopharyngeal and lung epithelial cells [59].  
1.2.2.2 Lipoproteins mediate adherence to cell-surface carbohydrates 
Pneumococcal lipoproteins are essential for both substrate transport and pneumococcal 
adherence. Pneumococcal surface adhesin A (PsaA) binds to E-cadherin, a transmembrane 
glycoprotein, and antibodies to PsaA have been shown to reduce pneumococcal adherence 
to nasopharyngeal epithelial cells [50,60]. Another group of lipoproteins, the Ami-AliA/AliB 
oligopeptide permease, was necessary for nasopharyngeal colonization in a mouse model 
[61]. Mutations in the ami locus have been suggested to decrease pneumococcal 
adherence to pulmonary epithelial cells as a result of reduced binding to a glycoconjugate 
receptor on lung epithelial or vascular endothelial cells [62].  
1.2.2.3 Protease production increases attachment  
Pneumococcal IgA1 protease has been shown to increase bacterial attachment to epithelial 
cells in vivo by cleaving human IgA1, causing a change in surface charge and resulting in 
ChoP interacting with rPAF [63]. 
1.2.2.4 Adhesins assist in binding to the extracellular matrix 
Two adhesins important for the binding of pneumococci to the extracellular matrix are 
pneumococcal adhesion and virulence factor (PavA) and enolase. PavA, found on the outer 
cell surface, binds fibronectin and has been shown to be necessary for long-term carriage 
of S. pneumoniae D39 in a murine carriage model [64,65]. Enolase, an anchorless surface 
protein, binds plasminogen [66]. A third component of the extracellular matrix, vitronectin, 
was recently shown to interact with PspC, allowing pneumococci to use vitronectin as a 
molecular bridge and facilitating adherence [67,68]. 
1.2.2.5 Neuraminidase facilitates persistence in the nasopharynx 
Colonization can also be enhanced by the pneumococcal enzyme neuraminidase (NanA). 
NanA cleaves N-acetylneuraminic acid from mucin thereby decreasing the viscosity of the 
mucus and increasing colonization, and it can expose host epithelial cell surface receptors 
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for pneumococcus [69,70]. The synergism that exists between pneumococci and 
respiratory viruses, such as influenza, in causing illness may be related to the action of 
neuraminidase and the increased adherence of pneumococci [71,72]. 
1.3 Immunity to S. pneumoniae 
Innate immunity is the body’s first line of defence against a foreign pathogen. It is 
immediate, non-specific and evolutionarily conserved [73]. However, if the pathogen is able 
to evade or overcome the innate defences, the adaptive immune system is activated. 
Natural immunity against the pneumococcus is a complex interaction between the innate 
and adaptive immune systems.  
1.3.1 Innate immunity to the pneumococcus 
When the body first encounters a pathogen the aim is simply to prevent its entry. The 
epithelial surfaces of the body provide a physical barrier to stop the pathogen and the 
mucosal lining of the epithelium traps pathogens in mucus. However, the mucosal 
epithelium also secretes a number of chemicals that can kill pathogens or inhibit their 
growth.  
1.3.1.1 Antimicrobial peptides against pneumococcus 
Three peptides are the most abundant antimicrobial factors in airway secretions [74]. 
Lysozyme is abundant in both upper and lower airway secretions and has been shown in 
vitro to inhibit the growth of clinical isolates of S. pneumoniae [75]. However, the 
pneumococcus has two enzymes, PgdA, a N-acetylglucosamine deacetylase, and Adr, an O-
acetyl transferase, that counter this mechanism by modifying the peptidoglycan structure 
[76]. This modification has a significant fitness cost for the pneumococcus but this is 
outweighed by the resulting elimination of the lysozyme target. Lactoferrin is also present 
in nasal secretions and acts by depleting iron and restricting bacterial growth however 
pneumococcal surface protein A (PspA) can bind it, preventing it from killing  pneumococci 
[77,78]. Secretory leukocyte protease inhibitor (SLPI) is secreted from submucosal glands 
and is thought to destabilize bacterial membranes as a result of its cationic charge [79].  
Two other important antimicrobial peptide families in mucosal host defence are the 
defensins and the cathelicidins. There are two main defensin subfamilies, α- and β- 
defensins, and both work by lysing the bacteria [80]. Both the α-defensins (human 
neutrophil proteins 1 to 3(HNP)) and the β- defensins (human β- defensin-2 and 3 (hBD)) 
have been shown to have an antimicrobial effect on S. pneumoniae in vitro [81,82]. Human 
 Introduction 
10 
 
cathelicidin LL-37 also acts by disrupting the bacterial membrane [83]. Pneumococci have 
been shown to induce hBDs in human pulmonary epithelial cells [84] and the 
pneumococcal toxin pneumolysin (PLY) has been shown to induce the release of LL-37 from 
human lung mast cells, which reduced pneumococcal viability [85].  
In the lung, the pulmonary surfactant proteins A (SP-A) and D (SP-D), members of the 
collectin family, are found in the fluid that bathes the epithelial surfaces of the lung. SP-A 
and SP-D can bind and agglutinate a number of pathogens as well as act as opsonins [86]. In 
mice that were SP-D deficient, pneumococcal colonization and infection in the upper and 
lower respiratory tract increased [87]. The collectins, including SP-A and SP-D, are also 
known as pattern recognition receptors (PRRs) and they, along with numerous other PRRs, 
play a crucial role in host defence.   
1.3.1.2 The role of pattern recognition receptors in defence against 
pneumococcus 
When pathogens manage to breach the epithelium, the immune system must be able to 
distinguish self from non-self. To do this, it uses a variety of PRRs which can be expressed 
on the host cell surface, intracellularly, or secreted and which recognize highly conserved 
microbial structures known as pathogen-associated molecular patterns (PAMPs) [88]. PRRs 
include soluble receptors, like a number of components of the complement system, and 
membrane-bound receptors, including members of the Toll-like receptor (TLR) family, as 
well as the NOD-like receptors and cytosolic DNA sensors.  
1.3.1.3 Complement system action against pneumococcus 
The complement system consists of more than 30 circulating and membrane-bound 
proteins that, upon activation, initiate an enzyme cascade that eventually results in 
pathogen death. There are three overlapping pathways through which complement is 
activated: the classical pathway, the alternative pathway, and the lectin pathway. All three 
pathways converge on the activation of C3 to lead to the same effector molecules [89]. 
Complement activation results in cleavage of C3 to C3b which is deposited on the surface 
of the pathogen and processed to iC3b, both of which are important opsonins [90]. 
Pathogens are then eliminated either through opsonophagocytosis, membrane attack 
complex-mediated lysis, and/or the induction of inflammation.  
1.3.1.3.1 Complement pathways involved in protection against pneumococcus 
The classical pathway is activated by direct binding of C1q to the pathogen surface or to 
antibody-antigen complexes. Brown et al. demonstrated that the classical pathway is the 
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most important complement pathway for innate immunity to pneumococcus in mice and it 
is partially activated by the binding of natural IgM to bacteria [91]. However, there are 
other mechanisms that can activate the classical pathway during pneumococcal infection. 
These include the acute phase PRRs C-reactive protein (CRP) and serum amyloid protein 
(SAP), which bind ChoP [92-94], and SIGN-R1, a cell surface lectin, which binds capsule [95].  
The alternative pathway is spontaneously activated at low levels but will only amplify when 
attached to a foreign surface. During pneumococcal infection, the alternative pathway is 
responsible for amplification of complement activation, leading to increased C3 deposition 
[91]. The pneumococcal cell wall can activate the alternative pathway, inducing the 
inflammatory reaction and cytokine production [96-98]. 
The lectin pathway is initiated by binding of the mannose-binding lectin (MBL), a soluble 
receptor, to PAMPs, mainly carbohydrates, on the microbial surface. There are two other 
recognition molecules, ficolin (1, 2 and 3) and collectin kidney 1 that, along with MBL, can 
form a complex with three MBL-associated serine proteases (MASPs) [99,100]. Until 
recently, the role of the lectin pathway in defence against pneumococcus appeared 
negligible. However, it has now been shown in mice that MASP-2, ficolin, and collectin are 
key PRRs that can activate complement via the lectin pathway and protect against 
pneumococcal disease [101,102].  
1.3.1.3.2 The role of complement in the progression from carriage to disease 
Humans with complement deficiencies are at an increased risk of IPD [103] but until 
recently it was not known if complement could prevent colonization from leading to sepsis. 
Using a murine model, Bogaert et al. showed that complement-depletion did not impact 
colonization density but mice were more likely to progress from carriage to disease than 
control or neutrophil-depleted mice [104]. This demonstrates a critical role for complement 
in stopping colonization from progressing to disease. 
1.3.1.3.3 Pneumococcal mechanisms used to resist complement  
Given the importance of complement in innate immunity, it is not surprising that the 
pneumococcus has developed a number of mechanisms to resist it (Figure 1.4).  
1.3.1.3.3.1 Polysaccharide capsule  
The pneumococcal capsule has been shown to have numerous effects on complement 
activity against the pneumococcus. Hyams et al. [105] demonstrated that capsule inhibits 
the binding of IgG, IgM, and CRP to S. pneumoniae which, in turn, inhibits classical pathway 
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activity. C3b/iC3b opsonization by the alternative pathway and the conversion of C3b to 
iC3b on the bacterial surface were also impaired, as was phagocytosis mediated by 
complement, IgG, and nonopsonic phagocytic receptors [105]. 
1.3.1.3.3.2 Serotype 
Different serotypes vary in their susceptibility to complement deposition and there exists 
an association between serotype prevalence in carriage and resistance to nonopsonic 
neutrophil-mediated killing [37,106,107]. Opsonophagocytosis can also vary between 
serotypes and has been linked with serotype-specific mortality [43,106,108]. However, 
serotype alone does not determine the effect of complement-mediated immunity, rather it 
is a combination of serotype and genetic background [106,109].  
1.3.1.3.3.3 Proteins 
A number of pneumococcal proteins also inhibit complement-mediated immunity. It has 
long been known that PspA inhibits complement activation but only recently was it 
discovered that it does so by blocking CRP binding to ChoP, thereby decreasing 
complement activation [110-112].  
PspC mediates immune evasion by binding human FH and C3 [113,114]. The interaction 
between FH and PspC protects the pneumococcus from complement-mediated clearance 
[115]. However, FH binding varies by serotype and is negatively correlated with C3b/iC3b 
deposition, with serotype invasiveness associated with high levels of FH binding and 
resistance to complement [116].  
PLY, a key pneumococcal virulence factor that activates the classical pathway, directs 
complement activation away from the bacterial surface and prevents C3 deposition on the 
cell [117,118]. Recently, Ali et al. found that PLY can also trigger complement activation via 
the lectin pathway [119].  
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Figure 1.4: Pneumococcal mechanisms used to resist complement. 
 
1.3.1.3.3.4 Biofilm 
Biofilms are increasingly being studied as they are known to be important in resistance to 
host-defence and antimicrobials. For S. pneumoniae, in vitro growth as a biofilm has been 
shown to impair C3b deposition and target both the classical and alternative pathways 
through impaired activation of CRP and C1q and increased recruitment of FH [120].  
1.3.1.4 Toll-like receptors involved in protection against pneumococcus 
As PRRs, the role of TLRs is to detect pathogens and initiate the immune response by 
leading to the production of mediators such as cytokines and chemokines. There are 10 
known TLRs in humans, of which three have been described in protection against the 
pneumococcus.  
1.3.1.4.1 TLR2 
TLR2 is located on the cell surface and was thought to recognize pneumococcal 
peptidoglycan and lipotechoic acid until recently when it was suggested that both 
peptidoglycan and lipotechoic acid may stimulate inflammatory responses by TLR2-
independent mechanisms [121-123]. Instead, lipoproteins may be the major pneumococcal 
TLR2 ligand [124]. Regardless of the ligand, TLR2 is important in protection against both 
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carriage and disease [125,126]. In TLR2-deficient mice, clearance of colonization is impaired 
and susceptibility to pneumococcal meningitis is increased, with intensified disease severity 
and bacterial numbers [127-129]. However, the importance of TLR2 does not extend to 
protection against pneumococcal pneumonia [130].  
1.3.1.4.2 TLR4 
TLR4 is also found on the cell surface and has been shown to interact with PLY [131]. 
However, its role in carriage clearance is unclear; Malley et al. [132] found TLR4-deficient 
mice had increased colonization density and risk of disease however, van Rossum et al. 
[127] saw no difference between wild-type and TLR4-deficient mice. In vivo disease studies 
have found TLR4-deficient mice have less upper respiratory tract (URT) cell apoptosis and 
higher bacterial loads in their lungs [131,133]. Recently, McNeela et al. [134] found that 
PLY directly activates innate immune cells, independently of TLR4, and there is no 
interaction of TLR4 with PLY.   
1.3.1.4.3 TLR9 
TLR9 is expressed within endosomal compartments and plays a protective role in the lung; 
TLR9-deficient mice are more susceptible to pneumococcal pneumonia and have an 
increased bacterial load in the lung [135]. 
TLRs are a crucial link between innate and adaptive immunity. TLR recognition of a PAMP 
induces production of inflammatory molecules through the activation of an intracellular 
pathway including nuclear factor-κB, mitogen-activated protein kinases and interferon-
regulatory factors which initiate the activation of the adaptive immune response [136].  
1.3.2 Adaptive immunity to the pneumococcus 
Although slow to start, the adaptive immune system is highly specific and has memory, and 
is comprised of a humoral response and a cell-mediated response.   
1.3.2.1 Humoral immunity against pneumococcus 
Humoral immunity consists of the production of antibodies by B cells. In children, 
antibodies to pneumococcal capsular polysaccharide arise through natural exposure and 
following vaccination with a conjugate vaccine but are serotype-specific [137,138]. In 
adults, anticapsular IgG can be detected in the serum following carriage [139]. However, in 
animal models protection against colonization and clearance of carriage were both 
independent of antibody [140,141].  
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In the mucosa, the dominant antibody is IgA and it is thought to mediate protection by 
blocking adherence to the host tissues. There are two forms of IgA, IgA1 and IgA2, with 
IgA1 making up approximately 90% of the total IgA in the URT [142]. A number of common 
respiratory pathogens have an IgA1 protease which, in the case of S. pneumoniae, cleaves 
human IgA1, increasing adherence to respiratory epithelial cells in vitro and preventing 
phagocytic killing [63,143] .  
1.3.2.1.1 Agglutination of pneumococcus 
Another important role for antibodies in the mucosa is agglutination of bacteria into a 
cluster that can then be cleared by the host. This was recently demonstrated in mice 
where, following passive immunization with IgG and intra-nasal challenge with 
pneumococcus, colonization was prevented, as was transmission between littermates 
[144]. When mice were immunized with human IgA1, colonization was only prevented 
following challenge with an IgA1-protease-deficient mutant; challenge with an IgA1-
protease-producing strain did not result in agglutination, again highlighting the role of 
pneumococcal virulence factors in evasion of the host immune response. 
1.3.2.2 Cellular immunity against pneumococcus 
If a pathogen crosses the epithelial barrier, it will often be immediately recognized by a 
phagocyte. Macrophages are a phagocytic cell found throughout the body, including the 
lung, and are derived from monocytes. Upon activation they recruit another phagocyte, the 
neutrophil, which is a short-lived cell found in the blood. Macrophages and neutrophils 
display a number of cell-surface receptors which recognize the surface molecules of 
pathogens, leading to phagocytosis.  
1.3.2.2.1 Macrophages 
In mice, recruitment of monocytes/macrophages to the upper airway cleared 
pneumococcal colonization by phagocytosis [145]. The retention of macrophages in the 
nasopharynx was the result of an innate cytokine, macrophage migration inhibitory factor 
(MIF). In MIF-deficient mice, carriage was prolonged and was correlated with reduced 
numbers of macrophages [146]. MIF activity has also been shown to inhibit alveolar 
macrophage migration in a rabbit model of pneumococcal pneumonia [147]. 
Alveolar macrophages are very important in protection against pneumonia. In a mouse 
pneumonia model, depletion of alveolar macrophages resulted in increased disease 
susceptibility and higher mortality [148]. But the ability of macrophages to clear bacteria is 
finite and when they fail to control infection the recruitment of neutrophils becomes 
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critical for bacterial clearance [148]. At this point the role of the macrophage changes and 
it begins to regulate the immune response through the production of cytokines.  
1.3.2.2.2 Neutrophils 
Neutrophils are crucial for phagocytic clearance of pneumococci. During pneumococcal 
colonization in mice, there is an influx of neutrophils into the nasal space [127]. When 
these neutrophils interact with pneumococcal PLY, the resulting neutrophil lysis enhances 
the delivery of pneumococcal antigen to the nasal-associated lymphoid tissue [149]. This 
neutrophil lysis combined with pneumococcal degradation by neutrophils alone results in 
rapid clearance of the pneumococcus from the nasopharynx. 
The importance of neutrophils in carriage clearance also extends to disease. In a mouse 
model of colonization, neutrophil depletion resulted in a 50% death rate with a normally 
asymptomatic carriage strain [149]. In models of disease, depletion of neutrophils in mice 
increased susceptibility to pneumococcal infection [150,151].  
1.3.2.2.3 CD4+ T cells 
Trzciński et al. [141] and McCool et al. [140] have found that protection against 
colonization and clearance of carriage using murine models, respectively, were 
independent of antibody. Other studies have shown that in mice lacking immunoglobulin, 
intranasal immunization with a killed, nonencapsulated whole cell vaccine, a cell wall 
polysaccharide, or a selection of pneumococcal proteins, protected against colonization 
[152-154]. Further examination demonstrated that both protection from, and clearance of, 
carriage required CD4+ T cells in these models [141,153,155]. The CD4+ T cell subset 
responsible for protection against colonization in mice was shown to be Th17 [156].  
1.3.2.2.4 Th17 cells 
Interleukin-17A (IL-17A), a cytokine that induces neutrophil recruitment and activation, is 
secreted by the Th17 subset of CD4+ T helper cells. In mice, expression of IL-17A was 
correlated with increased clearance of a secondary carriage episode and levels in the blood 
of mice immunized with killed pneumococcal whole cell antigen prior to challenge were 
inversely correlated with carriage density [156]. Protection against colonization was 
neutrophil-dependent and recombinant human IL-17A enhanced antibody-dependent and -
independent pneumococcal killing in vitro [156]. 
Zhang et al. further confirmed the importance of Th17 cells in clearance of colonization 
[157]. The recruitment of monocytes/macrophages to the upper airway during colonization 
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was dependent on the production of IL-17A-expressing CD4+ T cells via TLR2 signalling. In 
mice that had previously been colonized, clearance was enhanced by an influx of 
neutrophils. 
1.3.3 The effect of carriage on defence against future carriage and 
disease 
Although colonization can generate an immune response that, in the majority of the 
population, prevents disease and leads to clearance of carriage, it is still not clear how this 
impacts on subsequent carriage and disease. In a mouse model of carriage, mice that had 
cleared carriage and were re-challenged with the same strain had similar colonization 
density to mice that were not initially colonized, even though they had generated a whole 
immunoglobulin response to the strain [140]. In contrast, a separate study found that when 
mice were challenged following carriage, mucosal protection and protection from sepsis 
required both CD4+ T cells and antibody [158].  
Immunological protection against subsequent disease following carriage has also been 
demonstrated in mice; carriage of a PLY negative mutant strain significantly increased 
survival following invasive pneumococcal challenge and also resulted in cross-serotype 
protection [159]. In a pneumonia challenge model, prior pneumococcal colonization 
prevented bacteraemia by antibody-mediated phagocytosis which led to protection from 
lethal pneumonia [160]. 
In humans, carriage is known to be an immunizing event [161]. In the absence of infection, 
carriage has been shown to induce immunoglobulins against pneumococcal capsular 
polysaccharide and proteins in the serum [137,162]. In Gambian infants that were followed 
longitudinally, the rate of reacquisition and the duration of carriage, even with the same 
serotype, did not differ [4]. However, in this natural setting where sampling is intermittent, 
it is possible that carriage episodes can be misclassified or missed completely.  
1.4 Vaccination against S. pneumoniae  
Current pneumococcal vaccines have had great success in decreasing IPD but do not confer 
optimal protection against non-bacteraemic pneumonia and otitis media which account for 
the largest burden of disease (Figure 1.5) [163,164]. Current pneumococcal vaccines target 
the polysaccharide capsule because it is the target of the mature human immune response 
and it influences pathogen transmission [165], the epidemiology of infection [166] and 
disease virulence [167].  
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Figure 1.5: Burden of pneumococcal disease demonstrating the inverse relationship 
between frequency and severity.  
 
1.4.1 Early attempts at pneumococcal vaccination 
The first vaccine against the pneumococcus consisted of heat killed, locally isolated, 
uncharacterized pneumococcal strains that had been suspended in saline and were given 
subcutaneously. The first clinical trials were conducted in 1911 in South Africa among mine 
workers where pneumococcal pneumonia had a case fatality rate of 20 to 40% [168]. These 
first whole cell vaccine trials had vaccine efficacies ranging from 25% to 82% and were 
generally considered to have been positive [169,170]. This was an important period in 
pneumococcal vaccine development as vaccine preparation, administration and dosage 
methods were developed, as were methods for detecting and measuring protective 
immunity. 
1.4.2 Pneumococcal polysaccharide vaccines 
Polysaccharide vaccines were first tested in 1945 on students at an army-air force school 
[171]. The results were promising and the vaccine efficacy, at 84%, clearly prevented 
pneumococcal pneumonia due to the vaccine serotypes. However, penicillin became 
readily available at the same time as the vaccine was developed and the vaccine was 
quickly forgotten and withdrawn. 
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When the widespread availability and overuse of penicillin led to a dramatic increase in 
pneumococcal antibiotic resistance, interest in developing new pneumococcal vaccines was 
renewed. Based on the study in 1945 that found links between immunization with 
pneumococcal polysaccharide capsule and protection from pneumonia [171], work was 
done to develop a new vaccine against the pneumococcus. 
 In 1977 a 14-valent polysaccharide vaccine was licensed for use in adults in the United 
States. This was expanded to a 23-valent pneumococcal polysaccharide vaccine (PPV23) in 
1983 which is currently licensed for use in adults and in children over the age of 2 with 
underlying medical conditions. A 0.5 ml dose of the vaccine contains 25 μg of purified 
capsular polysaccharide from each of 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) and includes the most common drug-
resistant serotypes [172]. 
1.4.2.1 Pneumococcal polysaccharide vaccine efficacy 
Despite numerous trials over many years, the effectiveness of PPV23 in protection against 
pneumonia and IPD is controversial and inconclusive. It is difficult to measure the efficacy 
and effectiveness because of the low frequency of invasive infection, the inaccuracy of the 
diagnostic criteria for pneumococcal pneumonia and the variation with age and underlying 
illness.  
A recent meta-analysis that looked at the efficacy of PPV23 in adults found the relative risk 
for presumptive pneumococcal pneumonia to be 0.64 [95% Confidence Interval 0.43-0.96] 
but with a significant heterogeneity between trials (P<0.001) due to variable trial quality 
[173]. In trials of higher quality there was little evidence of vaccine protection among the 
elderly and at-risk groups (1.04 [0.78-1.38]). These findings suggest that pneumococcal 
vaccination is not effective in preventing pneumonia, even among the groups for whom the 
vaccine is recommended. 
The limited success of the polysaccharide vaccine in its target group has been 
overshadowed by its failure to induce immune memory in children. Pneumococcal 
polysaccharides are unable to bind with class II major histocompatibility complex and are 
therefore T cell independent antigens. A long-term protective immune response in infants 
and children requires T cell help and the generation of immunological memory which is 
achieved by conjugating a polysaccharide to a protein.  
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1.4.5 Pneumococcal conjugate vaccines  
Conjugation of purified pneumococcal polysaccharide to a nontoxic carrier protein was 
based on the success of the Haemophilus influenzae type B vaccine where use of a 
conjugate vaccine lead to a rapid reduction in disease [174]. The first pneumococcal 
conjugate vaccine on the market was the 7-valent pneumococcal conjugate vaccine (PCV7) 
(Prevnar) which offered protection against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F [175]. 
 In 2009, conjugate vaccines containing 10 (Synflorix, PCV10) or 13 (Prevnar, PCV13) 
capsular polysaccharides were introduced and have led to the gradual replacement of 
PCV7. Serotypes 1, 5, and 7F have been added to both PCV10 and PCV13; PCV13 also 
includes 3, 6A, and 19A. 
PCV10 and PCV13 cover >70% of serotypes that cause IPD in children from all geographic 
regions [3]. Both have been licensed to protect against IPD, pneumonia and acute otitis 
media in infants and children from 6 weeks of age to 5 years. PCV13 has also been licensed 
for the prevention of pneumococcal disease in adults over 50 years of age [176].  
1.4.5.1 Pneumococcal conjugate vaccine efficacy 
Pneumococcal conjugate vaccines are protective against invasive pneumococcal diseases 
caused by vaccine serotypes [25,177]. Mucosal and systemic anti-capsular antibody 
responses are induced by the vaccine [178] leading to protection from invasive disease, 
however, the vaccine is less effective against mucosal diseases such as otitis media and 
pneumonia.  
1.4.5.1.1 Immune correlates of protection 
Immune correlates of protection for the conjugate vaccine are based on detecting anti-
capsular antibody to polysaccharide using enzyme-linked immunosorbent assay (ELISA) and 
opsonophagocytosis, since it is essential in host defence against the pneumococcus. The 
World Health Organization (WHO) has proposed a level of 0.35 µg of IgG anticapsular 
antibody per ml for protection against IPD [179,180]. The opsonophagocytic killing assay 
(OPA) was developed to evaluate pneumococcal vaccines as immunogenicity and 
protection were not closely associated. Antibodies opsonize pneumococci (and protect the 
host) and an OPA can be used to measure the ability of the serum to opsonize the bacteria. 
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1.4.5.1.2 Protection against carriage 
The impact of conjugate vaccines on carriage has been shown in a number of populations. 
In American Indian infants, a colonization study nested within a phase 3 efficacy trial 
showed a decrease in vaccine-type carriage after the primary vaccination at 7 and 12 
months [181]. In another nested carriage study, Gambian children were also protected 
against vaccine-type carriage following vaccination [182]. 
In both of these populations there was also a decrease in carriage density following PCV7 
vaccination, with the decrease in rural Gambia seen across different age groups [181,183].  
1.4.5.1.3 Protection against invasive disease 
The real benefit of conjugate vaccines has been in reduction of invasive disease. In the first 
PCV7 trial in Northern California, invasive disease caused by vaccine serotypes was reduced 
by 87.3% in children under 1, by 58.1% in children under 2 and by 62.4% in children less 
than 5 years of age [177]. Similar decreases have been seen all over the world including 
South Africa where the vaccine efficacy in infants was 83% [184]. 
1.4.5.1.4 Protection against mucosal disease 
Conjugate vaccines are less effective against mucosal disease. This may be a result of 
difficulty in diagnosing pneumonia or it could be due to differences between mucosal and 
systemic defence.  
In a study of Finnish infants, those vaccinated with PCV7 had a 6% reduction in the number 
of acute otitis media episodes as compared to those not vaccinated [185]. The actual 
incidence of acute otitis media due to vaccine serotypes was reduced by 57%. This is similar 
to the 64% reduction in vaccine serotype otitis media in American Indian infants following 
vaccination with PCV7 [186]. 
All-cause pneumonia admissions were reduced in children under the age of 2 in both the 
United States and parts of Europe following vaccination with PCV7 [187,188]. In Gambian 
children aged 6-51 weeks, the efficacy of PCV9 was 37% against radiologically confirmed 
pneumonia and 16% against mortality [189]. In Filipino children under 2, PCV11 reduced 
community-acquired radiologically confirmed pneumonia by 23% [190]. 
1.4.5.1.5 Indirect effects of pneumococcal conjugate vaccination 
Aside from the direct immunological protection as a result of vaccination, PCV success is 
also a result of herd protection. The reduction in carriage of vaccine serotypes in children 
resulted in a reduction in the number of circulating vaccine serotypes (and hence 
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population exposure), so much so that, one year after the introduction of the original PCV7 
vaccine, the reduction in disease in the United States was greater than the percentage of 
children who had been vaccinated [177]. This disease reduction was seen in young infants 
that were too young to receive the vaccine [191], in children that were not vaccinated, and 
in older children and adults too old to have received the vaccine [192].  
1.4.5.2 Drawbacks of pneumococcal conjugate vaccines 
Despite the significant impact of pneumococcal conjugate vaccines on invasive disease 
there are a number of clinical drawbacks.  
The first of these is the lack of universal serotype coverage. Protection from current 
vaccines is limited to the serotypes they contain and the prevalence of these serotypes 
varies geographically.  
Secondly, as vaccination reduces carriage of vaccine-type pneumococci, the void is being 
filled by non-vaccine-type pneumococci, a phenomenon known as serotype replacement. 
As with serotype prevalence, the rate of replacement also varies geographically. In most 
American children and older adults, the increase in carriage of non-vaccine-types has had 
little effect on increasing IPD by these serotypes [193]. However, an increase in IPD caused 
by non-vaccine serotypes has been seen in Alaskan children where the IPD rate caused by 
non-vaccine-types has increased 140% as compared to the pre-vaccine period [194].  
In adults with HIV, the switch to IPD caused by non-vaccine-types has been quite dramatic, 
a 44% increase between 1999 and 2003, and demonstrates the ability of non-vaccine-types 
to cause disease in immunosuppressed hosts [195]. There has also been a change in the 
clinical presentation of disease following conjugate vaccination as complicated 
pneumonias, such as parapneumonic empyema, seem to be on the rise [196,197]. 
Continuing surveillance is the key to determining if PCV vaccines are having the desired 
effect on disease reduction over the long term. 
One other major drawback is cost. Conjugate vaccines are expensive and difficult to 
produce which limits their implementation in most developing countries [198]. To combat 
this, the GAVI Vaccine Alliance has helped introduce the pneumococcal conjugate vaccine 
into the national immunization programs of more than 30 countries and has launched an 
Advance Market Commitment to speed up the development and availability of 
pneumococcal vaccines to the developing world [199]. As part of this commitment, 
conjugate vaccines will be supplied to developing countries for 10 years at $3.50 per dose. 
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1.4.6 Novel pneumococcal vaccine development 
Due to the high costs and difficult manufacturing complexity of PCVs, an affordable vaccine 
that confers broad protection against pneumococcal disease is a major priority. 
1.4.6.1 Live attenuated vaccines 
A live immunization may offer both mucosal and systemic immunity. A phase I dose 
escalation trial of three recombinant attenuated Salmonella enterica serovar Typhi vaccine 
vectors expressing PspA was recently completed in the USA [200]. Unfortunately while all 
three vaccines were safe and well-tolerated, the immune response was limited which the 
authors suggest may be due to high pre-existing antibody titers to S. Typhi.  
Another live attenuated pneumococcal vaccine was recently shown to protect against otitis 
media, pneumonia and invasive disease in a serotype-independent manner [201]. Crucially, 
this vaccine, which was generated by deleting genes necessary for microbial adaptation to 
the host environment, was protective against mucosal disease in mice and chinchillas.  
A whole cell vaccine, similar to what was first used in 1911, would be both affordable to 
produce and would offer serotype-independent protection. In mice, subcutaneous injection 
of an inactivated whole cell vaccine was protective against nasopharyngeal colonization 
and aspiration-sepsis [202]. It was also shown to induce IgG and Th17 immune responses in 
mice against 23 clinical isolates of diverse multilocus sequence type and serotype [203]. 
This vaccine has recently been produced to current Good Manufacturing Practice standards 
[204] and, in a phase I trial with 14 healthy adults, 8 developed serum antibody responses 
post-vaccination that passively protected mice following intravenous infection with 
serotype 3 [205].  
1.4.6.2 Protein vaccines 
A number of pneumococcal proteins have been shown to be protective against carriage 
and invasive disease in animal models but their efficacy in humans has not yet been 
established.  
An ideal protein antigen should be found on the cell surface, expressed at all pathogenesis 
stages and be highly conserved between serotypes. In order to fit these criteria it is likely 
that a protein vaccine would be made up of a number of different proteins. A few studies 
have examined the protective effect of protein combinations and found that in many cases 
combinations of multiple proteins demonstrate a synergistic protective effect whereas the 
proteins on their own have little effect on protection from disease [206,207]. 
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An effective protein vaccine could provide coverage worldwide and give serotype-
independent protection, helping to eliminate the threat of serotype replacement. Since 
proteins can be engineered efficiently and cheaply, vaccines could be produced at a much 
lower cost in comparison to PCVs making them much more affordable for developing 
countries.  
If these vaccines do provide serotype-independent protection it is possible that carriage 
will be completely eliminated. Whether it is eliminated or simply reduced, it is crucial to 
have a better understanding of the pneumococcus and the mechanisms behind carriage in 
order to aid vaccine development.  
1.5. The role of co-colonizers in S. pneumoniae carriage 
The nasopharynx, aside from being the residence of the pneumococcus, is home to millions 
of other bacteria and viruses. This complex and ever-changing community of microbes 
influences the ability of the pneumococcus to colonize and become established in the 
nasopharynx. 
1.5.5.1 Intraspecies competition 
Intraspecies competition and co-colonization can impact pneumococcal carriage. 
Horizontal gene transfer amongst pneumococci is very common and can be facilitated by 
co-colonization [208]. In a longitudinal study of carriage in Danish children, acquisition of a 
new serotype was weak when the child was already colonized [209]. This dataset was 
examined further, along with longitudinal carriage data from American Indian and Gambian 
infants, and, when combined, the data showed strong between-strain competition which 
occurred at acquisition [210]. However, using a mouse model of co-colonization, Marks et 
al. recently demonstrated that strains with a lower ability to colonize are better able to 
persist when a different strain with a high colonization ability is already established, thus 
potentially enhancing the ability of unencapsulated and rare serotypes to colonize [211].  
The mechanisms behind pneumococcal competition are not completely understood but 
bacteriocins, which are small, antimicrobial peptides produced by numerous bacterial 
species, are thought to be important. The blp locus of pneumococci encodes both a 
bacteriocin peptide and an immunity peptide and, when the pneumococci is missing these 
peptides, it is unable to compete against a parent strain or another serotype in a mouse 
model of co-colonization [212]. 
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1.5.5.2 Co-colonization of pneumococcus and respiratory viruses 
It has long been reported that there is an association between influenza infection and 
bacterial pneumonia [213-215]. The synergism between virus and pneumococcus can also 
be extended to other respiratory viruses including human metapneumovirus and 
respiratory syncytial virus (RSV) [216,217]. Co-infection of influenza and pneumococcus has 
been shown to increase pneumococcal adherence to the epithelium and synergistically 
stimulate type I interferons, inhibiting clearance and resulting in a higher bacterial load 
[72,218]. This was observed in Vietnamese children with radiologically confirmed 
pneumonia, who had a marked increase in density of colonizing pneumococci if co-infected 
with influenza A, RSV, or rhinovirus, and, more recently, in South Africans being treated for 
acute lower respiratory tract infection where there was a relationship between high 
pneumococcal colonization density and respiratory virus co-infection [219,220]. This 
increase in density can not only increase the risk of transmission to normally sterile parts of 
the body, it can also increase the risk of transmission within the population [20,221,222]. 
1.5.5.3 Co-colonization of pneumococcus and Staphylococcus aureus 
Although Staphylococcus aureus resides in the anterior nares, there exists an inverse 
correlation between carriage of S. pneumoniae and S. aureus [16,223,224]. In vitro 
experiments suggested hydrogen peroxide (H2O2) produced by the pneumococcus was the 
cause however, this was not replicated in a neonatal rat model of co-colonization, nor was 
it predictive of co-colonization in children [225-227]. This inverse relationship has also been 
found between carriage of S. aureus and vaccine-type pneumococci [16,224]. However, 
there are conflicting results following introduction of the pneumococcal conjugate vaccine; 
some studies found S. aureus carriage remained steady, while others found it increased 
[228,229]. Interestingly, this inverse correlation is missing in people with HIV, suggesting an 
immunological mechanism is involved [230,231].  
1.5.5.4 Co-colonization of pneumococcus and Gram negatives 
In vitro H2O2 killing by pneumococcus has also been demonstrated for H. influenzae, 
Moraxella catarrhalis, and Neisseria meningitidis  [232] and, just as the killing of S. aureus is 
not mirrored in vivo, neither is it indicative of the interaction between S. pneumoniae and 
H. influenzae. Lysenko et al. showed co-colonization in a mouse model resulted in rapid 
clearance of the pneumococcus, which was associated with increased neutrophil 
recruitment [233]. Recently, Margolis et al. demonstrated a more synergistic relationship; 
in a neonatal rat model, density of H. influenzae was increased if S. pneumoniae was 
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present [234]. The impact of density has been extended in a study of Peruvian children 
where a positive correlation was found between carriage densities [223].  
1.5.5.5 The nasopharyngeal microbiome 
Classical studies of co-colonization have relied on in vitro experimentation and have mainly 
focused on potential pathogens. But the microbiota of the human nasopharynx is a 
complex community of harmless commensals intermingled with potential pathogens, and is 
generally assumed to be beneficial to the host [235]. Microbiome analysis can reveal the 
intricate balance of the polymicrobial state and might help us understand the progression 
from asymptomatic colonization to disease. A recent study of healthy Dutch children found 
the nasopharyngeal microbiota varied strongly with season and was highly diverse [236]. 
Further investigation of the paediatric nasopharyngeal niche by a 16S rDNA sequencing 
approach revealed associations between pneumococcal carriage and specific bacterial 
genera and found that microbial communities with pneumococcus were less diverse and 
less even [237]. 
1.6 Detection of S. pneumoniae carriage 
Detection of carriage is of great importance as it could be used as an endpoint in vaccine 
trials. Limitations of detection in conventional microbiology have led to the development of 
molecular based detection systems. Microarray and immunoblot methods have been used 
to enhance detection of multiple serotypes from nasopharyngeal samples [238,239]. The 
development of PCR-based serotyping systems could aid surveillance of vaccine-targeted 
serotypes and help overcome difficulties associated with serological testing. 
1.6.1 Nasopharyngeal sample collection  
As pneumococci reside in the posterior nasopharynx, the ideal sampling method must 
reach there; anterior nasal swabs will not work. 
1.6.1.1 Sampling methods in children and infants 
In children, a nasopharyngeal swab (NPS) has been shown to be better at detecting 
nasopharyngeal pathogens than an oropharyngeal swab (OPS) but the transoral route is 
better tolerated [240]. Nasal wash has been shown to have higher sensitivity in 
pneumococcal detection than NPS but is less well tolerated [241]. The current WHO 
recommendation for detecting nasopharyngeal carriage of S. pneumoniae in infants and 
children is the NPS [242].  
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1.6.1.2 Sampling methods in adults 
Lieberman et al. [243] showed that samples taken from the nasopharynx of adults, either a 
NPS or nasal wash, detected 59% more pneumococcal colonization than OPS. Similarly, 
nasopharyngeal aspirate cultures were shown to be positive more often for pneumococci 
than OPS cultures but results were best when both specimens were taken [244]. Recently, 
nasal wash was shown to be more comfortable and better able to detect pneumococci and 
other potential respiratory pathogens than NPS [245]. However, this method of sampling is 
dependent on a fresh sample, rather than a frozen one [246]. The current WHO 
recommendation is to collect both NPS and OPS samples if possible and if not, then the NPS 
sample should be the one taken [242].  
 Since the updated WHO recommendations in early 2014, a few studies have focused on 
the usefulness of the OPS. In a study of healthy Italian adolescents, S. pneumoniae was 
found in 35.8% of OPS samples as compared to 3.5% of NPS [247]. This study did not use 
culture to detect pneumococci but relied on detection of the autolysin (lytA) and capsular 
(cpsA) genes using real-time polymerase chain reaction (PCR).  
Similarly, Trzciński et al. [248] compared paired trans-oral and nasopharyngeal swabs using 
conventional and molecular methods in healthy adults. After primary culture, significantly 
more NPS samples were culture-positive as compared to OPS (P<0.001) but following 
culture enrichment significantly more OPS samples were positive for pneumococci 
(P<0.001) by quantitative real-time PCR (qPCR).  
1.6.2 Methods used to detect pneumococcal carriage 
1.6.2.1 Microbiological culture 
Microbiological culture is the current gold standard for detection of pneumococci. A 
sample should be plated on defibrinated blood agar (sheep, horse, or goat) supplemented 
with 2.5-5 µg/ml gentamicin, which is used to prevent the growth of other organisms [242]. 
Following overnight incubation at 37°C in 5% CO2, alpha-haemolytic, draughtsman-like 
colonies should be sub-cultured for optochin sensitivity and bile solubility (Figure 1.6). A 
Gram stain should be performed to confirm the presence of Gram positive diplococci.  
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Figure 1.6: Overnight growth of S. pneumoniae on a blood agar plate. A zone of inhibition 
can be seen around the optochin disk.  
 
1.6.2.2 Culture enrichment 
Culture enrichment can be used to enhance the detection of pneumococcus [249,250] but 
it is not currently recommended by the WHO and it cannot be used to determine density of 
colonization [242]. In the study by Trzciński et al. culture enrichment did not impact on the 
NPS results but enhanced pneumococcal detection in OPS samples. It is possible that the 
enrichment step was detecting the transient presence of pneumococci rather than actual 
colonization, especially since the volunteers were parents of 24-month old children.  
1.6.2.3 Non-culture based detection methods 
Non-culture based methods of detection can overcome some of the issues associated with 
detecting pneumococcus in the nasopharynx including the requirement of viable organisms 
and the difficulty of distinguishing between pneumococci and other streptococci, including 
members of the viridans group [251].  
A number of PCR-based assays targeting numerous pneumococcal genes have been 
developed but many have had issues with specificity [252-255]. The most widely used real-
time PCR assay at present targets the autolysin gene lytA. However, a lytA-like gene has 
been found in other streptococcal species [256]. The ability of pneumococci to share 
genetic information with other oral streptococci warrants further development of non-
culture detection techniques.  
One possible technique is multilocus sequence typing (MLST). MLST can provide 
information on the genetic relatedness of isolates by identifying pneumococcal clones and 
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clonal complexes [257]. It has been shown to be very useful in identifying non-serotypeable 
and atypical pneumococci [258,259]. 
1.6.2.4 Serotyping 
Detection of the serotypes involved in carriage has traditionally been done by the Quellung 
method but latex agglutination, which is easier to interpret and cheaper than Quellung, is 
equally as effective [4,239]. However, as of 2014, the WHO continues to recommend the 
Quellung reaction as the core method for serotyping pneumococcal isolates.  
New serotyping methods that are based on genotypic detection, rather than phenotypic 
detection, are currently being developed. Microarray is an example of a genotypic method 
that can not only determine pneumococcal serotype but can also be used to detect 
multiple serotype carriage [239]. 
1.6.3 Determining pneumococcal carriage density  
Detection of carriage has long been important, especially in the context of vaccine trials. 
Recently, the importance of carriage density following vaccination, as well as the 
relationship between carriage density and disease, has been gaining attention.  
1.6.3.1 Methods to determine density 
Historically, density was determined using semi-quantitative colony counts, where bacterial 
load was categorized according to the number of colonies in each quadrant of an agar plate 
[260]. However, a quantitative value can easily be obtained by serially diluting a sample on 
agar, although this may not be sensitive enough to detect changes at low density [261].   
The development of real-time PCR has provided a molecular method able to detect low-
level density. But a drawback of PCR is that it cannot distinguish between live and dead 
pneumococci. It may be that culture and qPCR are complementary in detection of 
pneumococcal carriage density. 
1.6.3.2 Role of density in disease and transmission 
Determination of density is also important because of the link between carriage and 
disease. It has been suggested that there may be a point at which the density of 
pneumococci in the nasopharynx greatly increases the chance of disease within the host 
and, potentially, transmission.  
An inverse correlation between nasopharyngeal density and age exists which may explain 
why children are such efficient transmitters of the pneumococcus [183]. In Vietnamese 
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children, a high pneumococcal density in the nasopharynx was associated with 
radiologically confirmed pneumonia and viral co-infection [219]. In adults with CAP, qPCR 
on sputum samples suggested that clinical infection correlated with increased 
pneumococcal load, and in adults with lower respiratory tract infection, density greater 
than 105 colony forming units (CFU)/ml was suggested to indicate clinically significant 
infection [262,263]. However, both these studies used the ply gene which is not an ideal 
target as it has been identified in oral streptococci [264]. Using the gene fragment Spn9802 
as a target, another study of adults with CAP also determined 104 DNA copies/mL was a 
clinically significant cutoff in nasopharyngeal aspirate samples [265]. More recently, a study 
of HIV-infected South African adults suggested a nasopharyngeal pneumococcal load ≥8 x 
103 copies/mL could be used to diagnose pneumococcal pneumonia [266].  
This link between density and disease suggests that simply detecting carriage as a binary 
variable is no longer enough. Detecting changes in density will be vital when testing novel 
vaccines as an impact on carriage density could alter both disease and transmission.   
1.7 Models of S. pneumoniae carriage 
Pneumococcal carriage and/or disease does not occur naturally in animals, with the 
exception of serotype 3 which has been found in the respiratory tract of horses [267]. Even 
though animals are not natural hosts for pneumococcus, animal models have been 
essential in the study of pneumococcal carriage and disease. Not only have they been used 
to examine the mechanisms of disease pathogenesis and the role of host and bacterial 
factors, but they have also been important in testing novel vaccine candidates, providing 
safety and efficacy data to support progression to human clinical trials. To be successful, an 
in vivo animal model must be well characterized, predictive, and use clear, measurable 
readouts.  
1.7.1 Mouse model of carriage 
The most commonly used animal model for pneumococcal carriage is the mouse model. 
Generally, mice are inoculated intranasally by dropping the bacteria onto the nares. 
Carriage can be established using multiple serotypes and both density and duration can be 
measured [268].  
The murine model has been shown to be similar to experimental human carriage; using a 
clinical isolate, colonization was achieved with a similar minimum dose (<104 CFU), the 
average duration was several weeks, and the episode was a self-limited event [140].  
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1.7.2 Infant rat and chinchilla models of carriage 
Infant rat models have been used to investigate differences in the abilities of transparent 
and opaque strains to colonize [45]. They have also been used to examine transmission by 
inoculating infant rats and putting them in a cage with uninoculated infant rats [269].  
Chinchillas have been used to investigate the interaction between respiratory viruses and 
the pneumococcus in both colonization and otitis media models [270,271].  
1.7.3 Nonhuman primate model of carriage 
In the past, nonhuman primate models focused on pneumonia or sepsis however a rhesus 
macaque model of carriage was recently developed. In this model, carriage was self-
limiting and lasted up to 7 weeks in more than 60% of animals at a dose of 1x106 CFU/naris 
[272]. Nonhuman primate models are the animal model closest to resembling human 
disease but are both cost-prohibitive and difficult to get approval for.   
Unfortunately, no animal model can mimic the natural interaction between a pathogen and 
its human host and therefore cannot guarantee an authentic human response. This has 
resulted in the development of human challenge models.  
1.8 Experimental human challenge studies 
Controlled human challenge experiments allow us to examine the impact of a pathogen on 
the immunological complexity and normal microbiota of humans, both of which cannot be 
done using animal models. They also offer the ability to follow infection from the initial 
interaction between host and pathogen - something not possible during natural infection.  
Human challenge experiments have been used to study disease pathogenesis, progress 
development of antimicrobials, and to evaluate vaccine efficacy as a pre-cursor to large-
scale trials. Bacteria, viruses, and parasites have all been used in experimental infection 
models, causing illness that is either self-limiting or can be treated within a short time 
frame.  
The most famous human challenge experiment to date was performed in 1796 [273]. 
Edward Jenner took a scraping from a cowpox lesion on the hand of dairymaid and 
inoculated it into an 8-year old boy. Two months later he inoculated the boy again, this 
time with smallpox, and the boy did not get ill, demonstrating protection against disease. 
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1.8.1 Ethical framework behind human challenge models 
There were no written guidelines for performing human challenge experiments in 1796. 
Today, challenge models involving humans require strong ethical and legal frameworks.  
In 2001, Miller and Grady [274] published an ethical framework that could be used to 
evaluate human infection models. In the framework they explore the rationale behind 
challenge experiments, suggesting that a challenge model used to investigate novel vaccine 
candidates could, not only, limit the number of people exposed to a candidate vaccine in 
field trials, but could also increase the efficiency and reduce the time and cost of vaccine 
development. However they should not be performed if the work could be done using an 
animal model.  
They also discuss the importance of evaluating the level of risk to both the volunteer and 
their contacts and of creating a plan for how the risks might be minimized. Symptoms, both 
physical and psychological, need to be monitored.  
When it comes to recruitment, it is important to only include those that have a solid 
understanding of what is involved and can give informed consent. This means excluding 
vulnerable populations, such as children and incompetent adults, and ensuring that 
financial compensation is appropriate for the participation required but will not entice 
someone to overlook the risks and join the study.  
One final ethical consideration suggested by Miller and Grady is how to treat isolation. In 
some cases it is necessary to isolate volunteers in order to prevent transmission but this 
interferes with the ethical practice of allowing a volunteer to withdraw from a research 
study at any time. This must be dealt with during the informed consent process and must 
not impact on a volunteer’s right to withdraw following the period of isolation.  
1.8.1.1 Regulation of human challenge models 
At present, human challenge models are handled differently in the UK and the USA. In the 
UK, human infection studies are the responsibility of the study sponsor and ethics 
committee and are not regulated by the Medicines and Healthcare Related Products 
Agency (MHRA). In the USA, a live organism used in humans falls under federal regulations 
and requires an Investigational New Drug application [275].  
1.8.2 Human challenge models with potential respiratory pathogens 
A number of potential bacterial respiratory pathogens have been used in human infection 
experiments to further what was discovered in animal models. For example, a human 
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carriage model of S. aureus was used to confirm the importance of a protein found to be a 
major determinant of nasal colonization in the mouse [276].  
Experimental carriage of Neisseria lactamica, a commensal related to N. meningitidis, has 
been shown to restrict acquisition of meningococcal carriage and induce cross-reactive 
opsonophagocytic antibodies to the meningococcus [277]. Experimental carriage of 
nontypeable H. influenzae resulted in two genes, licA and igaB, being switched from phase-
off to phase-on, suggesting a role for these genes in early colonization [278].  
The common thread between these pathogens is they all exclusively infect humans, limiting 
the conclusions that can be drawn from animal models of colonization and necessitating 
the use of human challenge.  
1.8.3 Experimental human pneumococcal carriage  
1.8.3.1 Experimental human pneumococcal carriage in the United States 
The first experimental human pneumococcal carriage (EHPC) study was performed in the 
United States [161]. Healthy adults were recruited if they satisfied the following inclusion 
criteria: aged between 18 and 40 years old, HIV-seronegative, non-pregnant, having an 
intact spleen, no history of pneumococcal vaccination, no penicillin allergy, no history of 
recurrent respiratory tract infections or chronic illnesses, non-smoker, consume <3 
alcoholic beverages per day, no close contact with individuals at increased risk for 
pneumococcal disease, and lack of pneumococcal colonization for 2-4 weeks prior to 
challenge as determined by nasal and throat cultures.  
Serotypes 23F and 6B were used in dose-escalation studies to determine an optimal 
colonizing dose and to examine the antibody response to carriage. Nasal wash and serum 
were taken before challenge and every 2 weeks after, until carriage was not detected for 
two consecutive visits. The serum antibody response to pneumococcal polysaccharides, 
which are in the PCV, was minimal and the specific antibody levels in serum did not predict 
if an individual would become colonized. Pre-existing high levels of PspA, a potential 
vaccine candidate, correlated with protection against carriage of the experimental strain, 
suggesting a role for the protein in preventing pneumococcal carriage in humans.  
Candidate vaccine antigens were also assessed for their immunogenicity in the EHPC model 
[279]. Serum samples were taken before, and 1 month following, challenge, and then every 
2 weeks until carriage had cleared. The serum antibodies to seven different antigens were 
measured but only two, CbpA and PspA, showed an increase in serum IgG during carriage. 
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The immune response to both proteins induced measureable strain-to-strain cross-
reactivity. These studies focused on serum IgG responses and so mucosal antibody 
responses still need to be investigated.   
1.8.3.2 Experimental human pneumococcal carriage in England 
The first EHPC trials in England used the same serotype 23F strain as that used by McCool 
et al. in the USA but a different serotype 6B strain [161,280]. Healthy adult volunteers 
challenged with pneumococcus which did not result in carriage had increased 
immunoglobulin responses in nasal wash and bronchoalveolar lavage (BAL), but not blood, 
6 weeks after challenge [281]. In nasal wash, both IgG and IgA were increased compared to 
baseline and IgG anti-PspA was increased in nasal wash after 6B challenge and in BAL after 
23F challenge. The frequency of pneumococcal specific, cytokine producing, CD4+ T cells in 
BAL or blood did not change after challenge. This suggests that pneumococcal exposure 
may immunize mucosal surfaces by enhancing anti-protein immunoglobulin responses, but 
not cellular or capsular responses.   
1.8.3.3 Applications of the experimental human pneumococcal carriage model  
The value of the EHPC model extends beyond the exploration of host immunity to include 
microbial interactions in the nasopharynx as well as vaccine discovery and testing (Table 
1.1).  
 
Table 1.1 Summary of EHPC model applications 
Applications of the EHPC Model Investigations undertaken 
Host Pressure on  
S. pneumoniae  
Exploration of cellular, innate and adaptive humoral 
immune responses in relation to pneumococcal 
carriage 
Microbial Interactions Examine changes in the host milieu following 
inoculation with pneumococcus 
Vaccine Development and  
Testing of Novel Vaccines 
Detection of a reduction or elimination in 
pneumococcal nasopharyngeal carriage 
Live Whole Bacteria  
Responses to Inoculation 
Determination of specific immune responses to 
pneumococcal antigens 
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1.8.3.4 Usefulness of an experimental human pneumococcal carriage model in 
novel vaccine testing 
There is a number of design complexities involved in testing new pneumococcal vaccines. 
One problem is the lack of licensing criteria. Another is that opsonophagocytic assays used 
to detect anti-capsular antibody to polysaccharide may not be the best way to determine 
immune correlates of protection. It is also difficult to trial a new vaccine using clinical 
disease endpoints as it is not ethical to administer a placebo vaccine when the existing 
conjugate vaccine is very effective. Non-inferiority trials comparing a new vaccine against a 
conjugate vaccine and using clinical end-points would require very large sample sizes and 
be prohibitively expensive.  
It is still uncertain how the next generation of vaccines will protect against the 
pneumococcus. A reduction in carriage density or duration, a complete elimination of 
nasopharyngeal colonization, or a prevention of bacterial invasion, are all possibilities. 
Using a reduction in or elimination of carriage as an endpoint could be a useful mechanism 
to test a vaccine with cross serotype protection and mucosal immunogenicity. As the EHPC 
model is based on the detection of carriage, it could be very useful in comparing new 
vaccines.  
1.8.3.4.1 Carriage as an endpoint in vaccine trials  
An international consultation recently examined the potential for using colonization as an 
alternative endpoint in vaccine licensure [282]. They suggest five reasons a colonization 
endpoint is important in a phase 3 or 4 vaccine trial: carriage is the necessary precursor to 
disease and an effect on colonization could serve as an indication of protection against 
pneumococcal disease [283]; vaccine impact in the community depends on the level of 
direct protection against colonization; colonization incidence and prevalence is higher than 
disease meaning smaller sample sizes; a shorter sample collection period means 
confounding factors are less likely to interfere with the measurement of vaccine efficacy; 
endpoints can be more directly estimated for individual serotypes [284]. 
An EHPC model could be used to determine the protective effect of a novel vaccine against 
carriage in a small and controlled population in comparison to placebo groups and/or the 
current PCV. Carriage can be followed weekly and assessed by acquisition, density and/or 
duration. Mucosal samples, such as nasal wash and BAL, could be collected alongside 
systemic samples to assess mucosal immune responses and help establish new immune 
correlates of protection.  
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Using EHPC to detect a reduction in carriage and/or carriage density following vaccination 
could inform on the potential ability of the vaccine to decrease transmission and achieve 
herd protection. It could also provide proof of concept and be a stepping stone to pursuing 
large and expensive clinical trials.  
1.8.3.5 Usefulness of an experimental human pneumococcal carriage model as a 
vaccine model 
EHPC offers, not only an opportunity to test vaccine efficacy but also, the chance to 
measure the immunogenicity of the live whole bacteria used for pneumococcal 
immunization via the intranasal route (Table 1.1). The nature of the model allows the 
investigation of cellular responses, innate and adaptive humoral immune responses, and 
microbiological interactions in the upper and lower respiratory tracts and systemic 
circulation [285]. 
Mucosally active vaccines should enhance both mucosal and systemic immunity for 
protection against pneumococcal infection [286]. A mucosal vaccine is an attractive option 
as it mimics the natural route of exposure to pneumococcus. By using the EHPC model to 
deliver whole bacteria, specific immune responses to pneumococcal antigens can be 
examined and these results can be applied to the development of a potential mucosal 
vaccine.  
The EHPC model can be used to determine changes within the nasopharynx that occur 
during initial acquisition and the establishment of pneumococcal carriage. This includes 
changes within the inoculated pneumococcus in response to the host milieu as well as 
challenges the pneumococcus faces when confronted with other commensals that are 
already established in the nasopharynx. 
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1.9 Project aims 
There were three main aims in this project, each with a number of specific objectives.  
Aim 1: To further develop an experimental human pneumococcal carriage model  
Objectives:  
 Determine an appropriate inoculation dose to achieve carriage by dose-response 
tests 
 Test the reproducibility of the model at the chosen dose 
 Examine the presence of symptoms following experimental challenge  
 Determine the protective effect of a carriage episode on subsequent carriage 
Aim 2: To discover factors associated with experimental carriage  
Objectives:  
 Explore differences between two pneumococcal serotypes used in the model 
 Examine the host innate immune response following experimental challenge  
 Determine the role of respiratory viruses in experimental carriage establishment 
Aim 3: To explore the density and duration of experimental carriage  
Objectives:  
 Compare detection of carriage by culture and qPCR 
 Compare detection of carriage density by culture and qPCR 
 Assess carriage density during a carriage episode 
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Chapter 2  
 
 
 
 
 
 
Materials and methods 
2.1 Initial model development 
The first step in developing an experimental carriage model was to determine the 
nasopharyngeal sampling method that would be used for detection. As part of my MSc 
(Medical Microbiology) thesis, I compared the sensitivities of the nasopharyngeal swab and 
nasal wash in detecting potential respiratory pathogens and showed that the nasal wash 
was significantly more likely to detect pathogens than the swab using microbiological 
culture and was also the more comfortable sampling method [245]. The other part of my 
MSc project was to begin developing the experimental carriage model. Using a serotype 
23F strain, we challenged one volunteer with 9,300 CFU; carriage was not detected by 
culture or PCR [287].  
Following this first attempt at experimental carriage, we performed a series of pilot studies. 
These pilot studies were used to refine the experimental carriage method in preparation 
for the studies described in Chapter 3 and were completed prior to the start of this PhD 
(Table 2.1, page 39). During these studies I was responsible for preparing the inoculum and 
detecting pneumococcal carriage. 
In study 1, volunteers were intranasally challenged with two doses of a serotype 23F strain, 
approximately two weeks apart [281]. Nasal wash, serum and BAL samples were taken 2 
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weeks before challenge and again 6 weeks after the second challenge dose. Nasal wash 
was also collected 1 week before inoculation and on days 2, 4, and 7 after each challenge. 
The two doses were similar (10,448±5289 and 13,226±4215 CFU/100 µl) and the carriage 
rate was 11% (1/9).  
For study 2, bronchoscopy prior to challenge was removed and volunteers were again 
double-challenged with serotype 23F using a similar sampling schedule to study 1. There 
was no carriage in this group (0/6) at doses of 9,933±2828 and 18,000±3471 (unpublished 
data).  
Because of the low carriage rates with 23F in studies 1 and 2, a serotype 6B was tested. In 
study 3, volunteers had nasal wash samples taken one week prior to challenge and then on 
days 2, 7, 21, 28, and 35 after challenge. The carriage rate was 71% (5/7) at a dose of 
33,286±12,829 (unpublished data).  
Based on the high carriage rate with serotype 6B in study 3, volunteers in study 4 were 
again challenged with serotype 6B but bronchoscopy was re-added two weeks prior to, and 
6 weeks after, challenge [281]. There were no carriers in this group (0/9) at a dose of 
44,889±12,085. Bronchoscopy with bronchoalveolar lavage has been shown to cause 
inflammation in the lower respiratory tract so bronchoscopy prior to challenge was 
stopped following this study in case the inflammation was affecting the ability of the 
pneumococci to colonize [288]. 
Study 5 was similar to study 3. Volunteers were again challenged with serotype 6B but 
there was no bronchoscopy. The carriage rate was 22% (2/9) at a dose of 28,789±6877 
(unpublished data).  
Study 6 was used to examine to effect of experimental carriage on reacquisition of the 
same strain. Three carriage positive volunteers from study 3 returned 6-11 months after 
the initial inoculation to be re-challenged with the homologous 6B strain; all three were 
protected from reacquisition of carriage [289]. This is discussed further in Chapter 4.  
Finally, studies 7 and 8 were used to test the inoculum stocks that had been prepared for 
the Dose-Ranging study described in Chapter 3. In study 7 the carriage rate following 
challenge with 6B was 25% (1/4); in study 8 the carriage rate after challenge with 23F was 
50% (2/4) (unpublished data).  
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2.2 Clinical procedures 
2.2.1 Recruitment and ethics 
Healthy adult volunteers were enrolled with informed consent to an Experimental Human 
Pneumococcal Carriage trial using one of two pneumococcal serotypes, 6B or 23F. 
Participants were recruited to the study if they were:  
 between the ages of 18-60 
 spoke fluent English  
 were able to communicate easily by both mobile telephone and text message 
 
They were excluded from the study if they: 
 had close contact with at-risk individuals (young children, immunosuppressed 
adults, elderly, chronic ill health) 
 were a current smoker or had a significant smoking history (>10 pack years) 
 had asthma or other respiratory disease 
 were pregnant 
 were allergic to penicillin 
 were involved in another clinical trial (unless observational or in a non-
interventional phase) 
 were unable to give fully informed consent   
 
Ethical approval was obtained from the National Health Service Research Ethics Committee 
(11/NW/0592) and the studies were sponsored by the Royal Liverpool and Broadgreen 
University Hospitals Trust. Recruitment occurred through poster advertisements and on the 
University of Liverpool website, according to the NHS Research Ethics Committee guidance. 
All volunteer appointments took place at the Clinical Research Unit located in the Royal 
Liverpool University Hospital. 
2.2.2 Study schedules 
An initial screening visit was scheduled for one week prior to pneumococcal challenge. This 
visit included a focused clinical history and targeted clinical examination. If a previously 
unrecognized abnormality was found, the volunteer was excluded from the study and an 
appropriate investigation was arranged through primary care. 
During initial screening a full blood count was obtained to ensure the white cell count was 
within normal range before inoculation. Prior to inoculation, volunteers were educated on 
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the risks involved with participation and were provided with an emergency patient leaflet, 
digital thermometer, emergency telephone numbers and a 3 day course of amoxicillin.  
2.2.2.1 Dose-Ranging study schedule  
At the screening appointment for the Dose-Ranging study, nasal wash, serum, saliva and 
urine samples were taken (Figure 2.1). A viral throat swab was taken at the screening and 
day 2 appointments for the 6B 4x104 CFU/naris dose and all the 23F doses. For the first five 
doses, volunteers naturally carrying pneumococcus at the pre-screen appointment were 
excluded from the study. Natural carriers screened as part of the 3.2x105 dose for either 6B 
or 23F were followed in parallel to challenged volunteers. 
Inoculation occurred one week after screening and then samples were taken on days 2, 7 
and 14 (Figure 2.1). In a subset of volunteers additional blood samples were taken 
(Appendix D). Carriage positive volunteers were invited to have a bronchoscopy following 
antibiotics and carriage clearance.  
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Figure 2.1: Flow chart of Dose-Ranging study appointments. The throat swab was not 
taken for the 6B 1x104 and 2x104 dose groups. Only natural carriers screened as part of the 
3.2x105 dose for either 6B or 23F were followed in parallel to those that were challenged. 
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2.2.2.2 Reproducibility study schedule  
Volunteers recruited to the Reproducibility study followed a similar schedule to the Dose-
Ranging study, including additional blood samples in a subset of volunteers (Appendix E). 
However, there were three changes: the day 2 throat swab was removed based on results 
from the Dose-Ranging study, the study was extended by 3 weeks to better examine 
carriage duration, and bronchoscopy was offered to all participants, regardless of carriage 
status (Figure 2.2). All natural carriers were followed in parallel to challenged volunteers.  
2.2.2.3 Re-challenge study schedules 
Volunteers followed the same schedule of appointments as the Dose-Ranging study with 
one exception: those re-challenged with the homologous 6B serotype completed the study 
after day 7. This was done because carriage status was determined by this point.  
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Figure 2.2: Flow chart of Reproducibility study appointments. All volunteers, regardless of 
carriage status, were offered a bronchoscopy but participation was optional.  
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2.2.3 Safety monitoring 
While the risk to healthy volunteers of developing pneumococcal infection (i.e. sinusitis, 
otitis media, pneumonia, bacteraemia or meningitis) was very low, the study was designed 
to minimise risk by appropriate study design, volunteer education and rigorous safety 
procedures. 
Following experimental challenge, volunteers were required to send a text message to the 
clinical team by 2pm every day for a week. If the text was not received by 2pm the 
volunteer was contacted to ensure his/her well-being. If he/she did not respond, the 
allocated next of kin was contacted. 
Each volunteer received an emergency pack at the inoculation appointment. This pack 
contained a post-inoculation information sheet with all the necessary emergency contact 
information, a thermometer, and a course of amoxicillin. The amoxicillin was only to be 
taken under three circumstances: if he/she was carrying pneumococcus at the end of the 
study; in the event he/she was unwell and was instructed to do so by the research team; or 
if he/she was unwell and unable to contact the research team. The volunteer was 
encouraged to keep the emergency pack with them at all times during the study.  
The clinical team was available 24/7 with nurse contact during working hours and two 
doctors available out of hours. All queries were dealt with by telephone call and/or 
immediate review. Provisions were available for immediate, direct admission to the 
Infectious Disease ward at the Royal Liverpool University Hospital, if needed. 
2.2.3.1 Data monitoring and safety committee 
As an additional measure of protection a Data Monitoring and Safety Committee, 
consisting of clinicians and scientists from outside the research group, was set up. The 
committee received updates on recruitment and a weekly safety report that contained the 
bacterial dose each volunteer received and whether any symptoms or illness were 
reported. This report allowed the safety of the study to be externally critiqued without 
bias. The committee was also available for consultation in the event of any adverse events. 
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2.2.4 Symptom reporting 
2.2.4.1 Passive reporting of symptoms 
To examine symptoms related to experimental challenge, we asked volunteers to report 
any URT symptoms to the clinical team at every appointment. This passive data collection 
was done for nine of the twelve groups in the Dose-Ranging study: the first five serotype 6B 
doses and the first four serotype 23F doses. Any complaints were recorded in the case 
notes.  
2.2.4.2 Active reporting of symptoms  
To better understand if symptoms were related to carriage or to the inoculation itself, we 
planned to recruit 10 volunteers to a saline control arm. These volunteers did not know 
they were being challenged with saline and were required to actively complete a daily 
symptom log (Figure 2.3) on the day of challenge and for 7 days post-challenge. 
To compare symptoms following saline challenge with symptoms following bacterial 
challenge, volunteers that received the 3.2x105 6B dose and the 1.6x105 and 3.2x105 23F 
doses in the Dose-Ranging study, as well as the volunteers in the Reproducibility study, also 
filled out a daily symptom log.  
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Figure 2.3: Daily symptom log. Volunteers in the 6B 3.2x105 dose group, the 23F 1.6x105 
and 3.2x105 dose groups, the saline control arm and the Reproducibility study filled out a 
daily symptom log on the day of challenge (Day 0) and for 7 days post-challenge. Adapted 
from Spector et al. [290].  
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2.3 Laboratory procedures 
2.3.1 Bacterial strains and growth conditions 
Clinical isolates of serotype 6B strain BHN418 (GenBank accession number 
ASHP00000000.1) (a gift of Prof. P Hermans, Radboud University Nijmegen) and serotype 
23F strain P833 (a gift of Prof. JN Weiser, University of Pennsylvania) [161] were cultured 
on Columbia Blood Agar with horse blood (Oxoid) and incubated at 37°C overnight in 5% 
CO2. The following day a “parent” bead stock was made by scraping all the overnight 
growth from the blood agar plate and adding it to a cryovial containing ceramic beads and 
a cryopreservative fluid (Technical Service Consultants Ltd.). Vials were stored at -80°C and 
were tested for contamination and colony uniformity before being used to prepare 
inoculation stocks. This “parent” stock was used to prepare all subsequent inoculation 
stocks. 
Pneumococcal 23F strain P1123 was isolated from the nasopharynx of a volunteer during 
experimental carriage in the study performed by McCool et al. [161]. It is a derivative of the 
23F inoculum (P833) that was used to challenge volunteers in that study.  
S. pneumoniae serotype 2 strain D39 was used in the pneumococcal adherence and 
internalization assay in Chapter 7. D39 pneumococci were grown in Todd-Hewitt broth 
(Oxoid) supplemented with 0.5% yeast extract (Becton Dickinson) (THY) at 37°C in 5% CO2 
until reaching an optical density (OD) of 0.4-0.5 nm at OD600. Bacteria were either used 
immediately for flow binding assays, or re-suspended in THY 10% glycerol and stored at -
80°C for adherence assays.  
2.3.2 Experimental pneumococcal challenge  
2.3.2.1 Inoculum stock preparation 
Preparation of inoculum stocks was done in a clean environment, using a dedicated 
fumehood, incubator, and pipettes. It was crucial that no animal products were inoculated 
into volunteers so Vegitone Infusion broth (Fluka), a vegetable-based growth medium, was 
used to grow the inoculum.  
From the “parent” bead stock, the desired serotype was streaked for heavy growth onto a 
blood plate, ensuring that the entire plate was covered (Figure 2.4). The plate was then 
incubated overnight at 37°C, 5% CO2. The following day half of the plate was swabbed and 
mixed in 12 ml of warmed Vegitone. This was repeated for the other half of the plate. The 
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cultures were incubated at 37°C for at least 2 hours or until a visual change in turbidity was 
detected.  
The 12 ml of culture was then added to 40 ml of warmed Vegitone medium and the OD was 
measured and adjusted to 0.15 at OD600nm. The stock was quantified at this point using the 
Miles and Misra method (M&M, see section 2.3.2.2) and incubated at 37°C, 5% CO2. OD 
readings and M&M quantification were done every hour until an OD600 of 0.25, early-mid-
log phase, was reached. To one of the tubes 10% sterile glycerol was added and 1 ml 
aliquots were prepared and stored at -80°C. The other tube was centrifuged at 3345 x g for 
15 minutes, the supernatant was removed, and the pellet was resuspended in 22.5 ml of 
Vegitone to concentrate the bacteria. 10% sterile glycerol was added and 1ml aliquots were 
prepared and stored at -80°C.  
After a minimum of 48 hours in the freezer, three stock aliquots were quantified using the 
M&M method to ensure reproducibility. This value was then used to dilute the stock to the 
desired inoculum dose.  
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Figure 2.4: Flow chart diagram of inoculum stock preparation 
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2.3.2.1.1 Confirmation of inoculum serotype and sensitivity 
Prior to use in a human carriage study, bacterial stock purity, penicillin sensitivity and 
serotype were confirmed by an independent reference laboratory (Public Health England, 
UK). 
2.3.2.2 Quantification of S. pneumoniae – Miles and Misra method 
A modification of the M&M method was used to perform viability counts [291]. A blood 
agar plate was divided into six sections and labelled 1 to 6. In a 96 well U-bottom plate 
(Corning Inc.), 20 μl of bacteria was added to 180 μl of sterile phosphate buffered saline 
(PBS) and serially diluted (ten-fold) until a dilution of 106 was reached. Three drops of 10 μl 
from each dilution were placed on the corresponding section of the plate and allowed to 
dry. The plate was then inverted and incubated overnight at 37°C, 5% CO2. 
The next day, visible colonies in each dilution section were counted and recorded (Figure 
2.5).  
 
 
Figure 2.5: Miles and Misra bacterial quantification. Three 10 μl drops from a serial 
dilution were placed on the corresponding dilution section of the plate. The plate was then 
inverted and incubated overnight at 37°C, 5% CO2. Individual colonies can be counted in 
the 5th dilution section. 
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2.3.2.2.1 How to calculate CFU per ml 
The dilution section with a count between 30 and 300 was used to determine the CFU/ml 
with the formula: 
CFU
ml
= (
(average number of colonies in section) x (dilution factor)
the volume of the drop plated
) x 1000 
 
2.3.2.4 Determination of inoculum dose 
The dilution of the inoculum stock to the desired dose had to be determined prior to the 
start of an experimental carriage study. This was done using the calculated density of the 
inoculum stock after 48 hours at -80°C and plugging it into: 
𝐶1𝑉1 = 𝐶2𝑉2 
where   C1 = the density of the inoculum stock 
 V1= the unknown volume the stock must be diluted in  
 C2 = the desired quantity for inoculation 
 V2 = the desired total volume of the final inoculation 
  
2.3.2.4.1 Quantification of inoculum dose 
Once the dilution volume for the inoculum stock was determined, quantification by M&M 
was performed; this was considered the “pre-inoculation” count. It takes approximately 30 
minutes to complete the entire inoculation procedure and pneumococci suspended in 
saline will start to die in this interval. To account for this, the diluted inoculum sat at room 
temperature for 30 minutes and then a “post-inoculation" quantification was performed. 
The average of the before and after counts was used to determine the final inoculated 
concentration.  
An inoculum dose was considered out of protocol if it was less than half or more than 
double the desired concentration. 
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2.3.2.5 Preparation of inoculum on day of challenge 
A half an hour before a scheduled inoculation appointment an aliquot of the desired 
serotype was thawed, centrifuged at 17,000 x g for 3 minutes, and the bacterial pellet was 
washed before being re-suspended and diluted in sterile, hospital grade 0.9% saline to 
reach the desired concentration of bacteria.  
Once prepared, the inoculum was quantified using a modified version of M&M. Instead of 
plating the dilution as drops within a sector, each dilution had its own plate and the three 
10 μl drops were placed in a line on a slightly inclined plate and allowed to run down the 
length of the plate (Figure 2.6).  
 
 
Figure 2.6: Quantification of inoculum on blood agar plate. Three 10 μl drops from the 
inoculum were dropped in a line on a plate and the plate was tilted slightly to allow the 
drops to run down it. This was done before and after the inoculation appointment. All 
colonies were counted and used to calculate inoculation dose.  
 
The prepared inoculum was then taken to the Clinical Research Unit at the Royal Liverpool 
University Hospital. Following completion of all volunteer inoculations, the inoculum was 
taken back to the laboratory for the post-inoculation quantification.  
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2.3.2.6 Nasopharyngeal inoculation 
Intra-nasal inoculation with S. pneumoniae was carried out by a Research Nurse. The 
inoculation was performed while the volunteer was seated comfortably in a semi-
recumbent position. With the head tilted back slightly, the tip of a P200 pipette was 
inserted just inside the nasal cavity and 100 µl of the bacterial inoculum was slowly 
dispersed across the nasal mucosa in a circular motion (Figure 2.7).  
 
 
Figure 2.7: Inoculation of the nasal mucosa with 100 µl of S. pneumoniae. Volunteers 
were seated in a semi-recumbent position, with the head tilted slightly back. The tip of a 
P200 pipette was inserted just inside the nasal cavity and 100 µl of the bacterial inoculum 
was slowly dispersed across the nasal mucosa in a circular motion. 
 
During the inoculation, it was important that the pipette tip did not come in contact with 
the nasal mucosa as a disruption in the integrity of the epithelium could result in bacteria 
entering the bloodstream.  It was also important that the inoculum was not expelled too 
far back in the nasal cavity as it would run down the throat and be swallowed instead of 
remaining in the nasopharynx.  
The inoculation was repeated for the other nostril and then the volunteer remained in the 
semi-recumbent position for 10 minutes without sniffing or blowing the nose.  
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2.3.2.7 Nasal wash sampling method 
Nasal wash was used to sample the nasopharynx of volunteers. Samples were collected one 
week before inoculation and at all visits post-inoculation [292,293]. A volunteer was seated 
comfortably and the head was tilted back 30° from the vertical. The volunteer was then 
asked to take a deep breath in and hold their breath whilst pushing their tongue up and 
backwards against the roof of the mouth. A syringe filled with 20 ml of sterile saline was 
inserted into the anterior nasal space and 5 ml of saline was expelled. The volunteer then 
leaned forward immediately and expelled the fluid by exhaling rapidly through the nose 
into a foil bowl (Figure 2.8).  
The procedure was repeated three more times so that each naris had been washed twice 
and a total of 20 ml was used. Following collection the samples were pooled in a centrifuge 
tube and transported to the laboratory at room temperature. 
 
 
Figure 2.8: Nasal wash. A syringe filled with 20 ml of sterile saline was inserted into the 
anterior nasal space and 5 ml of saline was expelled. The volunteer then leaned forward 
and expelled the saline by exhaling rapidly through the nose into a foil bowl. Picture 
reproduced with permission of Dr. J. Rylance. 
 
2.3.2.7.1 Adaptations for the nasal wash procedure 
In some cases the nasal wash method needed to be adapted to obtain an adequate sample. 
If a volunteer had a blocked/congested nose and the saline ran out anteriorly after 
insertion, the volunteer blew the nose and then the syringe was inserted a little further 
back and the head was tilted back further. If a volunteer tasted saline during the nasal wash 
then the connection between the posterior nasopharynx and oropharynx had not been 
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adequately closed. The procedure was then explained again, with an emphasis on pushing 
the tongue against the roof of the mouth. In either case if the yield was less than 5 ml the 
procedure was repeated using up to an extra 20 ml. 
2.3.2.8 Nasal wash sample processing 
Prior to centrifugation, nasal wash samples were examined for debris or mucus. If a nasal 
wash sample contained a substantial amount of mucus, the sample was vortexed to break 
it up. Any large pieces of mucus were then removed with a pipette, ensuring as little saline 
as possible was removed.  
Nasal wash samples were centrifuged at 3345 x g for 10 minutes. Following centrifugation 
the volume of supernatant was recorded and then stored in 1 ml aliquots at -80°C.  
The nasal wash bacterial pellet was re-suspended in 100 μl of skim milk, tryptone, glucose, 
glycerol (STGG) medium (Appendix A) and the total volume in the centrifuge tube was 
determined. A 20 μl drop of the sample was streaked onto Columbia Horse Blood Agar 
containing 4 μg/ml gentamicin (Sigma). If the nasal wash was post-inoculation 10 μl was 
serially diluted in a 96 well U-bottom plate and M&M quantification to determine the 
density of pneumococcal carriage (section 2.3.3.2) was performed using blood agar 
containing 4 μg/ml gentamicin.  
The nasal wash pellet was then diluted by adding 800 μl of STGG and 25 μl was streaked 
onto both blood and chocolate agar (Columbia Agar with Chocolated Horse Blood, Oxoid) 
to determine co-colonising flora.  The remainder of the sample was split into two cryovials 
and stored at -80°C.  All plates were incubated overnight at 37°C, 5% CO2. 
2.3.2.8.1 Removal of microbial flora from nasal wash plates 
The nasopharynx is not a sterile environment and microbial flora can obscure the presence 
of S. pneumoniae (Figure 2.9A). To remove any microbial flora it was crucial to add 
gentamicin (4 μg/ml) to the blood agar plate for both the M&M quantification and the 
concentrated nasal wash pellet (Figure 2.9B).  
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Figure 2.9: Blood agar plate inoculated with nasal wash, without and with gentamicin 
added to the media. Blood agar plates inoculated with nasal wash can be difficult to read 
due to the presence of other nasopharyngeal flora. (A) A blood agar plate with a nasal wash 
sample. Growth of microbial flora hides the pneumococci. (B) Gentamicin was added to a 
blood agar plate before the same nasal wash sample was streaked out. Pneumococci are 
clearly visible and all other microbial flora has been removed.  
 
2.3.3 Detection of pneumococcal carriage  
2.3.3.1 Detection of pneumococcal carriage by culture 
Following overnight incubation plates were examined for the presence of S. pneumoniae. 
Any alpha haemolytic, draughtsman-like colonies were sub-cultured for purity. A Gram 
stain was performed and optochin sensitivity and bile solubility were tested.  
Serotype confirmation was performed using latex agglutination (Statens Serum Institute). If 
serotype 6 or 23 was detected at any time point, the volunteer was considered carriage 
positive. 
2.3.3.2 Measurement of pneumococcal carriage density  
M&M was used to determine carriage density by culture. To calculate the CFU/ml of nasal 
wash returned, the CFU/μl was determined in the same way as described in section 
2.3.2.2.1. The CFU/μl was then multiplied by the volume of the bacterial pellet suspension 
after the addition of 100 μl of STGG. This value was then divided by the amount of nasal 
wash returned by the volunteer to obtain CFU/ml of nasal wash [292].  
CFU
ml nasal wash
=
CFU
μl x STGG total pellet volume
nasal wash volume returned
 
 Methods 
59 
 
We chose to divide the CFU by the amount of nasal wash returned, rather than the amount 
of saline instilled, because the return volume contained the pneumococci and varied 
between volunteers. There is a possibility that a nasal wash misses pneumococci that are 
tightly adhered to the epithelium however, Wu et al. [268] showed in adult mice that the 
CFU recovered from a nasal wash strongly correlated with the CFU from a paired 
homogenized nasal tissue sample taken after the wash.  
2.3.3.3 Bacterial DNA extraction 
Directly after the nasal wash collection, 2 ml was added to 4 ml of RNAprotect Bacteria 
Reagent (Qiagen). After 5 minutes incubation at room temperature the sample was 
transferred to the laboratory on ice and stored at -80°C until processing.  
Thawed samples were pelleted in a 2 ml tube by three centrifugation steps at 19,090 x g for 
20 minutes at 4°C. The pellet was resuspended in 0.3 ml lysis buffer with protease (Agowa 
Mag mini DNA extraction kit, LGC Genomics), 50 mg sterilized zirconia/silica beads 
(diameter 0.1 mm, Biospec Products) and 0.3 ml phenol (Phenol BioUltra, Sigma-Aldrich). 
The sample was mechanically disrupted by bead beating in a TissueLyser LT (Qiagen) twice 
at 50 Hz for 2 minutes. After centrifugation the aqueous phase was transferred to a sterile 
1.5 ml tube. Binding buffer was added in twice the volume of the aqueous phase plus 10 µl 
of magnetic beads, after which the sample was incubated in a mixing machine for 30 
minutes at room temperature. The magnetic beads were washed with 200 µl of both wash 
buffer 1 and 2 and eluted with 63 µl elution buffer according to the manufacturer’s 
instructions. 
2.3.3.4 Quantification of pneumococcal DNA by qPCR 
Determination of carriage density by qPCR was performed through partial amplification of 
the lytA gene. The primer and probe sequences were: forward primer 5’- 
ACGCAATCTAGCAGATGAAGCA-3’; reverse primer 5’-TCGTGCGTTTTAATTCCAGCT-3’; probe 
5’-(FAM)-GCCGAAAACGCTTGATACAGGGAG-(BHQ1)-3’ as previously published [253]. The 
20 μl PCR mix consisted of 1x TaqMan® Universal PCR Master Mix (Life Technologies), 0.1 
μM of each primer, 0.1 μM probe and 1 μl of the extracted DNA. Thermal cycling was 
performed in an ABI 7500 Fast Real-Time PCR System (Life Technologies) under cycling 
conditions: 2 minutes 50°C, 10 minutes 95°C and 40 cycles of 15 sec 95°C and 1 minute 
60°C.  
A standard curve of a 10-fold dilution series of genomic DNA extracted from S. pneumoniae 
(TIGR4, ATCC BAA-334) was used. The genomic DNA was extracted using the Qiagen 
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Genomic-tip 20/G Kit (Qiagen), and quantified by a spectrophotometer (Nanodrop ND-
1000, Thermo Fisher Scientific). The conversion from weight pneumococcal DNA to number 
of DNA copies S. pneumoniae was based on the weight of one genome copy TIGR4 
calculated by the genome length in base pairs times the weight of a DNA base pair (650 
Dalton). The lower limit of detection (LLOD) of the method was set at 40 cycles. A nasal 
wash was considered positive if both duplicates yielded a qPCR signal below 40 cycles. 
2.3.4 In vitro assays 
2.3.4.1 Microarray 
Microarray was used to investigate the potential of multiple serotype carriage in one 
volunteer. The bacterial pellet from the pre-screen and days 2, 7, and 14 visits, was diluted 
1:10 and 1:100 and 50 µl of each dilution, as well as a neat suspension, were spread onto 
selective agar plates (Colistin sulphate, Oxolinic acid, blood agar; Oxoid) and incubated 
overnight at 37°C in 5% CO2.  All colonies from the plate with the highest density of distinct 
non-confluent colony growth were scraped into 1 ml of sterile PBS. DNA extractions were 
performed using the QIAamp DNA Mini Kit (Qiagen), including lysis buffer (20 mM Tris/HCl, 
2 mM EDTA, 1% v/v Triton, 20 mg/ml lysozyme) and RNase treatment as previously 
described [239].  
Molecular serotyping was performed using the BµG@S SP-CPSv1.4.0 microarray. Briefly, 
DNA samples were fluorescently labelled and hybridized to the Agilent 8×15K format 
microarray according to manufacturer’s instructions for the Agilent genomic DNA ULS 
labelling and oligo aCGH hybridisation reagent kits.  
Microarray data was statistically analysed using a Bayesian hierarchical model which  
calculates the probabilities of serotype combinations based on the data from the 
microarray and determines the serotype, or combination of serotypes, present in the 
sample [294].  
2.3.4.2 Determination of phase morphology 
Pneumococcal isolates were streaked on tryptic soy agar plates containing catalase and 
incubated at 37°C in the presence of CO2. Determination of phase morphology was done 
under magnification and transmitted, oblique illumination as previously described [45]. 
Briefly, transparent colonies were bluish in colour and appeared smaller and more 
transparent in the centre, due to a central depression, giving the impression of a 
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“bullseye”. Opaque colonies were whitish in colour and slightly bigger, appearing more 
uniform and with a domed shape.  
2.3.4.3 Complement deposition assay 
Pneumococci were cultured in THY broth at 37°C, 5% CO2 to an OD600 of 0.4. Bacteria were 
then centrifuged at 3,350 x g for 10 minutes, the supernatant removed, and the pellet 
resuspended in 1 ml of PBS. 100 µl of the pneumococcal suspension was added to two 
Eppendorf tubes and centrifuged at 17,000 x g for 3 minutes. The supernatant was 
removed and one pellet was resuspended in 1% gelatine veronal buffer (GVB) (Sigma). This 
was the control tube which was resuspended in 1% GVB at every step. The experimental 
condition pellet was resuspended in 20% normal human sera (plasma from buffy coats) and 
then both tubes were incubated at 37°C, 5% CO2 for 30 minutes.  
Bacteria were centrifuged at 17,000 x g for 3 minutes, the supernatant removed and the 
experimental tube re-suspended in a 1:300 dilution of IgG2a mouse-anti-human-C3 
(Abcam) for 30 minutes at 37°C, 5% CO2. Following this incubation, bacteria were 
centrifuged at 17,000 x g for 3 minutes, the supernatant removed, and the experimental 
tube resuspended in a 1:500 dilution of anti-mouse IgG, IgA, IgM-FITC (Sigma) for 30 
minutes at 4°C in the absence of light. Bacteria were then centrifuged at 17,000 x g for 3 
minutes, washed with PBS, re-suspended in PBS, and stored at 4°C in the absence of light 
until acquisition. 
Samples were acquired using a nine-colour LSR II flow cytometer (BD). The Mean 
Fluorescence Intensity (MFI) (±SD) was calculated as the percentage of the bacterial 
population positive for C3 deposition multiplied by the geometric mean fluorescence of the 
total cell population. 
2.3.4.4 Measurement of anti-pneumococcal polysaccharide antibodies in 
intravenous immunoglobulin by ELISA  
To measure the level of polysaccharide antibodies to serotypes 6B and 23F in intravenous 
immunoglobulin (IVIG), 96-well plates were coated with 5 µg/ml of purified 6B or 23F 
polysaccharide (Statens Serum Institute) for 5 hours at 37°C. All samples were diluted in 
10% foetal bovine serum in PBS (PBS-F) and plates were washed 3 times with PBS-Tween 
0.05% between each step using a microplate washer (Wellwash 4 MK2, Thermo Scientific).  
In a separate 96-well plate, IVIG was diluted in PBS-F containing 10 µg/ml of cell wall 
polysaccharide (CWPS Multi, Statens Serum Institute) and incubated at room temperature 
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for 30 minutes. When CWPS Multi is used, separate adsorption with the 22F capsule is not 
required. Pneumococcal reference serum lot 89-SF5 (U.S. Food and Drug Administration) 
was used as a standard. Diluted/adsorbed samples were then transferred to the pre-coated 
plates and incubated overnight at 4°C. Bound antibodies were detected using goat anti-
human IgG conjugated with alkaline phosphatase (Sigma) for 2 hours at room temperature. 
0.5 mg/ml of p-nitrophenyl phosphate (PNPP) was added as a substrate.  Absorbance was 
measured at 405 nm using a FLUOstar OMEGA plate reader (BMG Labtech). Samples were 
run in triplicate, twice. 
2.3.4.5 Opsonophagocytic killing assay 
2.3.4.5.1 Isolation of neutrophils from peripheral blood 
Ethical approval to take peripheral blood from healthy adults was acquired through the 
Liverpool School of Tropical Medicine Research Tissue Bank (REC ref. 11/H1002/9).  
15 ml of blood was obtained from healthy volunteers in heparin containing tubes (BD). 
Neutrophils were isolated from the blood using a standard density gradient separation 
method. First, 15 ml of Histopaque 1119 (Sigma) was added to a 50 ml falcon tube followed 
by carefully layering an equal volume of Histopaque 1077 (Sigma) on top. 15 ml of whole 
blood was then carefully layered on top of the Histopaque gradient and the tube was 
centrifuged at room temperature for 30 minutes at 677 x g with the brake off. Following 
centrifugation, the top two layers were removed with a Pasteur pipette and discarded and 
the neutrophil layer was transferred to a fresh 50 ml tube, taking care not to carry over red 
blood cells. The tube with the neutrophils was topped up to 50 ml with Hanks’ Balanced 
Salt Solution (HBSS) without calcium or magnesium (-/-) (Gibco) and washed by 
centrifugation at 200 x g for 10 minutes.  
If the cell pellet showed signs of residual red blood cell contamination, 2 ml of RBC lysis 
buffer 1x (Biolegend) solution was added and the pellet was incubated at room 
temperature, protected from light, for 10 minutes. The tube was then topped up to 50 ml 
with HBSS-/- and centrifuged at 200 x g for 10 minutes. This step was repeated and then 
the cell pellet was resuspended in 0.5 ml of HBSS-/- and the cell number and viability was 
assessed using Trypan Blue and a haemocytometer.  
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2.3.4.5.2 Neutrophil opsonophagocytic killing assay 
Aliquots of 6B and 23F pneumococci were thawed, centrifuged at 17,000 x g for 3 minutes 
and diluted to 5x104 CFU/ml in HBSS with Ca2+ and Mg2+ (+/+) (Gibco). IVIG (Grifols Lot 
26NLVH1) was used as a source of pathogen-specific antibody and was diluted 1:8 in 
HBSS+/+. 500 µl of diluted IVIG was mixed with 500 µl of diluted 6B pneumococci in a 
bijoux tube. This was repeated for serotype 23F. 500 µl of both pneumococcal suspensions 
were also added to 500 µl of HBSS+/+ as non-opsonized controls. All four tubes were then 
placed in a shaking incubator (100 RPM; Sarstedt TPM-2 Shaker) at 37°C for 20 minutes.  As 
two serotypes were being tested, quantification of the diluted pneumococcal suspensions 
was performed as previously described (Chapter 2, section 2.3.2.2) to ensure the same 
number of pneumococci had been added for both serotypes.  
Following opsonization, 20 µl of the bacterial suspension was added to a 96 well plate with 
10 µl of baby rabbit complement (Pel-Freez Biologicals). Neutrophils were diluted to 
1.7x106 cells in Opsonization Buffer B (OBB) containing HBSS+/+, 1% GVB (Sigma) and 5% 
heat inactivated foetal bovine serum (Invitrogen) and 30 µl was then added to each well, 
giving a multiplicity of infection of 1:100 (1 pneumococcus to 100 phagocytes). 30 µl of OBB 
was added to each well for a final volume of 80 µl/well. Control wells contained non-
opsonized bacteria  
Plates were incubated at 37°C for 45 minutes on a shaking platform (200 RPM). 
Phagocytosis was stopped by resting plates on ice for 10 minutes. 10 µl of the reaction 
mixture was tilt-plated onto a blood agar plate in triplicate. Plates were incubated 
overnight at 37°C, 5% CO2 before counting bacterial colonies. Results were expressed as 
percent killing which was determined by the average CFU recovered from the control wells 
minus the average CFU recovered from the experimental wells, divided by the average CFU 
from the control wells.  
2.3.4.6 Sequencing 
2.3.4.6.1 Genetic comparison of the 6B and 23F strains 
The 23F inoculum strain (P833) was sequenced using the Roche 454 platform at the Centre 
for Genomic Research, University of Liverpool. Annotations were transferred from S. 
pneumoniae 23F, ST81 to the assembled 23F genome using Rapid Annotation Transfer Tool 
(RATT) [295]. The genome of 23F was compared to the publicly available 6B genome [280] 
in the Artemis Comparison Tool (ACT) [296] to identify areas of genomic difference, 
focusing on known adherence factors.  
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The accession number for S. pneumoniae 23F, ST81 is FM211187. 
2.3.4.6.2 Genetic comparison of 23F strains P833 and P1123 
The two 23F strains (P833 and P1123) were also sequenced on an Illumina Hi-Seq as 
previously described [297].  
All analysis of Illumina data was performed using CLC Main Workbench 6 (CLC bio, Boston, 
MA).  First, de novo assembly was performed on the reads from P833 and then the reads 
from P833 and P1123 were mapped to the resulting contig sequences. Single nucleotide 
polymorphism (SNP) and deletion-insertion polymorphism (DIP) analysis was then 
performed and true genetic variations were scored as being present in the P1123 mapping 
while being absent from the P833 mapping.  
2.3.4.7 Determination of a mutation in amiC 
2.3.4.7.1 Confirmation of amiC mutation by sequencing  
The presence/absence of a frameshift mutation in the amiC gene was determined by PCR 
amplification and sequencing using ABD233 (5’-GAATCCAAATGGCTGTAACAGGAGC-3’) and 
ABD234 (5’-AACCTATGCTAATACACCAGTTCTTCAGG-3’).  
2.3.4.7.2 Phenotypic confirmation of a mutation in the ami locus 
Mutations in the ami locus have been shown to confer resistance to aminopterin [298]. To 
phenotypically assess the presence/absence of the amiC mutation in the 23F strains (P833 
and P1123), the two strains were serially diluted on blood agar containing 2x10-6 M 
aminopterin and examined for growth, indicative of aminopterin resistance, following 
incubation.  
2.3.4.8 Pneumococcal adherence and internalization assays 
Nasopharyngeal human carcinoma epithelial cells (Detroit 562 ATCC-CCL-138) were grown 
to confluence in Eagle’s Minimal Essential Media (EMEM) supplemented with 10% foetal 
bovine serum, 2 mM L-glutamine (Sigma), 40 U/ml penicillin and 40 µg/ml streptomycin 
(Sigma). Cells were grown to confluence and then monolayers were released by incubation 
with EDTA/trypsin (Invitrogen). Cells were re-suspended in 20 ml of complete medium and 
counted on a haemocytometer. Cell cultures were seeded at 1x105 cells/ml in a 24 well 
plate.  
Confluent monolayers of Detroit 562 epithelial cells were washed three times with warmed 
PBS and then 500 µl of antibiotic free EMEM was added to each well. Bacterial suspensions 
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were added to each well at a density of 1x106 CFU for serotypes 6B and 23F and 2x106 CFU 
for strain D39. Plates were then gently shaken and 20 μl was obtained from each well for 
dilution and initial CFU quantification via M&M on blood agar plates. After allowing for 
adherence at 37°C, 5% CO2 for 3 hours, the wells were washed five times with PBS to 
remove non-adherent bacteria and cells were either lysed with 300 µl of 1% saponin 
(Sigma) for 10 minutes (for adherence) or treated with 100 µg/ml of ampicillin in EMEM (1 
ml per well) for 3 hours at 37°C, 5% CO2 before lysing (for internalization). Recovered 
bacteria were quantified by serial dilution on blood agar plates. Plates were incubated at 
37°C 5% CO2 overnight and initial and recovered CFU were counted. 
2.3.4.8.1 Epithelial cell inflammation  
For inflamed epithelium, cells were stimulated with interleukin-1β (IL-1β), tumor necrosis 
factor (TNF) and interferon gamma (IFN-γ) (50 ng/ml each) in 500 µl of complete EMEM for 
16-18 hours at 37°C 5% CO2.  Cells were then washed 3 times with warmed PBS and 500 μl 
of EMEM without antibiotics was added to each well before addition of pneumococci.  
2.3.4.8.2 Epithelial pIgR and rPAF expression by flow cytometry 
Stimulated (inflamed) and non-stimulated (non-inflamed) cells were scraped from plate 
wells after washing with warmed PBS. Tubes containing cells were centrifuged for 5 
minutes at 836 x g and cells were washed again to ensure epithelial cells were in a single 
cell suspension. Cell suspensions were incubated with platelet-activating factor receptor 
(rPAF) human monoclonal antibody (1:62.5) and polymeric immunoglobulin receptor (pIgR) 
rabbit polyclonal antibody (1:25) (Cambridge Bioscience) at 4˚C for 15 minutes. Anti-human 
PE conjugate and anti-rabbit FITC-conjugate antibodies were added for 15 minutes at 4˚C. 
Cells were washed and stored at 4˚C prior to acquisition using a BD LSR II flow cytometer. 
10,000 gated events were recorded. PE goat anti-mouse IgG2a (1:250) and FITC donkey 
anti-rabbit IgG (1:125) (Biolegend) were used as isotype controls.  
2.3.4.9 Detection and identification of URT viruses 
Oropharyngeal swabs were collected 5 days prior to intranasal inoculation and immediately 
put in viral transport medium (VTM) (MWE). Viral multiplex PCR was performed as 
described elsewhere [299,300]. Briefly, viral RNA was extracted from 200 µl of VTM and 
eluted into 85 µl buffer using the standard Pathogen Complex 200 protocol on the 
QIAsymphony (QIAGEN). The eluates were then analysed using four multiplex PCR assays 
on the LC480 real-time PCR machine (Roche Diagnostics). The assay panel covered the 
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qualitative detection of influenza A and B, RSV, human metapneumovirus, human 
rhinovirus, parainfluenza viruses 1-4, and coronaviruses OC43, NL63, 229E, HKU1. 
2.3.4.10 Levels of FH, lactoferrin, SLPI, and beta defensin 2 in nasal wash and 
anti-PspC in serum  
To measure levels of FH, 96-well plates were coated with nasal wash samples serially 
diluted in carbonate-bicarbonate buffer. Purified human FH (125 ng/ml) (Calbiochem) was 
used as a standard and plates were incubated overnight at 4°C. All plates were washed 3 
times with PBS-Tween 0.05% between each step using a microplate washer (Wellwash 4 
MK2, Thermo Scientific). Plates were blocked with PBS-1% BSA for 30 minutes before 
incubating with goat anti-FH antibodies (1:15000 dilution) (Calbiochem) for 1 hour. This 
was followed by HRP-conjugated anti-goat IgG (1:5000 dilution) (R&D Systems, Abingdon, 
UK) for 1 hour. Plates were developed with TMB Substrate Reagent Set (BD). 
Levels of lactoferrin (AssayPro), SLPI (R&D) and beta defensin 2 (Antigenix America) were 
measured by sandwich ELISAs following manufacturer’s recommendations. All plates were 
washed 3 times with PBS-Tween 0.05% between each step using the microplate washer. 
96-well plates were coated with anti-human lactoferrin (2 µg/ml) (AssayPro) or SLPI (0.5 
µg/ml) (R&D) and incubated at 4°C overnight. Plates were blocked with PBS-1% BSA before 
nasal wash samples serially diluted in PBS-0.1% BSA were added. Human lactoferrin (80 
ng/ml) (Assaypro) and recombinant human SLPI (30 ng/ml) (R&D) were used as standards. 
Plates were incubated at room temperature for 2 hours. Biotinylated rabbit anti-lactoferrin 
(2 µg/ml) or goat anti-SLPI (0.5 µg/ml) were used for detection and plates were incubated 
for 2 hours at room temperature. Streptavidin-alkaline phosphatase (1:1000) (AbD Serotec 
Ltd) was added and plates were incubated at room temperature for 1 hour prior to 
development with 0.5 mg/ml of PNPP.  
Beta defensin 2 levels were measured using the Human BD-2 Super X ELISA kit as per 
manufacturer’s instructions (Antigenix America). Briefly, neat nasal wash samples were 
added to a 96-well plate pre-coated with BD-2 capture antibody. Recombinant human BD-2 
(2 ng/ml) was used as a standard. Biotin detection antibody (0.1 µg/ml) was added to each 
well and the plate was incubated at room temperature for 1 hour. Plates were washed 4 
times with the provided wash buffer and streptavidin-HRP conjugate was added (1:1500), 
followed by incubation at room temperature for 30 minutes. Plates were developed with 
TMB Substrate solution.  
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For the FH, lactoferrin, SLPI, and BD-2 assays, absorbance was measured at 450 nm using a 
FLUOstar OMEGA plate reader (BMG Labtech).  
Levels of anti-PspC IgG were measured by ELISA using plates coated with recombinant 
purified PspC (1 µg/ml) [289]. Eight-fold serial dilutions of serum samples in 0.1% BSA were 
added and incubated for 2 hours at room temperature. PspC-specific IgG antibodies were 
detected using alkaline-phosphatase conjugated goat anti-human IgG (Sigma). 0.5 mg/ml of 
PNPP was added as a substrate and absorbance was measured at 405 nm. Anti-PspC IgG 
concentrations were calculated using a reference sera sample with a known anti-PspC 
concentration assigned in the laboratory of Prof. Helena Käyhty (National Institute for 
Health and Welfare, Helsinki, Finland). The sample concentration was calculated using the 
last dilution of the sample with OD>0.1.  
All samples were run in triplicate, and samples with a CV of greater than 15% were 
repeated. A 4-parameter fit was used to generate the standard curve.  
2.3.4.11 Depletion and purification of antibodies from nasal wash and sera 
samples 
Nasal wash samples from 10 volunteers were pooled and IgG and IgA were depleted by 
anti-human IgG and anti-human IgA agarose (Sigma-Aldrich), respectively. Samples were 
slowly added to an agarose column and then washed with 0.01 M sodium phosphate 
buffer. Flow-through fractions were used in pneumococcal adherence assays. A dot blot 
was used to confirm antibody depletion. Briefly, 4 µl of purified sample was spotted onto a 
nitrocellulose membrane (Sigma) and left to dry. The membrane was blocked by soaking in 
5% milk in tris-buffered saline with Tween20 (TBS-T) for 30 minutes at room temperature. 
Following blocking, the membrane was incubated with anti-human IgG-alkaline 
phosphatase (1:2000) or anti-human IgA-alkaline phosphatase (1:2000) and incubated for 
1.5 hours at room temperature. The membrane was washed with TBS-T for 10 minutes and 
developed with TMB substrate (BioRad).  
Serum samples from 7 volunteers were used for anti-PspC IgG purification. First, purified 
total IgG was obtained from individual samples by HiTrap protein G affinity column (GE 
Healthcare). Purified samples were then loaded in CNBr-activated Sepharose coupled with 
recombinant purified PspC. Coupling of the PspC ligand (1 mg of ligand PspC to 200 mg of 
sepharose) and anti-PspC purification was performed as per manufacturer’s instructions. 
To confirm anti-PspC IgG purification, ELISAs were performed using plates coated with PspC 
as described in section 2.3.4.10 [289].  
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2.3.4.12 FH binding and antibody binding assays  
Bacterial stocks were washed and re-suspended in PBS. For inhibition of FH binding, 107 
CFU were re-suspended in 100 μl of individual nasal wash samples, purified IgA and IgG 
samples (undiluted) or purified anti-PspC IgG (1:2 diluted) and incubated for 45 minutes at 
37°C. To evaluate the saturating concentration of FH binding and for positive control of 
inhibition of FH binding experiments, bacterial pellets were re-suspended in 100 μl of 
purified human FH (Calbiochem) (3 to 40 μg/ml) and incubated for 45 minutes at 37°C.  
Samples were washed with PBS and incubated in 100 μl of goat anti-FH (1:200) 
(Calbiochem) for 45 minutes at 37°C before wash and incubation in 100 μl of FITC-
conjugated anti-goat (1:500) (Sigma) at 4°C in the dark for 30 minutes. Samples were 
washed twice and re-suspended in 500 μl of PBS- 4% paraformaldehyde and stored at 4°C 
prior to acquisition using a BD LSR II flow cytometer. 20,000 bacterial events were acquired 
and samples were gated relative to a negative control containing no anti-FH. Anti-PspC IgG 
binding was evaluated by incubating bacterial pellets with individually purified human anti-
PspC IgG samples for 45 minutes at 37°C before detection using anti-human IgG FITC 
antibody (1:10000, Sigma). As FH binding to S. pneumoniae is often biphasic with strongly 
positive and weakly negative populations of bacteria, results are presented as fluorescence 
index (FI: percentage of positive bacteria multiplied by the geometric mean fluorescence 
index (MFI) in arbitrary units). 
2.3.4.13 Anti-PspC antibody epitope mapping 
Overlapping peptide arrays containing 15-mer peptides with a frameshift of four residues 
corresponding to the amino acid sequence of PspC3 (GenBank accession no EF424119) 
were synthesized in a slide support (CelluSpots, Intavis). Peptide arrays were incubated 
individually with 29 sera samples collected from 18 volunteers inoculated with 
pneumococcus or from mice immunized with 3 doses of 5 µg of PspC3 containing 50 µg of 
Alum as previously described [301]. Concentration of pneumococcal specific antibodies was 
standardized so that each sample used for incubation contained 10 μg/mL of PspC IgG. 
Detection was performed using alkaline phosphatase conjugated anti-mouse IgG and anti-
human IgG (Sigma). MTT 0.12M (Methylthiazolyldiphenyl-tetrazolium bromide), BCIP 
0.16M (5- Bromo-4-chloro-3-indolyl phosphate) and MgCl2 1M in citrate-buffered saline pH 
7.0 was used for development.  
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2.3.5 Mouse model of colonization 
All animal experiments were completed by Ankur B. Dalia at Tufts University in Boston, 
Massachusetts and were done in accordance with NIH guidelines, the Animal Welfare Act 
and US federal law. Tufts University School of Medicine’s Institutional Animal Care and Use 
Committee approved the experimental protocol "B2011-57" that was used for this study. 
All animals were housed in a centralized and AAALAC-accredited research animal facility 
that is fully staffed with trained husbandry, technical and veterinary personnel.  
Bacterial cultures were grown in THY broth to an OD600 of ~0.6 and then washed and 
concentrated in PBS. 107 bacteria in 10 µl were intranasally inoculated into both nares of 
anesthetized (isoflurane) 4-6 week old Swiss Webster mice. Five days post-inoculation, 
mice were euthanized, the trachea cannulated, and 500 µl of PBS instilled. Nasal wash was 
collected and plated for quantitative culture.  The lower limit for detection in these assays 
was 10 CFUs.  
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Chapter 3 
 
 
 
 
 
 
Dose-dependency and reproducibility of an experimental human 
pneumococcal carriage model 
3.1 Introduction 
Numerous studies have examined natural pneumococcal carriage and it is well known that 
rates vary by age and geographic area [5]. Limited data exist on the immune response to 
carriage because it is difficult to capture an entire carriage episode in nature. Previous 
EHPC studies have found an association between humoral responses and carriage 
[161,279] and shown that pneumococcal exposure without carriage immunizes mucosal 
surfaces [281]. 
In order to further examine both mucosal and systemic immunity in the upper and lower 
airway, we designed a human model of experimental pneumococcal carriage. Such a model 
could be used as an immunological probe of carriage, as a live mucosal vaccine model, and 
as a surrogate of protection for testing novel pneumococcal vaccines.  
To develop a standardized, reproducible model of carriage, we aimed to construct a dose-
response curve using pneumococcal serotypes 6B and 23F. We predicted that carriage 
rates of 50% or greater would allow the model to have high sensitivity for vaccine efficacy 
with small study numbers. To ensure the dose and the model were reproducible, a target 
carriage rate and dose were chosen based on the dose-response curve and tested in an 
independent group of volunteers. To investigate whether experimental carriage was 
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symptomatic, a control group of volunteers were challenged with 0.9% saline; volunteers 
from all groups were asked to report symptoms.  
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3.2 Materials and methods 
3.2.1 Recruitment  
Inclusion and exclusion recruitment criteria can be found in Chapter 2, section 2.2.1. The 
Patient Information Sheet is in Appendix B and the consent form is in Appendix C.  
3.2.1.1 Dose-Ranging study 
We planned to recruit 120 healthy adult volunteers; 60 for challenge with the 6B strain and 
60 with the 23F. For each serotype, the volunteers were subdivided into six groups of 10 
and each group was challenged with 0.1 ml of pneumococcus per nostril at an increasing 
dose.  
The targeted challenge dose for the initial 10 volunteers was 1x104 CFU/naris and this 
doubled for the following groups: 2x104, 4x104, 8x104, 1.6x105, and 3.2x105.  
3.2.1.2 Reproducibility study 
We recruited 24 volunteers to determine the reproducibility of the model (Reproducibility 
study). The inoculation dose was chosen based on the results of the Dose-Ranging study 
with the target set as the dose at which 50% carriage was achieved.   
3.2.2 Study schedules 
Study schedules are described in Chapter 2, section 2.2.2.  
3.2.3 Nasopharyngeal inoculation  
Preparation of the inoculum stock and determination of dose can be found in Chapter 2, 
sections 2.3.2.1 and 2.3.2.4. The inoculation method is described in Chapter 2, section 
2.3.2.6.  
3.2.4 Detection of carriage rate and density of carriage 
Nasal wash samples were collected and processed as described in Chapter 2, sections 
2.3.2.7 and 2.3.2.8. Detection of pneumococcal carriage by culture and measurement of 
carriage density were performed as described in Chapter 2, sections 2.3.3.1 and 2.3.3.2, 
respectively.  
3.2.5 Safety and symptoms 
Details on volunteer safety are given in Chapter 2, section 2.2.3. Details on symptom 
reporting are given in Chapter 2, section 2.2.4.  
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3.2.6 Microarray  
The microarray method and analysis was performed as described in Chapter 2, section 
2.3.4.1.  
3.2.7 Statistical analysis 
The Fisher’s exact test was used to analyse colonization rates, and both passive and active 
symptom complaints. Differences in 6B colonization density were analysed using a one-way 
ANOVA with Bonferroni's post-test. A Kaplan-Meier curve was generated for time to 
carriage clearance. Graph and statistical analysis was performed using GraphPad prism 
version 5.0 (California, USA). All P values were two-tailed and considered significant if 
P≤0.05.  
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3.3 Results 
3.3.1 Dose-Ranging study 
We recruited and challenged 120 volunteers. Sixty were challenged with a serotype 6B 
strain and 60 with a serotype 23F strain, according to protocol, with minimal adverse 
effects. The average age of the volunteers challenged with 6B (23.1 ±5.9 years) was similar 
to those challenged with 23F (21.4 ±3.9 years) as was the male:female ratio in each group 
(6B 28:32; 23F 27:33).  
During the initial screening process, 11% (18/157) of volunteers were natural carriers; 10 
during screening for 6B challenge, 7 during screening for 23F challenge, and 1 during 
screening for mock challenge.  
3.3.1.1 Inoculation doses were within the targeted range 
Inoculation doses complied with protocol if they fell within a halving or a doubling of the 
target amount; all inoculation doses were within the targeted range (Table 3.1). The 
average inoculation dose per group can be seen in Table 3.1. When the doses were 
compared across the two serotypes, only the 4x104 (P<0.0001) dose and the 1.6x105 
(P=0.0002) dose were significantly different.   
 
Table 3.1 Average inoculation dose per group for both serotype 6B and 23F 
Dose Group  
(CFU/naris) 
Serotype 6B  
Average Dose (± SD) 
Serotype 23F  
Average Dose (± SD) 
1x104 10,650  ± 704 10,127  ± 196 
2x104 23,433  ± 3,637 21,184  ± 1,671 
4x104 53,042  ± 3,266 37,167  ± 8,886 
8x104 89,833  ± 10,603 86,567  ± 3,298 
1.6x105 133,266  ± 3,492 150,000  ± 6,286 
3.2x105 312,500  ± 13,106 309,166  ± 31,193 
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3.3.1.2 Serotype 6B was more successful at establishing carriage 
Serotypes 6B and 23F had significantly different rates of colonization, regardless of dose 
(P<0.0001, Fisher’s exact test) (Figure 3.1). From the 4x104 dose onwards, percent 
colonization for those challenged with 6B was greater than 50%. Colonization with 23F 
never rose above 10% and was not detected at the 1x104, 1.6x105, or 3.2x105 doses.  
For serotype 6B at least one volunteer was carriage positive at every dose and the carriage 
rate was dose-dependent (Figure 3.1). Of the 6B carriage positive volunteers, 70% (19/27) 
remained carriage positive for more than two weeks.  
 
 
Figure 3.1: Experimental Human Pneumococcal Carriage Dose-Ranging curve. Groups of 
10 volunteers were intranasally inoculated with either serotype 6B (circle) or 23F (square) 
over a range of six doses, starting with 1x104 CFU per nostril and doubling up to 3.2x105. 
Percent colonization represents the number of volunteers in the group positive for 
pneumococcal carriage at any time point following inoculation. A P value ≤0.05 was 
considered significant using a Fisher’s exact test on overall carriage rates. 
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3.3.1.3 Carriage density was not a function of inoculation dose 
Since an inoculation dose above 4x104 did not significantly alter the carriage rate, we 
measured carriage density to determine if it would increase in parallel with the increasing 
inoculation dose. There was no significant difference in density of 6B colonization at any 
time point for doses over 4x104 (P>0.05 1-way ANOVA) (Figure 3.2). Carriage density 
remained stable over the two week sampling period. Density of 23F colonization could not 
be analysed due to the low rates of carriage. Similarly, the 6B 1x104 and 2x104 doses were 
removed from analysis because of the low colonization numbers.  
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Figure 3.2: Density of carriage is not a function of inoculated dose and shows stability 
over time. Nasal washes were performed on day 2 (A, B), day 7 (C, D) and day 14 (E, F) 
post-inoculation to determine carriage status and density. Nasal wash was serially diluted 
and pneumococcal colonies were quantified on blood agar. Density is reported as CFU/ml 
of nasal wash returned. Data bars represent the mean ± SD.  A P value ≤0.05 was 
considered significant using a one-way ANOVA test with Bonferroni’s post-test to compare 
the 6B doses above 4x104. 
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3.3.2 Reproducibility study 
Due to the lack of carriage with serotype 23F in the Dose-Ranging study, we did not move 
forward with it in the model.  
Since the carriage rates for serotype 6B at the 4x104, 8x104, 1.6x105 and 3.2x105 doses were 
not significantly different, we could have chosen any of these four to test the 
reproducibility of the model. The 8x104 dose was chosen because it resulted in 50% 
carriage and meant that if the dose was halved or doubled, a similar carriage rate would 
still be achieved (Figure 3.1).  
Twenty-four volunteers were challenged with serotype 6B. The average age of the 
volunteers was 22.3 ±2.9 years and the male:female ratio was 9:15. During the initial 
screening process, one natural carrier was detected and was followed in parallel with the 
challenged cohort.  
3.3.2.1 The model was reproducible above a dose of 4x104 CFU/naris 
The average inoculation dose with serotype 6B in the Reproducibility study was 61,944 
±4603 CFU/naris. Following challenge, 42% (10/24) of volunteers were carriage positive by 
microbiological culture. 
To determine if the model was reproducible, a confidence interval for the mean carriage 
rate of the model was determined. By allowing the assumption of no difference in carriage 
rate above the 4x104 dose in the Dose-Ranging study, we combined the carriage rates from 
those four doses with the carriage rate from the Reproducibility study. The mean carriage 
rate of the model was 52% with a 95% confidence interval of 40-64%.  
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3.3.2.2 Carriage density was stable up to one month post-challenge 
Carriage density remained stable over time (P=0.8, one-way ANOVA) at an average of 100 
CFU/ml (Figure 3.3), similar to the Dose-Ranging study. 
 
 
Figure 3.3: Density of carriage, when present, is stable up to one month post-challenge. 
Nasal washes were taken on day 2 post-inoculation and then weekly up to day 35 to 
determine carriage status and density. Nasal wash was serially diluted and pneumococcal 
colonies were quantified on blood agar. Density is reported as of CFU/ml of nasal wash 
returned. Data bars represent the mean ± SD. A P value ≤0.05 was considered significant 
using a one-way ANOVA test to compare density at days 2 to 28. All volunteers took 
antibiotics after day 28 except one. 
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3.3.2.3 Half of all carriers had cleared carriage one month after challenge 
Carriage clearance was considered the first negative nasal wash after which all successive 
washes were negative. Median carriage duration by Kaplan-Meier analysis was 31.5 days 
(Figure 3.4). By day 14, 20% (2/10) of carriage positive volunteers had cleared carriage; by 
day 28, 50% had cleared carriage (5/10). All volunteers still positive at day 28 were required 
to take 500 mg of amoxicillin for 3 days to clear carriage however, one volunteer did not 
take antibiotics until after the day 35 nasal wash; this volunteer was the only carrier at day 
35 (Figure 3.4).  
  
 
Figure 3.4: Kaplan-Meier survival curve for time to carriage clearance. Carriage clearance 
was considered the first negative nasal wash after which all successive washes were 
negative. One volunteer was still a carrier at the final appointment (day 35). All other 
volunteers took antibiotics to clear carriage after day 28. The 95% confidence interval is 
represented by the dotted lines.  
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3.3.2.4 Detection of potential co-colonization  
One volunteer was carriage negative by culture prior to inoculation and was subsequently 
challenged with serotype 6B. At days 2, 7, 14, and 28, serotype 6 was not detected by latex 
agglutination but the volunteer was carriage positive for serogroup 9. 
 To determine if co-colonization was being missed by culture and latex agglutination, 
microarray was performed using the pre-screen and days 2, 7, and 14 nasal wash bacterial 
pellets. Serotype 6B was not detected at any time point; serotype 9N was detected at days 
2, 7 and 14 but not at the pre-inoculation screen (Table 3.2).  
 
Table 3.2 Determination of serotype in a natural carrier challenged with serotype 6B 
Visit Serotype detected by 
culture (latex agglutination) 
Pneumococcal serotypes 
detected by microarray 
Pre-inoculation none none 
Day 2 9 9N  
Day 7 9 9N  
Day 14 9 9N  
 
 
3.3.3 Experimental carriage was not symptomatic 
3.3.3.1 Passive symptom detection 
90 volunteers were asked by the clinical team at each appointment if they had experienced 
any URT symptoms in the preceding days. 22.2% (20/90) of volunteers reported symptoms. 
Of these 20 volunteers, 25% were carriers (5/20) (Table 3.3). All five symptomatic carriers 
had been challenged with 6B and symptoms were not related to a specific dose (one at 
1x104, two at 8x104, two at 1.6x105). None of the 23F carriers complained of symptoms. 
Because the number of carriers complaining of symptoms was too small for individual 
serotype analysis, we compared the presence of symptoms between carriers (5/24) and 
non-carriers (15/66), regardless of serotype, and found no significant difference (P=0.99).   
Investigations were undertaken for any reported systemic symptoms, including fever. Of 
the three 6B carriage positive volunteers that reported systemic symptoms, none showed 
evidence of pneumococcal disease. One volunteer had symptoms consistent with 
concurrent viral infection. Another volunteer complained of gastric pain on deep 
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inspiration and, after meeting with the study doctor and undergoing multiple 
investigations, was advised to take antibiotics. The third volunteer was diagnosed clinically 
with tonsillitis. All volunteers had rapid resolution of symptoms.  
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3.3.3.2 Active symptom detection 
To further analyse if symptoms related to challenge or carriage, 10 volunteers were 
challenged with sterile saline and completed a symptom log on the day of challenge and for 
7 days post-challenge. For comparison, volunteers from the Dose-Ranging 6B 3.2x105 group 
and the Dose-Ranging 23F 1.6x105 and 3.2x105 groups, as well as volunteers from the 
Reproducibility study (8x104), filled out the daily symptom log.   
The average age of the saline control group was 23.1 ± 9.1 years and the male:female ratio 
was 5:5. Fifty-four volunteers completed the daily symptom log; 8 challenged with saline, 
17 with serotype 23F, and 29 with serotype 6B. Of the 17 volunteers challenged with 
serotype 23F, 9 were from the 1.6x105 dose group and 8 from the 3.2x105 dose group. Of 
the 29 volunteers challenged with serotype 6B, 10 were from the 3.2x105 dose group and 
19 were challenged with 8x104 as part of the Reproducibility study. None of the volunteers 
challenged with 23F were carriage positive; 14 challenged with 6B were carriage positive. 
3.3.3.2.1 Non-nasal symptoms 
There were five categories related to non-nasal symptoms: eyes, throat, cough, ears, and 
headache. The score awarded at inoculation (day 0) was considered the volunteer’s 
baseline score. At any point in the following seven days, if the score went above the 
baseline, the volunteer was considered symptomatic. Due to the small number of 
volunteers in each group, scores for the five categories were combined for an overall non-
nasal symptom score.  
Overall, 55.5% (30/54) of volunteers reported non-nasal symptoms. Of these, 11.1% (6/54) 
were challenged with saline, 16.7% (9/54) with 23F, and 27.8% (15/54) with 6B. To examine 
if challenge without carriage was symptomatic, we compared the saline challenge group 
with the two 23F challenge groups. 75% (6/8) of saline challenged volunteers were 
symptomatic, compared to 66.7% (6/9) of 23F 1.6x105 (P=0.99) and 37.5% (3/8) of 23F 
3.2x105 (P=0.31) (Figure 3.5A). There was no significant difference between the saline 
challenge group and the pneumococcal challenge groups. 
To determine if carriage was symptomatic, we compared the 6B carriers and non-carriers. 
57% (8/14) of carriers were symptomatic; 83.3% (5/6) were challenged with 3.2x105 and 
37.5% (3/8) with 8x104 (Figure 3.5B). 46.7% (7/15) of non-carriers were symptomatic. There 
was a significant difference in the report of non-nasal symptoms between carriers and non-
carriers in the 3.2x105 group (P=0.048) but not the 8x104 group (P=0.37).  
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There were only four complaints that scored higher than 5 or “moderately bothersome”: 
one from a volunteer in the saline challenge group that complained of a cough; one from a 
carriage positive volunteer in the 6B 3.2x105 dose group that had a sore throat; and two 
from carriage negative volunteers: one in the 6B 8x104 dose group complained of ear 
symptoms and one in the 23F 1.6x105 dose group complained of a headache.  
3.3.3.2.1 Nasal symptoms 
There were five categories related to local (nasal) symptoms: sneezing, runny nose, 
congestion/stuffiness, itchy nose and post nasal drip. As with the non-nasal symptoms, the 
score awarded at inoculation (day 0) was considered the volunteer’s baseline score. At any 
point in the following seven days, if the score went above the baseline, the volunteer was 
considered symptomatic. Due to the small number of volunteers in each group, scores for 
the five categories were combined for an overall nasal symptom score.  
In total, 61.1% (33/54) of volunteers complained of nasal symptoms. Of these, 11.1% (6/54) 
were challenged with saline, 16.7% (9/54) with 23F, and 33.3% (18/54) with 6B. To examine 
if challenge without carriage was symptomatic, we again compared the saline challenge 
group with the two 23F challenge groups. 75% (6/8) of saline challenged volunteers were 
symptomatic, compared to 44.4% (4/9) of 23F 1.6x105 (P=0.33) and 62.5% (5/8) of 23F 
3.2x105 (P=0.99) (Figure 3.5A). There was no significant difference between the saline 
challenge group and the pneumococcal challenge groups in the presence of nasal 
symptoms following inoculation. 
To determine if carriage resulted in nasal symptoms, we compared the 6B carriers and non-
carriers. 78.6% (11/14) of 6B carriers were symptomatic with 83.3% (5/6) challenged with 
3.2x105 and 75% (6/8) with 8x104 (Figure 3.5B). Just as in the non-nasal symptoms analysis, 
46.7% (7/15) of non-carriers were symptomatic. There was no significant difference in the 
report of nasal symptoms between carriers and non-carriers in the 3.2x105 group (P=0.19) 
or the 8x104 group (P=0.63).  
There were also no 6B carriage positive or saline challenged volunteers that scored any 
nasal symptoms higher than 4 or “mild” but for carriage negatives, there were a number of 
symptoms scored higher than 5. From the 6B 8x104 dose group, there was one complaint of 
congestion and one of an itchy nose. From the 23F 1.6x105 dose group there were eight 
nasal symptom complaints scored higher than 5: 1 sneezing, 2 runny nose, 2 congestion, 1 
itchy nose, and 2 postnasal drip. 
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Figure 3.5: Percentage of volunteers with actively reported symptoms. Volunteers filled 
out a daily symptom log on the day of challenge and for 7 days post-challenge. The score at 
inoculation was considered the baseline score. At any point in the seven days, if the score 
went above baseline, the volunteer was considered symptomatic. (A) Volunteers 
challenged with saline were compared to carriage negative volunteers challenged with 23F. 
There was no significant difference between the saline challenge group and the 
pneumococcal challenge groups in the presence of non-nasal or nasal symptoms. (B) 
Symptom complaints were compared between the 6B carriage positives and carriage 
negatives. There was a significant difference in non-nasal symptoms between carriers and 
non-carriers in the 3.2x105 group but not the 8x104 group. There was no significant 
difference in nasal symptoms. A P value ≤0.05 was considered significant using a Fisher’s 
exact test. *denotes significance.  
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3.4 Discussion 
We determined an appropriate inoculation dose to achieve 50% carriage, tested the 
reproducibility of the model at the chosen dose, and compared the presence of symptoms 
following experimental challenge in carriers, non-carriers, and saline challenged volunteers.   
3.4.1 Dose-dependent establishment of carriage 
We have developed a model of experimental human pneumococcal carriage. For serotype 
6B, carriage establishment was dose-dependent until 4x104 CFU/naris, after which carriage 
rates stabilized around 50%. Carriage rates for serotype 23F remained at or below 10%, 
regardless of dose.  
The first human carriage studies in the USA used a range of doses for challenge with 6B – 
4.4x104 to 7.8x104 CFU – with a carriage rate of 75% (6/8) [161,279]. These doses and the 
carriage rate were similar to what we found: 60% (6/10) carriage at 4x104 CFU and 50% 
carriage (5/10) at 8x104 CFU; however the 6B strains were not the same. Three doses were 
used for challenge with 23F in the USA studies: 5x103, 7x103, or 1.7x104 with carriage rates 
of 0% (0/4), 50% (3/6) and 75% (3/4), respectively. In comparison, the carriage rate in this 
study at a similar dose (2x104) was only 10% (1/10). This was surprising as the 23F strain 
used here was given to us by the group that performed the USA study and was therefore 
thought to be the same. The different carriage rates of 6B and 23F were unexpected and 
are investigated further in Chapter 5.  
3.4.2 Experimental carriage was reproducible 
We hypothesized that carriage rates would increase in a linear fashion along with dose. 
However, carriage rates actually plateaued after 4x104 CFU/naris. Based on these results, 
we chose 8x104 CFU/naris as the challenge dose for the Reproducibility study because it 
resulted in a 50% carriage rate and if the desired dose was halved or doubled, the carriage 
rate would remain around 50%.  
At an average dose of 61,944 (±4603) CFU/naris, 42% (10/24) of volunteers became 
colonized. We demonstrated that experimental carriage was reproducible with a mean 
carriage rate of 52% and a 95% confidence interval of 40-64%. To calculate the mean 
carriage rate, we combined the overall carriage rate from the four doses above 4x104 in the 
Dose-Ranging study (23/40) with the carriage rate from the Reproducibility study (10/24). 
We pooled the carriage rates of the four doses from the Dose-Ranging study because they 
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were not significantly different above 4x104 and combined this with the Reproducibility 
study carriage rate because the dose was chosen based on the Dose-Ranging results.  
3.4.2.1 Detecting potential pneumococcal co-colonization 
A volunteer that was carriage negative at the pre-screen appointment was challenged with 
serotype 6B. At 2 days post-challenge serogroup 9 was detected but not serogroup 6. 
Microarray was used to determine if co-colonization with both serogroups was being 
missed by culture. Serotype 9N was not detected in the pre-screen sample but was 
detected at days 2, 7 and 14. Serotype 6B was not detected at any time point. It is not 
possible to determine if serotype 9N was acquired before challenge or between challenge 
and the day 2 nasal wash however, it is important to know that the culture results matched 
the microarray results. 
If serotype 9N was present when the volunteer was challenged with serotype 6B, it is 
possible that the 9N outcompeted 6B. Competition between pneumococcal strains has 
been suggested to be behind the increase in non-vaccine serotypes following vaccination 
and competition experiments in a mouse model of carriage have shown that carriage of 
one strain can reduce colonization by a second strain [303]. Dawid et al. [212] have 
demonstrated that bacteriocins, specifically the blpMN operon, may be the mechanism 
behind intraspecies competition.  
3.4.3 Experimental carriage was not symptomatic 
Symptom reporting was split into two groups, passive and active. For passive symptom 
detection, volunteers reported any symptoms directly to the clinical team at each 
appointment. To address whether carriage was symptomatic, we combined all carriers and 
non-carriers, regardless of serotype, because the numbers were too low for individual 
serotype analysis. In this group, symptoms did not correlate with carriage.  
For all symptoms combined, 6B 1x104 was the only dosing group in which more carriage 
positive than carriage negative volunteers reported symptoms. Across all dosing groups 
and both serotypes, an equal number of carriage positive and carriage negative volunteers 
complained of systemic symptoms. For local symptoms, there was also an equal number of 
complaints from carriage positive and negative volunteers challenged with 6B. However, 
this was not the case following challenge with 23F; eight carriage negative volunteers 
complained of local symptoms as compared to zero carriage positive volunteers.  
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For active symptom detection, volunteers completed a daily symptom log. Using these 
scores, we first evaluated whether challenge without carriage was symptomatic. For both 
non-nasal and nasal symptoms, there was no difference in symptoms between volunteers 
challenged with saline and volunteers challenged with serotype 23F. Next, we examined if 
carriage was symptomatic. Carriage was not associated with increased nasal symptoms but 
was associated with increased non-nasal symptoms in the 6B 3.2x105 group. No 23F 
carriers completed a daily symptom log so we could not compare nasal symptoms between 
carriers of the two serotypes however, the percentage of 23F non-carrier volunteers 
complaining of nasal symptoms (53%) was higher than the 6B challenged non-carriers 
(46%).  
The percentage of volunteers that complained of symptoms following challenge with saline 
was similar to those challenged with pneumococci. The volume of saline inoculated is very 
small and unlikely to cause symptoms, therefore it is possible that challenge itself has a 
psychological effect whereby the idea of being colonized leads to symptoms.  
The observation that 23F carriage negative volunteers complained more often of local or 
nasal symptoms in both passive and active detection, respectively, is not surprising given 
that Wright et al. [281] demonstrated that experimental challenge with serotype 23F was 
immunizing in the absence of carriage. Although the number of volunteers analysed was 
small, this suggests that nasal symptoms following challenge with serotype 23F may be 
related to carriage clearance, not carriage establishment. Challenge with a different 
serotype 23F strain as well as other serotypes, such as serotype 3 which has a very thick 
capsule, could inform on whether serotype plays a role in symptoms related to carriage 
clearance, rather than carriage establishment.  
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Chapter 4 
 
 
 
 
 
 
The protective effect of a carriage episode on subsequent 
experimental carriage  
4.1 Introduction 
In the majority of the population, pneumococcal carriage generates an immune response 
that prevents disease and leads to carriage clearance. In infants and adults, carriage leads 
to an increase in both anticapsular and antiprotein antibody levels in serum [137,161,162], 
which are associated with a reduction in natural carriage.  
Direct re-challenge to understand how a primary carriage episode affects reacquisition of 
the same or a different serotype is difficult to study in nature because sampling is 
intermittent, meaning carriage episodes can be misclassified or missed completely. In mice, 
prior colonization has been shown to result in cross-serotype protection against 
subsequent carriage and invasive disease [159].  
We attempted direct re-challenge using the experimental human pneumococcal carriage 
model. To determine within-serotype protection from carriage, a subset of volunteers that 
had been successfully colonized with serotype 6B were re-challenged with the same 
serotype 6B strain. To examine cross-serotype protection from carriage, volunteers in 
whom we had detected natural pneumococcal carriage at an initial visit were challenged 
with serotype 6B once natural carriage had cleared.  
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4.2 Materials and methods 
4.2.1 Recruitment 
Inclusion and exclusion recruitment criteria can be found in Chapter 2, section 2.2.1. The 
Patient Information sheet is in Appendix B and the consent form is in Appendix C.  
4.2.1.1 Homologous re-challenge 
Up to 11 months following initial nasopharyngeal challenge, a subset of successfully 
colonized volunteers from pilot studies 6 or 7 (described in Chapter 2, section 2.1) and the 
Dose-Ranging study (Chapter 3) were recruited for re-challenge with the homologous 6B 
serotype. The target dose was 4x104 CFU/naris.  
4.2.1.2 Heterologous challenge 
Up to 15 months following a natural carriage episode with a strain different from the 6B 
challenge strain, volunteers were re-recruited for heterologous challenge with serotype 6B 
at a dose of 4x104 CFU/naris.  
4.2.2 Study schedules 
Study schedules can be found in Chapter 2, section 2.2.2 and section 2.2.2.3.  
4.2.3 Nasopharyngeal inoculation 
Preparation of the inoculum stock and determination of dose can be found in Chapter 2, 
sections 2.3.2.1 and 2.3.2.4. The inoculation method is described in Chapter 2, section 
2.3.2.6.  
4.2.4 Detection of carriage 
Nasal wash samples were collected and processed as described in Chapter 2, sections 
2.3.2.7 and 2.3.2.8, respectively. Detection of pneumococcal carriage by culture and 
measurement of carriage density were performed as described in Chapter 2, sections 
2.3.3.1 and 2.3.3.2, respectively.  
4.2.5 Statistical analysis 
Protection against reacquisition of carriage was analysed using the Fisher’s exact test. A 
one-way ANOVA with Bonferroni's post-test was used to examine carriage density over 
time. The Mann Whitney test was used to compare the carriage density between two 
carriage episodes and compare two inoculation doses. Graph and statistical analysis was 
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performed using GraphPad prism version 5.0 (California, USA). All P values were two-tailed 
and considered significant if P ≤0.05.  
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4.3 Results 
4.3.1 Re-challenge with the homologous serotype 6B was protective 
against reacquisition of carriage 
Ten volunteers that had previously been carriage positive for serotype 6B were re-
challenged, four from previous pilot studies and six from the Dose-Ranging study. The 
average age of the volunteers was 23.1 ± 3.1 years and the male:female ratio was 4:6 
(Table 4.1). 
 
Table 4.1 Details of volunteers re-challenged with serotype 6B 
Volunteer Age  
 (± SD) 
Gender Study Dose  
(CFU/100 µl) 
Interval* 
(weeks) 
1 21 Female Pilot 6 35,167 32 
2 21 Male Pilot 6 23,400 43 
3 19 Male Pilot 6 29,500 48 
4 23 Female Pilot 7 37,166 31 
5 21 Female Dose-Ranging 37,000 15 
6 26 Female Dose-Ranging 37,000 17 
7 21 Female Dose-Ranging 37,000 18 
8 25 Male Dose-Ranging 39,500 18 
9 25 Female Dose-Ranging 39,500 16 
10 29 Male Dose-Ranging 39,500 18 
 23.1 ± 3.1 M:F 4:6  35,473 ± 5,164  
* Interval time (weeks) between initial carriage episode and re-challenge 
Values are mean ± SD 
 
Volunteers were re-challenged with the same 6B strain that was used for the initial 
challenge at an average inoculation dose of 35,473 (±5,164) CFU/naris. None of the 
challenged volunteers became colonized (0% carriage rate). A previous carriage episode 
significantly protected against reacquisition of carriage of the same strain (P=0.01, Fisher’s 
exact test). 
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4.3.2 Challenge with a heterologous serotype was not protective 
against reacquisition of carriage 
Eight volunteers in whom we had detected natural pneumococcal carriage returned 
between 38 and 67 weeks after the natural carriage episode to be challenged with serotype 
6B. The average age of the volunteers was 26.8 ± 13.6 years and the male:female ratio was 
4:4 and the average inoculation dose was 35,375 (±2,651) CFU/naris (Table 4.2).  
 50% (4/8) of the volunteers became colonized with 6B. Serotypes carried at the initial 
screening appointment included: 3 (x3), 6, 15, 19, and 33 (x2) (Table 4.2). Of the carriage 
negative volunteers, one had previously carried a serogroup 6 strain, while the other three 
had carried a serotype 3 (x2) or 33. In this cohort, a previous carriage episode was not 
protective against reacquisition of carriage of a heterologous strain (P=0.08, Fisher’s exact 
test). 
 
Table 4.2 Reacquisition of carriage following heterologous experimental challenge 
Volunteer Age  
(± SD) 
Gender Dose  
(± SD) 
Interval* 
(weeks) 
Serotype at 
initial screen 
Experimental 
Carriage  
 
1 21 Male 41,667 44 3 Yes 
2 19 Female 34,000 61 15 Yes 
3 22 Female 34,000 46 19 Yes 
4 22 Male 34,000 67 33 Yes 
5 20 Female 34,000 53 3 No 
6 20 Male 35,667 53 3 No 
7 59 Male 34,000 60 6 No 
8 31 Female 35,667 38 33 No 
 26.8  
± 13.6 
M:F 4:4 35,375  
± 2,651 
   
* Interval time (weeks) between initial carriage episode and re-challenge.  
 
 
 
 Protective effect of a carriage episode on subsequent carriage 
95 
 
 
4.3.3 Carriage density following experimental challenge was similar 
to density following a recent natural carriage episode   
Although we do not know if we captured natural carriage at the beginning, middle, or end 
of the episode, we wanted to determine if natural carriage density was similar to 
experimental carriage density. We compared the natural carriage density from two 
volunteers at three time points with the experimental carriage density from the same 
volunteers at three time points post-challenge. There was no significant difference in 
density between the two carriage episodes (P=0.9, Mann Whitney test) (Figure 4.1).  
 
 
Figure 4.1: Carriage density is similar between natural carriage and experimental 
carriage. Carriage density from two volunteers was determined at three visits during 
natural carriage and compared to the density from the same volunteers at three visits after 
experimental challenge. Nasal washes were taken to determine carriage status and density. 
Nasal wash was serially diluted and pneumococcal colonies were quantified on blood agar. 
Density is reported as CFU/ml of nasal wash returned. Closed circles represent natural 
carriage density; closed squares represent experimental carriage density. 
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As there was no difference in overall density between two carriage episodes, we wanted to 
determine if a recent natural carriage episode would decrease carriage density during an 
experimental carriage episode. There was not enough density data from the recent natural 
carriage episodes to do this directly, so we compared carriage density over time from the 
Reproducibility study volunteers (Chapter 3, section 3.3.2.2) - considered the primary 
carriage episode - with the experimental carriage density from the recent natural carriers 
that were carriage positive following pneumococcal challenge- considered a secondary 
carriage episode (Figure 4.2). Although the inoculation dose between the two groups was 
different (61,944±4603 vs. 35,375±2651, P<0.0001, Mann Whitney test) there was no 
difference in density at any time point (P=0.7, one-way ANOVA). 
 
 
Figure 4.2: Carriage density is similar between an initial experimental carriage episode 
and an experimental carriage episode following recent natural carriage. Nasal washes 
were taken at days 2, 7 and 14 post-challenge to determine carriage status and density. 
Nasal wash was serially diluted and pneumococcal colonies were quantified on blood agar. 
Density is reported as CFU/ml of nasal wash returned. Closed circles represent carriage 
density from an initial experimental carriage episode; open circles represent carriage 
density during experimental carriage following a recent natural carriage episode. Data bars 
represent the mean ± SD. A P value ≤0.05 was considered significant using a one-way 
ANOVA with Bonferroni’s post-test. 
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4.4 Discussion 
We determined the protective effect of a carriage episode on subsequent carriage. 
4.4.1 Carriage was protective against reacquisition of the same 
serotype 
We showed that a single carriage episode is protective against subsequent carriage of the 
same serotype. None of the volunteers that were re-challenged with serotype 6B up to 48 
weeks after an initial carriage episode with 6B were re-colonized (0% carriage rate). In 
comparison, the carriage rate at the same dose in the Dose-Ranging study was 60%.  
Protection against carriage reacquisition has been shown in Bangladeshi infants that were 
followed for 1 year after birth. In these infants, prior carriage was associated with serotype-
independent protection against reacquisition of serotypes 6A, 6B, 15B and C, and 19F 
[307]. In a cohort of Israeli children aged 1-5 years, prior colonization with serotypes 6A, 
14, and 23F was associated with a lower risk of reacquisition of the homologous type [308]. 
In these children, protection against serotypes 14 and 23F was correlated with increased 
serotype-specific antibodies. The difference in protective mechanisms between these two 
populations is likely related to the age of the children; the immune system of the 
Bangladeshi infants has not matured enough to generate serotype-specific antibodies.  
4.4.2 Carriage was not protective against acquisition of a different 
serotype 
Only 50% of volunteers that had cleared natural carriage and were subsequently 
challenged with 6B became colonized. Two of the volunteers that carried serotypes 3 and 
33, respectively, in the recent natural carriage episode were protected against carriage 
following challenge. However, another two volunteers also initially carrying these 2 
serotypes became colonized with 6B following challenge.  
Cross-protective immunity has been shown within serogroup but not across serotype. 
Vaccination with PCV13, which contains serotypes 6A and 6B, induced functional antibody 
responses to 6C and showed cross-protection between serotypes 7A and 7F [310]. 
Intranasal immunization of mice with a live attenuated pneumococcal strain containing a 
capsular polysaccharide mutation protected against subsequent challenge with a different 
strain [158]. Although capsular serotypes do not elicit cross-protection, pneumococcal 
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proteins such as PspA do. Serum from humans immunized with recombinant PspA has been 
shown to protect mice against infection with three different serotypes [311].  
4.4.3 Previous carriage was not associated with reduced density of 
subsequent carriage  
Not only has previous carriage been shown to impact reacquisition, it has also been shown 
to alter carriage duration. A longitudinal carriage study of infants in rural Northwestern 
Thailand found that colonization with serotype 14 or 19F was associated with reduced 
duration of subsequent carriage episodes with the same serotype [312]. We have not yet 
evaluated the impact of a primary carriage episode on the duration of subsequent carriage 
in healthy adults; however we have looked at its impact on carriage density. There was no 
difference in carriage density between a recent natural carriage episode and an 
experimental carriage episode.  
We showed in Chapter 3 (section 3.3.1.3) that carriage density was not a function of 
inoculation dose so to examine density over time we compared carriage density from the 
Reproducibility study volunteers with carriage density from the volunteers that had cleared 
natural carriage and were experimentally colonized. Again, there was no difference in 
carriage density. One of the issues in comparing natural carriage density to experimental 
carriage density is that we don’t know where in the carriage episode the natural carrier was 
when the sample was taken: carriage could have been recently acquired or it could already 
have been established for a few weeks. 
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Chapter 5 
 
 
 
 
 
 
Bacteriological and genetic factors influence experimental human 
pneumococcal carriage 
5.1 Introduction  
Rates of S. pneumoniae carriage and disease determined in epidemiological studies depend 
on age, geographic area, socio-economic factors, and the host’s innate and adaptive 
immune response [19,139,156,313,314]. But carriage is not solely dependent on the host 
and few human studies have examined the bacteriological determinants of carriage 
acquisition.  
It has previously been demonstrated that pneumococcal serotype plays a large role in 
determining carriage as some serotypes are frequently carried and have low invasive 
potential whilst others are more commonly found in disease [35,36,315]. It is also known 
that the capsular phenotype switches between transparent and opaque according to 
location. The transparent phenotype expresses more cell wall teichoic acid, aiding 
adherence and stable colonization in the nasopharynx; the opaque phenotype, more 
common in invasive disease, produces higher quantities of capsular polysaccharide, 
resulting in a decrease in opsonophagocytic killing [45,47,316,317]. Attachment to the 
epithelium and acquisition of nutrients are also crucial to colonization and survival in the 
nasopharynx [61,318].  
The differing propensity of pneumococcal strains to establish carriage is of importance in 
transmission and disease. As discussed in Chapter 3, the different carriage rates following 
experimental challenge with 6B or 23F were unexpected. To investigate why the 23F strain 
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was less able to colonize than the 6B strain in this model, we assessed bacteriological 
factors thought to associate with carriage acquisition and compared them across the two 
strains. 
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5.2 Materials and methods 
5.2.1 Recruitment and ethics 
Inclusion and exclusion recruitment criteria can be found in Chapter 2, section 2.2.1. The 
Patient Information Sheet is in Appendix B and the consent form is in Appendix C.  
Ethical information for the animal experiments can be found in Chapter 2, section 2.3.5.  
5.2.2 Bacterial strains and growth conditions 
Details on the 6B (BHN418) and 23F (P833) strains used for inoculation and the 23F P1123 
strain can be found in Chapter 2, section 2.3.1.  
5.2.3 Inoculation and sampling 
Preparation of the inoculum stock and determination of dose can be found in Chapter 2, 
sections 2.3.2.1 and 2.3.2.4. The inoculation method is described in Chapter 2, section 
2.3.2.6.  
Nasal wash samples were collected and processed as described in Chapter 2, sections 
2.3.2.7 and 2.3.2.8. 
5.2.4 Determination of phase morphology 
The method used to determine phase morphology was performed as described in Chapter 
2, section 2.3.4.2.  
5.2.5 Complement deposition assay 
The complement deposition assay was performed as described in Chapter 2, section 
2.3.4.3.  
5.2.6 Measurement of anti-pneumococcal polysaccharide antibodies 
in intravenous immunoglobulin by ELISA  
The ELISA used to measure the level of polysaccharide antibodies to serotypes 6B and 23F 
in IVIG was performed as described in Chapter 2, section 2.3.4.4.  
5.2.7 Opsonophagocytic killing assay 
Isolation of neutrophils from peripheral blood was performed as described in Chapter 2, 
section 2.3.4.5.1.  
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The neutrophil opsonophagocytic killing assay was performed as described in Chapter 2, 
section 2.3.4.5.2.   
5.2.8 Sequencing 
5.2.8.1 Genetic comparison of the 6B and 23F strains 
The genetic comparison of the 6B and 23F strains was performed as described in Chapter 2, 
section 2.3.4.6.1.  
5.2.8.2 Genetic comparison of 23F strains P833 and P1123 
The genetic comparison of the two 23F strains (P833 and P1123) was performed as 
described in Chapter 2, section 2.3.4.6.2.  
5.2.9 Determination of a mutation in amiC  
5.2.9.1 Confirmation of amiC mutation by sequencing 
The sequencing method used to confirm the presence/absence of a frameshift mutation in 
the amiC gene was performed as described in Chapter 2, section 2.3.4.7.1.  
5.2.9.2 Phenotypic confirmation of a mutation in the ami locus 
Phenotypic confirmation of the amiC mutation was performed as described in Chapter 2, 
section 2.3.4.7.2.  
5.2.10 Pneumococcal adherence assay 
The pneumococcal adherence assay was performed as described in Chapter 2, section 
2.3.4.8.  
5.2.11 Mouse model of colonization 
The mouse model of colonization was performed as described in Chapter 2, section 2.3.5.  
5.2.12 Statistical analysis 
Data was compared using the Fisher’s exact test, unpaired Student’s t test, Mann Whitney 
test, and the one-way ANOVA.  Flow cytometric data was analysed using FlowJo software 
version 7.6.5 (Treestar Inc). Graph and statistical analysis was performed using GraphPad 
prism version 5.0 (California, USA). All P values are two-tailed and considered significant if 
P≤0.05. 
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5.3 Results 
5.3.1 Transparent colonies were the dominant phenotype in the 6B 
inoculum stock 
To determine if phase variation could partially explain why the 6B strain was better at 
colonization, both inoculum stocks were examined under magnification. Transparent 
colonies were the dominant phenotype in the 6B inoculum stock but the population was a 
mix of transparent and opaque (Figure 5.1). The opacity of the 23F inoculum could not be 
determined even though the appearance of the colonies was more homogenous than the 
6B.  
 
 
Figure 5.1: Transparent colonies are the dominant phenotype in the 6B inoculum stock. 
6B and 23F inoculum stock colony morphologies were determined under oblique, 
transmitted illumination. Arrows denote transparent (T) and opaque (O) colonies. 
Magnification, 10x. 
 
Eight 6B and three 23F isolates recovered at 48 hours post-challenge from eleven individual 
volunteers were examined to see if carriage altered phenotype. Four out of eight 6B 
isolates were uniformly transparent by 48 hours. Two isolates were a mixed population 
with a higher number of transparent colonies as compared to opaque – similar to the 
inoculum - and two isolates were a mixed 50/50 population of transparent and opaque. 
Similarly to the inoculum, the 23F isolates could not be characterized due to a high degree 
of autolysis. However, all three isolates appeared uniform and were comparable to the 
inoculum. 
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5.3.2 The 23F inoculum strain was more susceptible to complement 
deposition as compared to the 6B strain 
In a flow based assay of C3b binding, we found that C3 deposition varied significantly 
between the two strains with markedly less C3 deposited on 6B (MFI: 74.35±0.5 SD) as 
compared to 23F (152.2±3.1) (P<0.001) (Figure 5.2). 
 
Figure 5.2: The 23F inoculum strain of pneumococci is more susceptible to complement 
deposition than the 6B strain using a flow based assay of C3b binding. Pneumococci were 
grown to an OD600nm of 0.4. Human serum (20%), mouse-anti-human C3, and anti-mouse 
FITC were added at separate steps, with a control included for each. C3 deposition and 
Mean Fluorescence Intensity (MFI) were measured by flow cytometry. Grey broken lines 
represent control samples incubated with PBS. Solid black lines represent samples 
incubated with 20% human serum. MFI (±SD) was calculated as the percentage of the 
bacterial population positive for C3 deposition multiplied by the geometric mean 
fluorescence of the total cell population. A P value ≤0.05 was considered significant using 
an unpaired Student’s t test.  
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5.3.3 Opsonophagocytic killing did not differ between the 6B and 
23F strains 
Prior to comparing the opsonophagocytosis of the 6B and 23F strains, we determined the 
antibody concentration in IVIG to the 6B and 23F polysaccharides. There was no significant 
difference in the amount of anti-polysaccharide IgG to either serotype in the IVIG (P=0.06) 
(Figure 5.3).  
 
 
Figure 5.3: The amount of anti-polysaccharide IgG in IVIG is similar for both the 6B and 
23F strains. An ELISA was performed using 6B or 23F pneumococci to measure specific IgG 
in IVIG. Values are triplicates from two different experiments. A P value ≤0.05 was 
considered significant using an unpaired Student’s t test. 
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Using IVIG as the source of antibody in the opsonophagocytosis assay, there was no 
difference in the killing of 23F and 6B (21.5% vs. 37.9%) (P=0.7) (Figure 5.4). 
 
 
Figure 5.4: The percentage of opsonophagocytic killing does not differ between the 6B 
and 23F strains. Pneumococci were opsonized with intravenous immunoglobulin (IVIG) and 
added to freshly derived peripheral blood neutrophils and baby rabbit complement. 
Following incubation, pneumococci were quantified on blood agar plates. Percent killing 
was determined by taking the average CFU recovered from the control wells minus the 
average CFU recovered from the experimental wells, divided by the average CFU from the 
control wells. Killing is the average from three experiments using the blood of three 
different volunteers. A P value ≤0.05 was considered significant using a Mann Whitney test. 
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5.3.4 Two genetic mutations in the 23F strain are relevant for 
adherence 
We compared the whole genome sequences of 6B and 23F to look for differences in known 
adherence factors. The pcpA gene was unique to the 6B strain when the genomes of the 
two serotypes were compared. 
5.3.4.1 The 23F inoculum also contained a frameshift mutation in amiC 
The 23F strain used for inoculation was chosen because it successfully established carriage 
in a human experimental model in the USA [161]. However, it was recently discovered that 
a proportion of the inoculum in the USA study contained a frameshift mutation in the amiC 
gene (personal communication, Ankur B. Dalia and Prof. JN Weiser). We analysed the 23F 
inoculum used in this study, as well as the 6B inoculum, for the presence of a frameshift 
mutation in amiC. The 23F inoculum contained the amiC mutation while the 6B inoculum 
contained a wild-type amiC (Figure 5.5A).  
Functional proof of the amiC frameshift mutation in the 23F inoculum strain was obtained 
by testing for resistance to aminopterin. Mutations in the ami locus confer resistance to 
aminopterin [298]. Serotype 23F strain P1123, isolated from the nasopharynx of a 
volunteer in the USA study following challenge with a 23F P833 strain [161], was used as a 
comparator because it is the same serotype and it contains a wild-type (wt) amiC. In the 
presence of aminopterin, the amiC mutant P833 strain showed no inhibition of growth, 
confirming the presence of the amiC mutation (Figure 5.5B).    
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Figure 5.5: Genes unique to the 6B strain include those important for colonization. (A) 
Sequences of amiC wild-type 6B and amiC - 23F P833. A single base pair insertion resulting 
in a frameshift mutation in the 23F P833 strain is highlighted by a square box. The 
corresponding change in amino acids is shown below. (B) Aminopterin sensitivity of the 23F 
inoculum strain P833 (amiC -) and the derivative wild-type (wt) strain P1123 (amiC wt). Ten-
fold dilutions of the two 23F strains were plated on blood agar containing 2x10-6M 
aminopterin.  
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5.3.4.2 There were six genetic differences between the serotype 23F inoculum 
and a derivative strain  
We compared the sequences of the amiC mutant 23F inoculum (P833) and the amiC wild-
type derivative 23F strain (P1123) to determine if there were any other genetic differences 
that may impact adherence. There were five other genetic differences between the amiC 
mutant inoculum P833 strain and the amiC wild-type derivative P1123 strain (Table 5.1). 
None of the genes are known to play a role in pneumococcal adherence.  
 
Table 5.1 Five genetic lesions between P833 and P1123 resulting in an amino acid change 
TIGR4 
annotation 
P833 > P1123 
codon change 
AA 
change* 
AA in 
TIGR4 
Annotated  
Gene Function 
Description 
SP_1514 TTG > TTT L5F F F0F1 ATP Synthase 
subunit C 
Energy 
metabolism [319] 
SP_0416 AAG > GAG K21E E MarR Family 
transcriptional 
regulator 
Response to 
antibiotic and 
oxidative stress 
SP_1550 CAT > CGT H248R R Glutathione S 
transferase 
Detoxification 
SP_1179 AAT > AAG N267K K Ribonucleotide 
diphosphate reductase, 
alpha subunit  
Nucleic acid 
metabolism [320] 
SP_1243 ATC > AGC I157S S Glucose-6-phosphate-1 
dehydrogenase 
Pentose 
metabolism [321] 
* Displayed as (AA in P833) (AA position within protein) (AA in P1123). 
 
5.3.5 The 23F strain had decreased adherence to Detroit 562 
epithelial cells as compared to the 6B strain  
We used an in vitro epithelial cell model to compare the adherence of serotypes 6B and 
23F and found that the 6B strain was more likely to adhere to nasopharyngeal cells than 
the 23F strain (P=0.0013) (Figure 5.6A). 
As both amiC and pcpA have been shown to play roles in pneumococcal adherence, we also 
compared the 23F inoculum strain containing the amiC mutation (P833) with a derivative 
23F strain containing wild-type amiC (P1123). The 23F strain with the wild-type amiC was 
more likely to adhere to nasopharyngeal cells than the 23F inoculum with the amiC 
mutation (P=0.0024) (Figure 5.6B). 
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Figure 5.6: A 23F strain of pneumococci is less adherent to Detroit 562 epithelial cells in 
vitro than a 6B strain and a derivative 23F strain. 1x106 CFU of 6B or 23F pneumococci 
were added to confluent Detroit 562 nasopharyngeal epithelial cells and incubated. 
Following incubation, cells were lysed with saponin and adherent bacteria were quantified 
by serial dilution on blood agar. (A) Comparison of serotype 6B (closed circles) and serotype 
23F (closed squares). (B) Comparison of serotype 23F (P833) containing the amiC mutation 
(closed circles) and serotype 23F (P1123) containing wild-type amiC (open circles). Data 
bars represent the mean ± SD. (*) denotes statistical significance using an unpaired 
Student’s t test where P ≤0.05 was considered significant. 
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5.3.6 An amiC mutant did not establish sustained carriage in a 
mouse model of colonization 
A mouse model of colonization was used to determine if the frameshift mutation in amiC 
affected nasopharyngeal colonization. We compared the ability of the amiC wild-type strain 
(P1123) and the amiC mutant strain (P833) to colonize mice, keeping in mind that, although 
P1123 is a derivative of P833, they are not isogenic (Table 5.1).  
At 5 days post-inoculation, the amiC wild-type strain (P1123) had successfully established 
carriage, while the amiC mutant strain (P833) had not, suggesting that amiC is critical for 
colonization of the URT in this mouse model (Figure 5.7).  
 
 
Figure 5.7: AmiC is critical for colonization in a mouse model of colonization. Mice were 
intranasally inoculated with 107 CFUs of the 23F amiC mutant strain (P833) or the amiC 
wild-type strain (P1123). Colonization burden was determined 5 days post-inoculation. The 
horizontal line represents the median. The dotted line represents 10 CFUs, the limit of 
detection.     
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5.4 Discussion 
We determined bacteriological differences between the 6B and 23F inoculation strains that 
may have contributed to the different experimental carriage rates seen in Chapter 3. 
5.4.1 Serotype 23F was more susceptible to complement deposition 
but this did not translate to increased killing 
The 23F inoculum strain examined in this thesis was more susceptible to complement 
deposition than the 6B strain. The difference in susceptibility to complement deposition 
between serotypes has previously been shown, as has an association between serotype 
prevalence in carriage and resistance to nonopsonic neutrophil-mediated killing [37,106]. 
Melin et al. [106] have shown a significant correlation between antibody concentrations to 
PspA, PspC, and pneumococcal histidine triad D (PhtD) in normal human sera and C3 
deposition on pneumococci. As we did not measure antibody levels in the human serum it 
is possible that these could be the reasons for the difference in deposition. 
Opsonophagocytosis can also vary between serotypes and has been linked with serotype-
specific mortality [43,106,108]. However, we did not see a difference in killing between the 
6B strain and the 23F strain, even though there was more complement deposited on the 
surface of 23F. Similar levels of anti-polysaccharide specific antibodies in IVIG suggest the 
difference in killing is not related to IgG. Hyams et al. [105] showed that capsule can 
prevent phagocytosis, mediated, not only by complement receptors and IgG receptors, but 
also by nonopsonic receptors. Together with the suggestion by Melin et al. [106] that the 
capsule type might be more important than the genetic background in determining 
resistance to opsonophagocytosis, it is likely that the differences in opsonophagocytosis 
between 6B and 23F are the result of a number of factors. 
5.4.2 Two genes shown to have roles in adherence were attenuated 
in serotype 23F   
When we compared the whole genome sequences of the 6B and 23F strains we found a 
mutation in the pcpA gene of 23F. PcpA is a choline-binding protein that has been shown to 
facilitate pneumococcal adherence to nasopharyngeal and lung epithelial cells [59]. A 
recent study found 11% of carriage isolates and 3% of invasive disease isolates were 
missing the pcpA gene [280]. Upon examination of a pneumococcal genome database 
(Malawi-Liverpool-Wellcome Trust Clinical Research Programme), only 39% (55/140) of 
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isolates contained the pcpA gene (personal communication, Jen Cornick). Taken together, it 
is likely that pcpA is not crucial for survival in the nasopharynx.  
Serotype 23F also had a frameshift mutation in amiC. AmiC is a pneumococcal 
transmembrane protein that has been shown to play a role in both adherence and 
oligopeptide transport [62,323]. Recently, a high throughput transposon sequencing 
approach used to characterize the genes important for colonization in the mouse found 
that the amiC mutant was highly attenuated in the TIGR4 pneumococcal strain [324]. We 
also searched the aforementioned pneumococcal genome database for amiC and found all 
140 isolates contained a full length amiC gene.  
5.4.2.1 Serotype 23F had decreased adherence in vitro and decreased carriage in 
a mouse model  
The 23F inoculum strain with the amiC mutation was less likely to adhere to 
nasopharyngeal cells than both the 6B strain and the derivative 23F strain. In a mouse 
model of colonization, the 23F inoculum with the amiC mutation did not carry whereas the 
derivative isolate with a full length amiC did.  
Differences in adhesion have been shown in relation to the site of isolation, with strains 
derived from otitis media and healthy nasal carriage having better adhesive capacity to 
human pharyngeal cells as compared to strains from septicaemia or meningitis patients 
[318]. Similarly, strains of the same capsule type adhered better when isolated from the 
nasopharynx of otitis media patients as compared to those isolated from the blood or 
cerebrospinal fluid. These differences in adherence may largely be due to phase variation 
and the greater ability of the transparent phenotype to adhere to epithelial cells, rather 
than the genetic background of each capsule [47]. However, in this case, it is possible that 
the decreased adherence of 23F was a result of mutation, in either pcpA or amiC, rather 
than phenotype, especially since the phenotype of 23F was indeterminable.  
The much higher 23F carriage rate in the USA study [161], as compared to the rate 
reported here, was likely due to a mixed inoculum containing both amiC wild-type and 
mutant cells. All strains recovered from colonized volunteers in the USA study were wild-
type for amiC, suggesting that the wild-type amiC strongly outcompeted the amiC mutant 
(Dalia and Weiser, personal communication). Conversely, in this study the inoculum and 
isolates from all colonized volunteers had no detectable level of amiC wild-type. Despite 
this, we found colonization with the amiC mutant strain in 5% of volunteers.  
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Chapter 6 
 
 
 
 
 
 
Density and duration of experimental human pneumococcal 
carriage 
6.1 Introduction 
Understanding carriage is important as it is implicated in both person-to-person 
transmission and spread within the body, potentially leading to meningitis, bacteremia, or 
pneumonia. To what extent density and duration of pneumococcal carriage affect the risk 
of transmission and invasive disease is under increasing scrutiny [266,328].  
Detection of live pneumococci by culture is the current gold standard [242]. Culture and 
molecular methods can be combined to increase carriage detection, including detection of 
multiple serotypes [239]. This can be achieved by including an enrichment step prior to 
culture and molecular analysis or by combining data from both culture and molecular 
methods, which would allow density to be determined for each method separately [249].  
Understanding carriage is also important in the context of vaccination. Pneumococcal 
conjugate vaccines have resulted in a decrease in invasive disease and carriage of vaccine-
serotype pneumococci [181,329]. While carriage of vaccine-type pneumococci has 
declined, carriage of non-vaccine-type pneumococci has increased [330,331]. The long-
term impact of vaccination can be measured using carriage data, which can estimate post-
vaccine changes in invasive disease incidence [332]. Colonization has been suggested as an 
endpoint because it is relatively easy to measure and is more common than disease, 
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therefore requiring a much smaller sample size in a vaccine trial [282,284,333]. To identify 
small changes in density or duration of colonization, sensitive methods to accurately detect 
these changes will be important in estimating vaccine effects.  
We longitudinally followed pneumococcal carriage episodes and compared detection of 
carriage by culture and qPCR. We focused on density and duration in experimental carriers 
but also compared both parameters in natural carriers that were followed in parallel.   
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6.2 Materials and methods 
6.2.1 Recruitment and ethics 
Inclusion and exclusion recruitment criteria can be found in Chapter 2, section 2.2.1. The 
Patient Information Sheet is in Appendix B and the consent form is in Appendix C.  
6.2.2 Inoculation  
Preparation of the inoculum stock and determination of dose can be found in Chapter 2, 
sections 2.3.2.1 and 2.3.2.4. The inoculation method is described in Chapter 2, section 
2.3.2.6.  
6.2.3 Quantification of pneumococci by culture 
Nasal wash samples analysed in this chapter were from volunteers in both Dose-Ranging 
and Reproducibility studies. Nasal wash samples were collected and processed as described 
in Chapter 2, sections 2.3.2.7 and 2.3.2.8. If pneumococci were detected at the pre-
inoculation screen, the volunteer was not challenged but returned for a nasal wash at the 
same time points as those who were.  
Carriage density by culture was determined as described in Chapter 2, section 2.3.3.2.  
6.2.4 Bacterial DNA extraction 
The bacterial DNA extraction method was performed as described in Chapter 2, section 
2.3.3.3.  
6.2.5 Quantification of pneumococcal DNA by qPCR 
Determination of carriage density by qPCR was performed described in Chapter 2, section 
2.3.3.4.  
6.2.6 Statistical analysis 
Differences in proportion of samples positive for carriage were statistically tested by a Chi-
square test (Fisher’s exact if <10 cases in a cell). Quantitative data was compared using 
Spearman’s rank correlation coefficient. Graph and statistical analyses were performed 
using GraphPad prism version 5.0 (California, USA). All P values are two-tailed and 
considered significant if P ≤0.05. 
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6.3 Results 
6.3.1 Comparison of culture and qPCR in the detection of 
pneumococci 
331 nasal wash samples collected from 79 volunteers were tested by microbiological 
culture and qPCR for the presence of S. pneumoniae. The proportion of samples positive for 
carriage by qPCR was significantly more than the proportion of samples positive for 
carriage by culture (42.6% vs. 27.5%, P<0.0001) (Table 6.1). The sensitivity of detection by 
qPCR was 92.3% (84/91) compared with culture, and the specificity was 75.9% (183/241). 
In 2.1% of samples, pneumococci were detected by culture but not qPCR and in 17.2% of 
samples pneumococci were only detected by qPCR.  
 
Table 6.1 Comparison of bacterial culture and qPCR in detection of S. pneumoniae 
 Culture positive 
(%) 
Culture negative  
(%) 
Total 
qPCR positive (%) 84 (25.4%) 57 (17.2%) 141 (42.6%) 
qPCR negative (%) 7 (2.1%) 183 (55.3%) 190 (57.4%) 
Total 91 (27.5%) 241 (72.8%) 331 (100%) 
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6.3.1.1 The number of volunteers positive for carriage by qPCR was more than 
those positive for carriage by culture  
The proportion of carriage positive volunteers was also determined over time (Figure 6.1). 
Across all time points, the number of volunteers positive for carriage by qPCR was more 
than those positive for carriage by culture, but this was only significant at 2 days post-
challenge (P=0.009). 
 
 
Figure 6.1: Proportion of carriage positive volunteers detected by bacterial culture or 
qPCR over time. For detection by culture, nasal wash samples were plated on blood agar 
with gentamicin.  For qPCR detection, nasal wash was added to RNA protect and frozen 
until DNA extraction. A volunteer was considered positive by culture (white bar) if Gram 
positive, alpha-hemolytic, optochin-sensitive colonies were detected after 48 hours. 
Serotype was confirmed by latex agglutination. The target gene for qPCR was lytA. Samples 
with a Ct value <40 were considered qPCR positive (black bar). The number of samples 
analysed are indicated above each time point.*Statistical significance (P ≤0.05 using a Chi-
square test or Fisher’s exact if <10 cases in a cell). 
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6.3.2 Correlation of density detected by culture and qPCR  
The correlation of pneumococcal density between culture and qPCR was determined for 
147 samples. One sample was excluded from analysis because the number of colonies on 
the culture plate was too high for accurate determination of CFU/ml. Quantification of 
pneumococci by culture and qPCR were positively correlated (rs=0.73, P<0.0001) (Figure 
6.2). The detection limit for qPCR was the number of copies still detectable after 40 cycles, 
or 101 DNA copies/ml. The limit of detection for culture was set at the lowest density 
detected, or 0.2 CFU/ml.  
 
Figure 6.2: Correlation between bacterial culture and qPCR in quantifying S. pneumoniae 
in nasal wash samples. Quantification of pneumococci by culture and qPCR are positively 
correlated. The Spearman rank correlation coefficient for samples positive by both culture 
and qPCR is 0.73. Dotted lines represent lower limits of detection. P ≤0.05 was considered 
significant. 
 
  Density and duration of EHPC 
 
120 
 
 
6.3.2.1 Pneumococcal detection by culture, stratified by qPCR density  
When pneumococcal detection by culture was stratified by qPCR density, the difference 
between the two methods became apparent. If the qPCR density was greater than 103 
copies/ml, 94.8% (55/58) of samples were both culture and qPCR positive (Table 6.2). 
However, at densities ranging between 101 and 102, only 34.55% (29/84) of qPCR positive 
samples were also positive by culture (P<0.0001). Below the qPCR limit of detection, 7.7% 
(7/91) of samples were still positive by culture. In all but one of these samples, the culture 
density was lower than 10 CFU/ml. 
Table 6.2 Detection of pneumococci in nasal wash by bacterial culture and qPCR, 
categorized according to qPCR density 
Density by qPCR (copies/ml) No. culture positive/No. qPCR positive (%) 
<10 7/0  
101 6/37 (16.2) 
102 23/47 (48.9) 
103 30/32 (93.8) 
104 14/14 (100) 
105 11/12 (91.7) 
Total 91/142 (64.1) 
 
6.3.3 Fluctuations in carriage density are accurately detected when 
both culture and qPCR are used for detection 
Culture and qPCR were used to examine pneumococcal detection over time in four 
experimentally colonized and three naturally colonized volunteers. The fluctuations in 
density during a carriage episode were similar for both experimentally and naturally 
colonized volunteers (Figure 6.3). In Figure 6.3A, volunteer 1 had two consecutive time 
points (days 7 and 14) that were culture negative but qPCR positive. Contrastingly, 
volunteer 2 was culture positive but qPCR negative on day 28. In both cases, the carriage 
status varied depending on the method. This variation was also seen in natural carriers 
(Figure 6.3C). Both methods were beneficial when determining the length of a carriage 
episode. Volunteers 3 and 4 (Figure 6.3B) had at least two samples positive by both culture 
and qPCR but then at least three consecutive samples negative by culture but positive by 
qPCR. This pattern was also seen in natural carrier serotype 33 (Figure 6.3C). 
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Figure 6.3: Culture and qPCR are complementary for following a carriage episode. At low 
density, carriage results can vary by method, which can impact on (A) the number of 
carriage episodes and (B) the duration of carriage episodes. (C) Natural carriage episodes 
mimic the variation seen in experimental carriage. Filled shapes: carriage positive by 
culture. Open shapes: carriage negative by culture. Dotted lines represent lower limits of 
detection. NW, nasal wash.  
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6.4 Discussion 
Longitudinal nasal wash samples from adults who were intranasally challenged with 
pneumococci were assessed for carriage density by culture and qPCR. 
6.4.1 A higher pneumococcal carriage rate was detected using qPCR, 
as compared with culture 
The proportion of samples positive for carriage by qPCR was significantly more than the 
proportion of samples positive for carriage by culture. Detection of pneumococcal carriage 
by culture is the gold standard [242]. By isolating the pneumococcus, further tests can be 
performed to determine serotype and antibiotic sensitivity. Culture is also more feasible in 
resource-limited settings. Non-culture methods are increasingly being used to detect 
pneumococci. Several studies have focused on gene targets using qPCR, with lytA the most 
widely used, and have shown that a qPCR-based method is more sensitive than culture 
[223,253]. There have been concerns over the specificity of lytA and the possibility that it 
may not discriminate between S. pneumoniae and viridans streptococci however, our 
specificity (75.9%) was similar to that published by Carvalho et al. [253] in CSF samples 
(70%). To increase sensitivity, some studies include an enrichment step but this cannot be 
used when quantification is an endpoint [248,249].  
A lower detection rate in culture compared with qPCR could be explained by the potential 
for subclinical -or low density- carriage. Turner et al. [239] showed detection of multiple 
serotypes in nasopharyngeal samples is significantly underestimated when using the 
standard WHO protocol which is able to detect a predominant serotype but is not efficient 
at detecting low-abundance serotypes.  This links with serotype replacement where it is 
unclear if the increase in non-vaccine-type pneumococci is due to the elimination of 
vaccine-type pneumococci or if the replacement is because non-vaccine-types are carried 
at low density and are simply “unmasked” when vaccine types are inhibited or removed 
[181,330]. Low density carriage could explain the differences between culture and qPCR 
seen here; at a density of less than 102, the low abundance is missed by culture but picked 
up by qPCR.  
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6.4.2 Culture and qPCR were complementary in determining 
pneumococcal carriage density, as well as the number and duration 
of carriage episodes 
The number of pneumococcal lytA DNA copies were generally 1 to 2 log10 higher than the 
corresponding CFU count. It has been shown in children that at a density of less than 105 
CFU/ml, significantly less carriers were detected by culture, not only for pneumococcus but 
also for S. aureus and H. influenzae [223]. However, as we have shown here and discussed 
previously [246], we are able to detect carriage by culture at <10 copies/ml and suggest 
that, when using a fresh nasal wash sample, culture and qPCR are equally sensitive until 102 
CFU/ml. 
The parallel decrease of culture positivity rates and pneumococcal densities measured by 
qPCR, suggests that qPCR is more suitable for detecting low levels of carriage. However, 
qPCR is not informative on viability of pneumococci in the nasopharynx. As seen in Figure 
6.3B, continuous qPCR detection when culture results are negative may represent 
prolonged low density carriage, living cells that are in a culture-unfavourable metabolic 
state, or remaining pneumococcal debris. And intermittent culture positive results could be 
misconstrued as separate carriage episodes when they are actually a single carriage 
episode as supported by qPCR detection (Figure 6.3A). By applying both methods, the 
chance of missing pneumococcal carriage may be intercepted. In our controlled 
environment, the most advantageous approach to longitudinally study a carriage episode is 
to use both methods. 
Inconsistencies between culture and qPCR detection could also be explained by decreasing 
success rates at the threshold of detection. Culture densities were low (< 10 CFU/ml) in 6/7 
qPCR negative samples, and in 54 out of 57 culture negative samples qPCR densities were 
below 103 copies/ml. The higher density inconsistencies could be attributed to 
experimental error; culture positive/qPCR negative samples could be the result of faulty 
DNA extraction or the exclusion of qPCR signals below 10 copies/ml (> 40 cycles). Four of 
the seven exclusively culture positive samples were analysed again using a different lytA 
primer set but remained negative for pneumococcal DNA [334]. We chose a threshold of 40 
cycles which was used in the development of the lytA qPCR assay. We observed that the 
success rate of detection of the standard curve was still 100% at 40 cycles, and that the 
standard curve still followed a straight line at 40 cycles. In addition, almost all samples 
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detected between 35 and 40 cycles were positive in both duplicates. These observations 
imply that the lower limit of detection of our method had not yet been reached at 40 
cycles.  This cut-off is two cycles higher than that used in the study with children, possibly 
explaining the differences in detection limits between the two studies [223,253].   
Our study surveyed adult pneumococcal carriage in consecutive nasal wash samples. 
However, this sampling method is less suited for those who are unable to actively 
participate in sample collection (e.g. young children). Further studies would need to 
determine whether our observations hold true for different sampling methods and 
populations. 
The strength of this data is the determination of both culture and qPCR density during a 
controlled carriage episode. We observed a high correlation between the two methods in 
calculating density. Absolute numbers were 1 to 2 log10 lower by culture, which is in line 
with observations previously reported by Albrich et al. [266]. The difference may be due to 
the inability of qPCR to distinguish between live and dead bacteria - an important 
distinction in low density samples. Lower culture density may also be a result of the 
pneumococcal tendency to grow in pairs and chains. More than one pneumococcus can 
form a single colony but qPCR will detect each individual bacterium.  
Carriage is a dynamic event and we have shown that an experimental human carriage 
model mimics a natural carriage episode. The data from our study indicate that culture and 
qPCR methods are highly complementary when studying pneumococcal carriage episodes, 
especially when the carriage density is low. This is important information for future vaccine 
studies where carriage density or duration may be an endpoint. 
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Chapter 7 
 
 
 
 
 
 
Modulation of nasopharyngeal innate defences by viral co-infection 
predisposes individuals to experimental pneumococcal carriage  
7.1 Introduction 
Secondary bacterial infections with S. pneumoniae are a major cause of morbidity and 
mortality during pandemic influenza [335]. Pneumococcus commonly colonizes the URT in 
healthy individuals but viral infections transform this normally harmless commensal 
organism into a potentially fatal pathogen by increasing pneumococcal transmission [20], 
carriage density [219,336] and host disease susceptibility [218]. The current threat of 
influenza pandemics, increasing antibiotic resistance, and the burden of co-infection in the 
young and aged populations make it critical to understand how viral infection increases 
susceptibility to pneumococcal disease.  
Pneumococcal colonization at the mucosal surface is a prerequisite of invasive disease 
[7,337]. Children with radiologically confirmed pneumonia have a marked increase in the 
density of colonizing pneumococci if co-infected with influenza A, RSV or rhinovirus [219]. 
Several possible mechanisms may account for increased nasopharyngeal pneumococcal 
density, including influenza-induced damage to the epithelium and/or alterations in host 
cellular responses to bacterial pathogens [338,339]. Viral infections reduce mucociliary 
velocity, denude epithelial surfaces and expose basement membranes, and modulate 
chemokine and innate defences [340-342].  
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We used an EHPC model [292] to investigate the relationship between asymptomatic URT 
viral infections and pneumococcal colonization in humans. We also investigated a possible 
mechanism by which virus could modulate mucosal defences and increase colonization by 
measuring levels of several soluble innate factors at the nasal mucosa, including human FH. 
FH is a soluble protein found in human plasma that suppresses the alternative complement 
pathway [115]. The pneumococcus binds FH via PspC [113], facilitating adherence to 
epithelial cells [58]. PspC also interacts with the human polymeric immunoglobulin 
receptor (pIgR) to promote bacterial adherence to, and invasion of, epithelial cells, as well 
as binding to the secretory component of immunoglobulin A (sIgA) [56]. As a result of these 
important interactions with the host immune system PspC has been proposed as a vaccine 
candidate to block pneumococcal carriage [18]. 
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7.2 Materials and methods 
7.2.1 Recruitment and ethics 
Inclusion and exclusion recruitment criteria can be found in Chapter 2, section 2.2.1. The 
Patient Information Sheet is in Appendix B and the consent form is in Appendix C.  
Volunteers from both the Dose-Ranging and Reproducibility studies were included in this 
chapter as were 40 volunteers from a separate study. These 40 volunteers from the 
separate study followed a similar schedule as those in the above two studies with one 
major exception: they were vaccinated with the Hepatitis A (Avaxim) vaccine four weeks 
prior to pneumococcal challenge.  
7.2.2 Inoculation 
Preparation of the inoculum stock and determination of dose can be found in Chapter 2, 
sections 2.3.2.1 and 2.3.2.4. The inoculation method is described in Chapter 2, section 
2.3.2.6.  
7.2.3 Quantification of pneumococci by culture 
Nasal wash samples were collected and processed as described in Chapter 2, sections 
2.3.2.7 and 2.3.2.8. Detection of pneumococcal carriage by culture and measurement of 
carriage density were performed as described in Chapter 2, sections 2.3.3.1 and 2.3.3.2, 
respectively. 
7.2.4 Detection and identification of URT viruses 
URT viruses were detected as described in Chapter 2, section 2.3.4.9.  
7.2.5 Levels of FH, lactoferrin, SLPI, and beta defensin 2 in nasal 
wash and anti-PspC in serum  
The methods used to determine the levels of FH, lactoferrin, SLPI, beta defensin 2, and 
anti-PspC were performed as described in Chapter 2, section 2.3.4.10.  
7.2.6 Depletion and purification of antibodies from nasal wash and 
sera samples 
The methods used to deplete and purify antibodies from nasal wash and sera samples were 
performed as described in Chapter 2, section 2.3.4.11.  
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7.2.7 Bacterial strains and growth conditions 
Details on the 6B (BHN418) strain used for inoculation and the S. pneumoniae serotype 2 
strain D39 used in the pneumococcal adherence and internalization assay can be found in 
Chapter 2, section 2.3.1.  
7.2.8 FH binding and antibody binding assays 
The FH binding assay and the antibody binding assay were performed as described in 
Chapter 2, section 2.3.4.12.  
7.2.9 Epithelial cell assays 
7.2.9.1 Epithelial cell growth and inflammation of epithelium 
Detroit 562 epithelial cells were grown and maintained as described in Chapter 2, section 
2.3.4.8. Inflammation of the epithelium was performed as described in Chapter 2, section 
2.3.4.8.1.   
7.2.9.2 Epithelial pIgR and rPAF expression by flow cytometry 
Determination of epithelial pIgR and rPAF expression was performed as described in 
Chapter 2, section 2.3.4.8.2.  
7.2.9.3 Pneumococcal adherence and internalization assays 
The pneumococcal adherence and internalization assays were performed as described in 
Chapter 2, section 2.3.4.8.  
7.2.10 Anti-PspC antibody epitope mapping 
The antibody epitope mapping method was performed as described in Chapter 2, section 
2.3.4.13.  
7.2.11 Statistical analysis 
Fisher’s exact test was used to compare the proportion of carriers that were virus positive 
and virus negative. Pearson’s correlation coefficient was used to compare log transformed 
FH levels and pneumococcal carriage density. Flow Cytometry data were analysed using 
Flow Jo v7.6.1, except for the epithelial pIgR and rPAF expression which was analysed using 
v10. To account for possible correlation among the repeated measurements in carriage 
status and density, a generalized estimating equation (GEE) model was employed for the 
data analysis. For the GEE analysis of carriage presence (Yes or No), binomial distribution 
and logit link function were used.  For the GEE analysis of carriage density, log transformed 
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density was used as the dependent variable and normal distribution and identity link 
function were used. Three GEE models were estimated to assess the effects of FH levels 
and virus status on carriage status and density, separately and jointly. Model 1 has virus 
status (positive and negative) and day (Day 2, 7 and 14) as predictors; Model 2 has FH levels 
in log scale and day as predictors; Model 3 has FH levels and virus status, day, and 
interaction between FH levels and virus as predictors. Differences were considered 
significant if P ≤0.05. Statistical analyses and graphical presentations were performed using 
Graphpad Prism5 and SAS9.3. 
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7.3 Results 
7.3.1 Asymptomatic URT viral infections increased susceptibility to 
pneumococcal colonization  
One hundred and one healthy volunteers (age 18-50) were challenged with pneumococcus 
between November 2011 and April 2014. The average age (mean±SD) of volunteers was 
23±6 years and 38% were male (38/101). Oropharyngeal swabs taken 5 days prior to 
challenge were analysed by PCR for the presence of URT viruses. Nasal wash samples were 
taken 2, 7 and 14 days post-inoculation and analysed for the presence of pneumococcal 
carriage by classical microbiology. Experimental carriage of 6B pneumococcus was detected 
in 52 out of 101 volunteers (51%), as defined by the presence of pneumococci in nasal 
wash at any time point post challenge. 
We investigated whether the presence of virus predisposed certain individuals to 
colonization. There were no significant differences between virus positive and virus 
negative volunteers with regards to age (22±3 vs. 23±7 years, P=0.5), gender (M:F 6:14 vs. 
32:49, P=0.6), or inoculation dose (P=0.9). Amongst virus positive volunteers, 75% became 
colonized (15/20) as compared to 46% virus negative volunteers (37/81) (P=0.02) (Figure 
7.1A). We could not find an association between the presence of virus and increased 
density (Figure 7.1B). There was also no association between virus presence and season 
(Figure 7.1C). Only infections caused by a single virus were detected. The detected viruses 
amongst colonized volunteers were rhinovirus (8/15), coronavirus (4/15), RSV (2/15) and 
parainfluenza virus (1/15); similarly non-colonized individuals were positive for rhinovirus 
(3/5), coronavirus (1/5) and adenovirus (1/5).   
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Figure 7.1: Asymptomatic upper respiratory tract (URT) viral infections are associated 
with susceptibility to pneumococcal colonization but not increased density. (A) One 
hundred and one healthy volunteers were screened for URT viruses by multiplex PCR 5 
days before intranasal inoculation of 6B pneumococcus. The percentage of carriage 
positive (carriers) and carriage negative (non-carriers) volunteers are shown for virus 
negative or virus positive. Amongst virus positive volunteers 75% became colonized as 
compared to 46% virus negative volunteers (P=0.02, using Fisher’s exact test). (B) 
Colonization density recovered from the nasopharynx was measured in nasal wash samples 
collected 2, 7 and 14 days following pneumococcal inoculation and is expressed as CFU/ml 
recovered from nasal wash of virus negative and virus positive groups. There was no 
difference in colonization density between virus positive and virus negative volunteers. (C) 
The percentage of volunteers positive for asymptomatic URT virus or S. pneumoniae were 
analysed per month. There was no association between virus presence and season.  
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7.3.2 Levels of mucosal FH were increased in individuals co-infected 
with virus and pneumococci and associated with increased 
colonization density 
We investigated levels of mucosal FH, SLPI, β-defensin 2 and lactoferrin in nasal wash to 
determine whether modulation of these innate factors by a virus could predispose 
individuals to pneumococcal colonization. Levels of FH (Figure 7.2A), were slightly higher in 
the nasal wash samples of volunteers co-infected with virus and pneumococci compared to 
virus only individuals (P=0.04). In contrast, levels of the antimicrobial factor SLPI (Figure 
7.2B), beta defensin 2 (Figure 7.2C) and lactoferrin (Figure 7.2D) were not significantly 
different. 
As virally infected individuals colonized with pneumococci had slightly higher levels of FH 
we investigated the relationship between FH and bacterial colonization density. We found 
that individuals with high mucosal FH levels had increased 6B colonization density (Figure 
7.2E, P=0.005).   
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Figure 7.2: Levels of mucosal FH are increased in individuals co-infected with virus and 
pneumococci and correlate with colonization density. Mucosal levels of (A) FH (B) SLPI (C) 
beta defensin 2 and (D) lactoferrin were measured in nasal wash samples obtained 2 days 
after pneumococcal challenge with 6B. Levels are expressed in ng/ml and results are 
stratified by pneumococcal carriage and absence or presence of virus. Statistical 
differences were analysed using an unpaired Student’s t test (*P ≤0.05). (E) We observed a 
positive correlation between levels of FH and pneumococcal colonization density (CFU/ml) 
recovered from nasal wash 2 days after inoculation using Pearson's correlation test. P value 
and the correlation coefficient (r) is presented.  
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Using a GEE model we examined the association of virus presence and mucosal FH levels, 
individually as well as jointly, with carriage presence and density (Table 7.1). When we 
examined the effects of virus presence and mucosal FH levels individually (GEE model 1 and 
2), virus presence was associated with a 2.83 times increase in the odds of becoming 
colonized (P=0.023) and a doubling in FH levels was associated with a 2.54 times increase in 
the geometric mean of carriage density (P=0.002). When we examined their effects jointly 
(GEE model 3), we found an interaction. Specifically, amongst virus positives a doubling in 
FH levels was associated with a 9.33 times increase in the odds of carriage (P=0.034) and a 
4.26 times increase in the geometric mean of carriage density (P=0.009). 
 
Table 7.1 Association of virus presence and mucosal FH levels with carriage presence and 
carriage density 
Model$ Variable 
Carriage presence 
(Odds ratio [95% CI]) 
 P value 
Carriage density  
(Ratio [95% CI]) 
P value 
Model 1 Virus positive 2.83 [1.15-6.96] 0.023 0.96 [0.43-2.17] 0.930 
Model 2 FH levels 1.95 [0.82-4.64] 0.133 2.54 [1.43-4.51] 0.002 
Model 3 
  
FH levels  
(Virus negative) 
1.20 [0.43-3.34] 0.727 2.36 [1.06-5.25] 0.035 
 FH levels  
(Virus positive) 
9.33 [1.19-73.31] 0.034 4.26 [1.43-12.68] 0.009 
$ GEE model was used for the data analysis. Model 1 has virus status (positive and 
negative) and day (Day 2, 7 and 14) as fixed effects; Model 2 has FH levels in log scale and 
day as fixed effects; Model 3 has FH levels and virus status, day, and interaction between 
FH levels and virus as fixed effects. 
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7.3.3 Nasal wash fluid and epithelium inflammation increased 
pneumococcal adherence and internalization  
We used a model of non-inflamed and inflamed nasopharyngeal epithelium to investigate 
the role of mucosal FH in pneumococcal adherence during health and co-infection, 
respectively. Inflammation of epithelium was confirmed by increased expression of pIgR 
(Figure 7.3A) and rPAF (Figure 7.3B).  
 
 
Figure 7.3: Confirmation of epithelium inflammation. Stimulated (blue) and non-
stimulated epithelial cells (red) were incubated with (A) pIgR and (B) rPAF to confirm 
inflammation of epithelium through increased receptor expression. FITC donkey anti-rabbit 
IgG and PE goat anti-mouse IgG2a were used as isotype controls, respectively. 
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We observed more than a two-fold increase in pneumococcal adherence of D39 to 
inflamed epithelium compared to non-inflamed epithelium (Figure 7.4A, black squares). We 
tested whether pure FH or nasal wash containing FH would influence bacterial adherence. 
Pneumococcal IgA1 protease cleaves IgA1 antibodies found in nasal wash [281] and 
promotes pneumococcal adherence [143]. Because of this important mechanism we used 
nasal wash samples depleted of IgG or IgA.  
Pre-treatment of bacteria with pure FH increased D39 pneumococcal adherence to non-
inflamed and inflamed epithelium (Figure 7.4A, open dots) and adherence was dependent 
on PspC expression (Figure 7.4B). Pre-treatment of bacteria with nasal wash samples 
depleted of IgA (Figure 7.4A, grey dots) or IgG (Figure 7.4A, black dots) equally increased 
pneumococcal adherence to nasopharyngeal cells, and this effect was independent of PspC 
expression (Figure 7.4B). We observed increased internalization of bacteria when pre-
treated with FH (Figure 7.4C, open dots), nasal wash IgA-depleted (Figure 7.4C, grey dots) 
or nasal wash IgG-depleted (Figure 7.4C, black dots). This effect was more marked when 
the epithelium was inflamed. 
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Figure 7.4: Pneumococcal epithelial adherence and internalization are increased in the 
presence of human nasal wash or Factor H. Adherence of (A) D39 and (B) D39ΔPspC to 
human pharyngeal epithelial cells (D562) was evaluated in non-inflamed and inflamed 
epithelium. Epithelial adherence (A) and internalization (C) of pneumococci was increased 
following treatment of bacteria with human purified FH (open dots), nasal wash depleted 
of IgA (grey dots), nasal wash depleted of IgG (black dots) when compared to untreated 
bacteria (black squares). Epithelial adherence (B) was not increased when D39ΔPspC was 
pre-treated with FH (open dots). All conditions were performed in duplicate and 
experiments were repeated at least twice. For each experiment, the average recovered 
CFU from the control condition (adherence of D39 untreated bacteria to non-inflamed 
cells) was used to calculate fold change of all remaining conditions. + represents statistical 
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significance compared to control condition using an unpaired t test (+P≤0.05 and ++ 
P≤0.005). *represents statistical significance compared to untreated bacteria of same 
epithelial condition using an unpaired Student’s t test (*P≤0.05 and **P≤0.005). All 
conditions were performed in duplicate and experiments were performed at least twice. 
For each experiment, the average recovered CFU from the control condition (adherence of 
D39 untreated bacteria to non-inflamed cells) was used to calculate fold change for all 
remaining conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Modulation of nasopharyngeal innate defences 
139 
 
 
7.3.4 Anti-PspC IgG partially blocked FH binding to pneumococcus 
and pneumococcal adherence and internalization to pharyngeal 
cells 
We investigated whether anti-PspC antibodies purified from individuals participating in the 
EHPC model could block FH binding to pneumococcus in vitro and circumvent the increased 
adherence of pneumococcus during inflammation. The specific binding of FH via PspC to 
our laboratory strain was confirmed (Figure 7.5A and B).  
 
 
Figure 7.5: Binding of human FH to pneumococcus is mediated by PspC. (A) D39 and (B) 
D39 ΔPspC were employed in FH binding assays. Fluorescence intensity of bacteria (dotted 
line) and bacteria incubated with 10 µg/ml of FH (filled black) are shown on the Y axis. (C) 
Levels of anti-PspC IgG and FH were measured in samples purified from serum of 7 
volunteers. The two-step purification process was able to purify anti-PspC specific IgG but 
FH from sera could not be entirely removed.  
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Anti-PspC antibodies were isolated from serum where they are more abundant than in 
nasal wash. Flow cytometric analysis indicated that samples from each subject had anti-
PspC IgG that bound effectively to pneumococcus (Figure 7.6A, P=0.01 using unpaired t 
test). Levels of IgG binding were variable among samples and related to anti-PspC IgG levels 
measured by ELISA (Figure 7.5C). Purified samples also had measurable levels of FH 
remaining after the anti-PspC IgG purification process (Figure 7.5C). Purified samples were 
incubated with bacteria prior to addition of FH in order to block PspC-FH interaction. We 
observed a partial inhibition of FH binding to pneumococcus by purified human anti-PspC 
IgG samples (Figure 7.6B).  
We then investigated whether purified anti-PspC IgG could block pneumococcal adherence 
and internalization to host epithelial cells. Epithelial adherence was reduced by purified 
anti-PspC IgG (Figure 7.6C, grey dots) containing 3.5 µg/ml of residual FH (residual from 
anti-PspC purification process, Figure 7.6C) but not in the presence of higher levels of FH 
(20 µg/ml) (Figure 7.6C, open dots).  This interaction was specific to PspC as treatment with 
anti-PspC IgG did not alter adherence of D39 ΔPspC (Figure 7.6D, grey dots). Internalization 
of D39 was inhibited by anti-PspC IgG (Figure 7.6E, grey dots) but not by purified total IgG 
(open squares).   
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Figure 7.6: Purified human anti-PspC IgG binds to pneumococcus and partially inhibits 
Factor H binding and adherence to human pharyngeal epithelial cells. (A) We measured 
anti-PspC IgG binding to D39 and (B) inhibition of FH binding by purified anti-PspC. Each 
row represents one subject. Negative controls (without anti-PspC or FH) are represented by 
unfilled histograms (A and B). For the inhibition of FH assay the positive control (without 
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anti-PspC and with FH) is represented by black filled histogram. (C) Epithelial adherence of 
D39 was evaluated following treatment of bacteria with purified anti-PspC IgG containing 
low levels of FH (3.5 µg/ml residual from purification of serum samples, grey dots) or with 
anti-PspC IgG before addition of high levels of FH (10 µg/ml, open dots) and compared to 
untreated bacteria. (D) Adherence of D39ΔPspC untreated (black squares) or treated with 
purified anti-PspC IgG (grey dots) was evaluated. (E) D39 epithelial internalization was 
measured in untreated bacteria (black squares) and bacteria treated with the purified anti-
PspC IgG (grey dots) or the total IgG purified from the same serum samples as control for 
antibody specificity (open squares). + represents statistical significance compared to control 
condition using an unpaired t test (+P≤0.05 and ++P≤0.01). **represents statistical 
significance compared to untreated bacteria on inflamed epithelial condition (black 
squares) using an unpaired t test (*P≤0.05 and **P≤0.005). 
 
7.3.5 Anti-PspC epitope mapping revealed lack of human antibodies 
recognizing the binding site for FH after intranasal exposure to 
pneumococcus 
To explore reasons for the inefficient blocking of the FH-pneumococcus interaction by anti-
PspC IgG we used peptide arrays to define the epitopes of PspC recognized by human 
antibodies. We used serum from 18 healthy adults challenged with pneumococcus to probe 
peptide arrays containing the entire sequence of PspC group 3 (PspC3 - 491/00 strain). We 
observed that despite high levels of anti-PspC antibodies only one out of the 29 samples 
had antibodies recognizing the binding sites for FH which supports the partial inhibition of 
FH binding to pneumococcus observed in vitro (Figure 7.6B). Secretory IgA (sIgA) binding 
sites were recognized by all samples (Figure 7.7).   
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Figure 7.7: PspC epitope mapping using sera of healthy adults exposed to pneumococcus 
reveals the lack of antibodies to the FH binding site. The amino acid sequence of PspC 
group 3 variant was spotted on peptide arrays and is represented on the X axis. Peptide 
arrays covering the N-terminal region until the proline-rich region were probed with 29 
samples from 18 volunteers. The number of samples that recognized each peptide is 
represented on the Y axis. Sequences of the peptides recognized by human sera are in 
black and the ones not recognized are in grey. Binding sites for FH and sIgA are represented 
in dashed black and continuous grey boxes, respectively. 
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PspC-FH binding is specific to humans and does not occur in mice [343,344]. We repeated 
the peptide arrays using sera from mice immunized with PspC3 to test the hypothesis that 
PspC would not be masked by binding of FH and therefore mice would produce antibodies 
against this region. We found that sera from immunized mice recognized the binding site 
for FH as well as all the other peptides already identified by human sera (Figure 7.8). These 
findings support our previous results and suggest that PspC-FH is as an important 
interaction that occurs in the nasopharynx during pneumococcal colonization.  
 
 
Figure 7.8: PspC epitope mapping using sera from mice immunized with recombinant 
PspC3 reveals the presence of antibodies to the FH binding site. Sera from mice 
immunized with the recombinant protein PspC3 was used to probe peptide arrays covering 
the N-terminal region until the proline-rich region of PspC group 3. Sequences of the 
peptides recognized by murine sera are shown in black and the ones not recognized are 
shown in grey. Binding sites for FH and sIgA are represented in dashed black and 
continuous grey boxes, respectively.  
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7.4 Discussion 
We aimed to determine the role of respiratory viruses in experimental carriage 
establishment and examine how their presence might impact several soluble innate 
factors.  
7.4.1 Virus was associated with increased likelihood of colonization 
and levels of FH  
S. pneumoniae has evolved several strategies to adhere to host cells and evade host 
complement and immune attack. We have shown that virus co-infection was associated 
with three times increased odds of becoming colonized. In the presence of virus, mucosal 
levels of FH were increased and this may partly explain the predisposition of virally infected 
individuals to pneumococcal carriage in our EHPC model. Increased FH levels were also 
associated with increased carriage density. 
Our results corroborate previous reports showing that carriage isolates presented greater 
binding to FH than systemic isolates [345] which supports the relevance of the 
pneumococcus-FH interaction at the upper airway. However, we could not observe a 
correlation between viral co-infection and increased colonization density. This is in contrast 
to findings recently published by Wolter et al. who found a relationship between increased 
pneumococcal colonization density and respiratory virus co-infection in South Africans 
being treated for acute lower respiratory tract infection [220]. This could be the result of 
differences in recruitment; our study included healthy, asymptomatic adults, whereas the 
South African study recruited hospitalized individuals of any age, including 41% less than 2 
years and 51% who were HIV positive.   
Using a GEE model we found an interaction between virus presence, susceptibility to 
colonization, increased colonization density and increased FH levels. This is the first time 
that asymptomatic URT viral infection has been directly associated with increased 
pneumococcal colonization and increased mucosal FH levels in healthy adults.  
We were unable to detect FH expression in epithelial cells after in vitro stimulation with 
nasal wash samples containing virus (all values were zero). Previous transcriptome of 
epithelial cells have not found expression of the FH gene to be up regulated after virus 
infection [346]. It is therefore likely that increased FH levels at the mucosa were not 
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sourced by increased local expression but by leakage from blood stream into the nasal 
mucosa due to inflammation caused by pneumococcus virus co-infection [342].  
7.4.2 Epithelial inflammation and FH binding resulted in increased 
pneumococcal adherence to the epithelium 
We investigated the effect of nasal wash containing FH on pneumococcal adherence to 
non-inflamed and inflamed epithelium. We observed that treatment of pneumococcus with 
nasal wash containing several innate factors, including FH, promoted increased epithelial 
attachment and internalization. This effect was more pronounced when bacteria were 
treated with purified human FH or the epithelium was inflamed.  
We used a pneumococcal strain lacking expression of PspC (D39 ΔPspC) to show that PspC 
mediates the effect of FH on epithelial adherence. Although D39 expresses PspC3 and the 
6B strain used for human challenge expresses PspC9, there is a 58% similarity in the N 
terminal (first 110 amino acids) between the PspC amino acid sequences of both strains. 
With D39, increased adherence promoted by nasal wash was not only caused by existing FH 
in these samples. We observed no difference in adherence when nasal wash samples 
depleted of IgG or IgA were used to treat D39 ΔPspC and therefore the PspC-sIgA 
interaction was not the main mechanism for this increased adherence either. There are 
several pneumococcal specific host-pathogen interactions that could play a role in 
epithelial attachment [347]. The interaction between PspC and vitronectin has recently 
been highlighted as an important mechanism for pneumococcal adhesion [348].  
We hypothesize that in the presence of anti-PspC IgG and low levels of FH, there is 
decreased pneumococcal adherence as anti-PspC antibodies block adherence mediated by 
other factors such as vitronectin (Figure 7.9, middle). FH continues to facilitate low levels of 
adherence because human anti-PspC antibodies do not recognize the FH binding site. 
When FH levels are high, pneumococcal adherence increases due to more interactions 
between PspC and FH (Figure 7.9, right). Decreased adherence caused by the binding of 
anti-PspC antibodies to other factors such as vitronectin is masked by this increase in Pspc-
FH binding and adherence. 
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Figure 7.9: Schematic model of the proposed relationship between PspC, FH, anti-PspC 
IgG, and pneumococcal adherence. Left column: untreated condition – no FH or other 
factors such as vitronectin are present. Adherence is moderate. Middle column: in the 
presence of anti-PspC and low levels of FH there is decreased adherence because anti-PspC 
antibodies block pneumococcal adherence to the epithelium mediated by other factors, 
such as vitronectin. Human anti-PspC antibodies do not recognize the FH binding site of 
PspC and therefore the FH-PspC interaction will continue to facilitate low levels of 
pneumococcal adherence. Right column: in the presence of anti-PspC and high levels of FH 
there is increased adherence due to increased interactions between PspC and FH. 
 
7.4.3 PspC epitope mapping revealed individuals lacked antibodies 
against the FH binding region 
Since we observed that the PspC-FH interaction was associated with high rates and 
densities of carriage in humans co-infected with virus, we tested whether antibodies to the 
vaccine candidate PspC could block this interaction. PspC-based vaccines are protective 
against both invasive pulmonary disease and colonization in murine models of infection 
[349,350]. We observed a partial blocking of FH binding to pneumococcus by flow 
cytometry analysis and epithelial adherence assay. Anti-PspC IgG purified from serum 
blocked bacterial attachment when low levels of FH were present in the assay. These 
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results could be explained by the fact that healthy adults do not have antibodies specific to 
the PspC region that binds FH. By using sera from mice immunized with PspC in these 
assays we found that human carriage induces anti-PspC antibodies to the same epitopes as 
the ones induced by parenteral immunization with purified protein in mice. Two major 
differences were that i) mice did not have antibodies against the proline-rich region of PspC 
whilst this was one of the most recognized regions by human antibodies and ii) human 
antibodies did not recognize the binding site for FH on PspC whilst immunized mice did. 
Cross-reactive antibodies against the proline-rich region of the PspA could explain the high 
levels of recognition of the PspC proline-rich region in humans [351,352]. We have 
previously observed that colonization increased mucosal IgG antibodies to the N-terminal 
region of PspA but not PspC [289]. Most importantly, the fact that humans have an 
inefficient presentation of the PspC region that binds to FH, strongly suggests that FH 
binding to pneumococcus during colonization covers this site of the PspC antigen.  
Our findings confirm previous reports that PspC is the major, if not the only, protein that 
binds to FH. PspC-FH interaction allows pneumococci to protect themselves from the 
complement system [353] as well as facilitate pneumococcal adherence and uptake by 
human epithelial cells [354]. Increased adherence to lung epithelial cells was also reported 
when pneumococci were pre-incubated with FH [355] and could explain the associated 
high burden of pneumonia following influenza infections [356].   
Polymorphisms in the FH gene have been associated with increased susceptibility to S. 
aureus colonization in humans [357]. Binding to human FH has also been described as an 
important host-pathogen interaction for N. meningitidis [358] and a FH binding protein is a 
component in the first licensed vaccine against N. meningitidis serogroup B [359-361]. 
Point mutations that eliminate FH binding have been shown to enhance protective 
antibody responses to vaccination using this meningococcal FH binding protein [362]. Our 
results support the use of PspC as a mucosal vaccine candidate and highlight that 
mutations in the FH binding site which allow antibody generation against this region should 
be considered for any vaccine based on PspC. Blocking PspC-FH interaction with specific 
PspC antibodies at the mucosa has the potential to reduce viral associated pneumococcal 
colonization and burden of pneumonia associated with viral infections. 
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Chapter 8 
 
 
 
 
 
 
General discussion 
8.1 Introduction 
Experimental human pneumococcal carriage offers a plausible model of natural carriage 
and a potential model for use in vaccine development. The technique is valuable but 
complex and involves clinical risk by introducing a pathogen into a human. A model of 
carriage will allow accurate determination of the immunological correlates of protection, 
the immunizing effect of carriage and the effect of host pressure on the pathogen in the 
nasopharyngeal niche. Further, methods of carriage detection used in epidemiologic 
studies, and including vaccine studies, can be compared. 
This thesis had three aims: 
1. To further develop an experimental human pneumococcal carriage model  
2. To discover factors associated with experimental carriage  
3. To explore the density and duration of experimental carriage 
8.2 Summary and discussion of findings 
8.2.1 Development of an experimental human pneumococcal 
carriage model 
We have developed a model of experimental human pneumococcal carriage using S. 
pneumoniae serotype 6B. Carriage establishment was dose-dependent until 4x104 
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CFU/naris, after which carriage rates stabilized around 50% up to a dose of 3.2x105 
CFU/naris. Carriage rates for serotype 23F remained at or below 10%, regardless of dose. 
Carriage density was independent of dose for serotype 6B and could not be determined for 
serotype 23F because there was minimal carriage. The lack of a relationship between 
challenge dose and carriage density reassured us that higher doses did not result in 
increased density and thus, increased risk of disease and transmission. An independent 
relationship between carriage density and challenge dose was previously shown in an adult 
mouse model of colonization and we have now demonstrated it in humans [268].  
The natural carriage rate during the initial screening process of the Dose-Ranging study was 
11% (18/157). This is similar to what was found in the UK from 2001-2002 [6]. However, a 
recent study of children and their household contacts attending the same general practices 
in Hertfordshire, UK found that adult carriage rates have dropped from 7.6% to 3.4% 
following the introduction of PCV13 into the UK childhood vaccination schedule [302]. This 
decrease may not be evident in our study because our population was largely made up of 
university students who have less contact with vaccinated children than parents, especially 
as contact with children was a study exclusion criterion.  
In this model, the dose (104) required for 50% of volunteers to become colonized was lower 
than what is used in animal models of carriage (105-7) and resulted in safe, sustained 
carriage [159,268]. The next step is to examine the dose-dependency of a number of 
serotypes, both ones common in carriage and ones more often found in disease.  
8.2.1.1 Experimental carriage was reproducible  
We demonstrated that a carriage rate of 50% was reproducible using a target dose of 8x104 
CFU/naris. By combining carriage rates from the Dose-Ranging study above 4x104 CFU with 
the carriage rate from the Reproducibility study, we achieved a mean carriage rate of 52% 
with a 95% confidence interval of 40-64%. Reproducibility was very important for the 
model to be successful as a mechanism for novel vaccine testing.  
One month after challenge in the Reproducibility study, 50% of carriage positive volunteers 
had cleared carriage. In those still carrying at day 28, carriage density was stable. This 
duration is slightly longer than the 27 day median carriage duration seen by Högberg et al. 
[8] in Swedish adults. However, because we gave antibiotics at day 28 to eliminate carriage, 
we don't know the true length of the experimental carriage episodes. It is possible the 
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duration is more comparable to the USA study which reported duration of experimental 
carriage was between 27 and 122 days [161]. 
8.2.1.2 Experimental carriage was not symptomatic 
Experimental carriage was not symptomatic. Regardless of whether volunteers passively 
reported symptoms to the clinical team or actively filled out a daily symptom log, there was 
no difference in the presence of nasal symptoms between carriers and non-carriers. There 
was also no difference in the percentage of volunteers that complained of symptoms 
following challenge with saline as compared to those challenged with pneumococci. 
Although we did not see a correlation between symptoms and experimental carriage in 
adults, a number of studies have shown that carriage is symptomatic in children. In Kenyan 
children, URT symptoms, cough or coryza have been shown to be significant risk factors for 
carriage of pneumococcus, with coryza also a risk factor for H. influenzae carriage 
[304,305]. However, as these were both cross-sectional studies it is not known whether 
colonization resulted in symptoms or the presence of virus resulted in colonization.  
Recently, the relationship between rhinorrhea, colonization, and viral infections were 
examined in children attending daycare [306]. Rhinitis symptoms were associated with H. 
influenzae presence and density but not with S. pneumoniae. Nonetheless there was a 
significant association between both viral presence and load and pneumococcal presence 
and density. The alterations in the nasopharynx during viral infection may increase the 
detection of pneumococci, as well as the density, leading to an increase in transmission and 
may explain why symptomatic children who are heavily colonized with pneumococci are 
such spreaders.  
8.2.1.3 Experimental carriage was protective against reacquisition of the same 
serotype 
We have shown that a single carriage episode was protective against subsequent carriage 
of the same serotype. Volunteers that were re-challenged with serotype 6B up to 48 weeks 
after an initial carriage episode with 6B were not colonized (0% carriage rate). In 
comparison, only 50% of volunteers were protected against challenge with serotype 6B 
following clearance of a natural carriage episode, the same rate as primary study 
volunteers. 
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We have since examined the immune response behind protection from reacquisition in 
healthy adults and found that experimental carriage increased both mucosal and systemic 
IgG levels to pneumococcal capsule and proteins [289]. These responses protected mice 
against invasive disease in a serotype-independent manner following passive transfer of 
sera from colonized individuals. However, two of the ten volunteers challenged with the 
homologous serotype 6B did not have increased levels of IgG, suggesting protection 
requires more than capsular and protein antibodies and lends support to a role for mucosal 
CD4+ T cells in protection against carriage, as has been shown in mouse models [156]. This 
is also consistent with a mathematical model proposed by Cobey and Lipsitch [309] in 
which anticapsular immunity acquired during colonization is weak and only confers 30 to 
60% reduction in susceptibility to future carriage of that type. 
The difference in carriage reacquisition after heterologous challenge, as compared to after 
homologous challenge, is likely a result of individual differences in immunity although we 
can’t exclude the effect of cross-protection between pneumococcal proteins. To further 
examine the differences related to reacquisition, the levels of IgG to polysaccharides and 
proteins prior to re-challenge in the four volunteers could be measured. It would also be 
informative to compare the levels between those that carried and those that didn’t, 
irrespective of serotype. As the number of natural carriers that were re-challenged was 
quite small, increasing the numbers would enhance these findings. 
8.2.1.3.1 Previous carriage was not associated with reduced density of subsequent 
carriage  
There was no difference in carriage density between a recent natural carriage episode and 
an experimental carriage episode. As not all serotypes alter future carriage acquisition or 
duration, it is likely that there are also differences between serotypes when it comes to 
carriage density. Therefore it is not entirely surprising that recent carriage did not impact 
secondary carriage density, especially since challenge was with a different serotype. We 
couldn’t examine if challenge with the homologous serotype would have the same result 
because it did not result in carriage however, this has been performed in a mouse model of 
colonization. Using the same strain for both primary challenge and subsequent re-
challenge, there was no difference in colonization density between two consecutive 
carriage episodes [140]. Combining our human results with the mouse data, we suggest 
that what determines carriage density is the result of a delicate balance within the 
microenvironment of the nasopharynx and may be impacted by the microbial flora. While 
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colonization establishment may be determined by the immune system, it is possible that 
carriage density is a function of nutrient availability and is not related to previous carriage.  
To further explore how density is altered by reacquisition, successive carriage episodes 
would need to be evaluated. This should include challenge with different serotypes and, if 
possible, the homologous serotype. As we were not able to establish carriage with the 
homologous type, this may be difficult but could be attempted using a different strain or by 
re-challenging more than a year after the first carriage episode. If density is influenced by 
the microbial flora, a better understanding of the nasopharyngeal microbiota, both before, 
during, and after carriage, may further inform on carriage density.  
8.2.2 Factors involved in establishment of experimental carriage  
8.2.2.1 Bacteriological differences between the 6B and 23F inoculum strains 
We investigated differences between the 6B and 23F serotypes used in the model in an 
effort to determine why 6B successfully established carriage and 23F did not (Table 8.1). 
Transparent colonies were the dominant phenotype in the 6B inoculum stock however, the 
opacity of the 23F inoculum could not be determined. The 23F strain was more susceptible 
to complement deposition than the 6B strain. When we compared the whole genome 
sequences of the 6B and 23F strains we found a mutation in the pcpA gene of 23F as well as 
a frameshift mutation in amiC. The 23F inoculum strain with the mutations was less likely 
to adhere to nasopharyngeal cells than both the 6B strain and a derivative 23F strain that 
had a full length amiC. In a mouse model of colonization, the 23F inoculum with the amiC 
mutation did not carry whereas the derivative isolate with a full length amiC did.  
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Table 8.1 Summary of investigated differences between the 6B and 23F inoculum strains 
  6B (BHN418) 23F (P833) 
Phase phenotype Transparent ++ indeterminate 
Opaque + indeterminate 
Complement deposition + ++ 
Genes involved in adherence 
and nutrient uptake 
PcpA  + - 
AmiC + - 
Adherence (D562 cells) ++ + 
Colonization in a mouse model + - 
Experimental colonization in humans +++ + 
+/- represents presence/absence, >1 + indicates a larger difference   
The first difference between the two inoculum serotypes listed in Table 8.1 is the 
phenotype. The 6B phase phenotype was largely transparent however, the phenotype of 
the 23F strain could not be characterized due to a high degree of autolysis. Transparent 
colonies have been shown to have higher rates of autolysis than opaque variants [45], 
which suggests that the 23F strain was also transparent. Since transparent variants are 
better at colonizing the mouse nasopharynx than opaque variants, it is unlikely that 
phenotype is the reason for the different carriage rates of the 6B and 23F strains. However, 
excluding phenotype does not exclude the capsule itself. It is possible that the amount of 
capsule may be a contributing factor to the different colonization rates. Capsule size should 
be determined for both serotypes.  
The second major difference between the two strains was complement deposition, with 
more complement deposited on 23F than on 6B. An experimental chinchilla model of acute 
otitis media was used to compare high- and low-level C3-binding of 6A isolates. Isolates 
with low-level C3-binding were significantly more likely to cause experimental otitis media 
than high-level C3-binding isolates [322]. However, when the animals were challenged 
intranasally with either isolate, there was no difference in the density of colonization 
between the groups suggesting that nasopharyngeal colonization is independent of C3 
surface binding in chinchillas. If colonization in humans is also independent of complement 
deposition, this would suggest that the increased complement deposition on 23F was not 
the reason for the different colonization rates.  
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The third major difference between the 6B and 23F inoculum strains were the mutations in 
the amiC and pcpA genes of 23F. It is likely that these mutations led to the differences in 
adherence and in colonization, both in the mouse and human models. In order to better 
understand the role of pcpA and amiC in human carriage and to determine which gene was 
responsible for the reduced carriage of serotype 23F, both mutations need to be repaired 
to wild-type in the 23F inoculum strain. In parallel, knockout mutants of both genes should 
be created in the 6B inoculum strain. These strains should then be tested in both a mouse 
and human model of colonization.  
These experiments will address if either gene was the cause of the reduced 23F carriage 
rate however, they will not determine if the role of amiC in colonization is related to its 
involvement in nutrient transport or adherence. Pneumococci have complex growth 
requirements and are auxotrophic for a number of amino acids [325]. Acquisition of the 
necessary amino acids commonly occurs through oligopeptide uptake and can be mediated 
through the permease Ami [326]. The mutation in amiC could be limiting the 23F strain’s 
access to nutrients or causing an inability to compete with the commensal flora for 
nutrients, resulting in a low colonization rate. We hypothesize that the ability of the mutant 
to establish colonization may relate to the diversity of the nasopharyngeal microbiome. If 
the nasopharyngeal flora was able to alter the metabolic composition in the nasopharynx, 
the necessity for oligopeptide transport via the Ami-AliA/AliB permease may have been 
diminished and the strain’s ability to colonize restored. Early analysis of the pre-inoculation 
microbiome of two 23F carriage positive volunteers found an abundance of Prevotella 
species was positively associated with carriage establishment (Amelieke Cremers, 
unpublished data).  
In line with this finding, Hathaway et al. [327] recently showed that the AliB-like ORF 2 of 
non-encapsulated S. pneumoniae binds a peptide found in Prevotella species. It is 
suggested that this interaction then mediates early colonization. If this role in colonization 
could be extended to encapsulated pneumococci, it could explain the association between 
23F carriage establishment and increased presence of Prevotella species however, no 
definitive conclusions can be drawn due to the small number of carriage positive samples in 
this study. To determine if an amiC mutant could survive in the nasopharynx as a result of 
specific species in the microbiome, namely Prevotella, nasal wash fluid could be used as a 
medium to grow amiC wild-type and mutant strains. If growth of the mutant strains is 
inhibited as compared to the wild-type strains, different concentrations of Prevotella 
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species could be added to the nasal wash media to determine if there is a concentration at 
which growth of the amiC mutant is restored.   
8.2.2.2 Asymptomatic URT virus was associated with increased likelihood of 
colonization  
We have shown that the presence of virus in the nasopharynx was associated with a three 
times increase in the odds of becoming colonized and an increase in mucosal levels of FH. 
However, levels of the antimicrobial factor SLPI, antimicrobial beta defensin 2, and 
lactoferrin were not altered following challenge. Using a GEE model, we found an 
interaction between virus presence, susceptibility to colonization, increased colonization 
density and increased FH levels. This is the first time that asymptomatic URT viral infection 
has been directly associated with increased pneumococcal colonization and increased 
mucosal FH levels in healthy adults. Using an in vitro epithelial model, epithelial 
inflammation and FH binding resulted in increased pneumococcal adherence to the 
epithelium. Binding was partially blocked by antibodies targeting the FH-binding protein 
PspC. PspC epitope mapping revealed individuals lacked antibodies against the FH binding 
region. 
The lack of antibodies generated against the FH binding region suggests that a mutation in 
the FH binding site would result in antibody generation which may block the PspC-FH 
interaction. Pneumococcal strains with mutations in the FH binding site could be used to 
challenge healthy adult volunteers and the serum from colonized volunteers could be 
analysed for the presence of antibodies against the FH binding region.  
The immunological mechanisms behind carriage are wide and varied. Although we did not 
see a role for the innate factors SLPI, β-defensin 2, and lactoferrin in carriage establishment 
or clearance, Neill et al. [363] have shown that levels of transforming growth factor (TGF)-
β1 and interleukin (IL)-10 are higher in volunteers that establish pneumococcal carriage 
following challenge, than in those who don’t. The role of cytokines in carriage 
establishment/clearance requires further investigation.  
8.2.3 Density and duration of experimental carriage 
We compared culture and qPCR in the detection of pneumococci and found that the 
proportion of samples positive for carriage by qPCR was significantly more than the 
proportion of samples positive for carriage by culture. Across all visits, the number of 
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volunteers positive for carriage by qPCR was more than those positive for carriage by 
culture, but this was only significant at 2 days post-challenge.  
We have shown that quantification of pneumococci by culture and qPCR was positively 
correlated. At a qPCR density greater than 103 copies/ml, 94.8% of samples were both 
culture and qPCR positive. Below the qPCR limit of detection, 7.7% of samples were still 
positive by culture.  
We also used culture and qPCR to compare experimental and natural carriage and found 
that fluctuations in density during a carriage episode were similar for both experimentally 
and naturally colonized volunteers. The two methods were complementary when 
determining the length of a carriage episode. However, because we only followed 
volunteers for one month, we don’t know the true length of an experimental carriage 
episode using this model. Duration could easily be determined by following carriage 
positive volunteers until they naturally cleared carriage, instead of having them take 
antibiotics after 28 days.   
As discussed in Chapter 1 section 1.6.1.2, a recent study by Trzciński et al. [248] suggested 
that the trans-oral swab may be better than the nasopharyngeal swab in detecting carriage 
in adults. We have taken trans-oral swabs alongside nasal washes as part of a recent study 
and will compare the detection of pneumococci using both conventional and molecular 
methods. Although pneumococcal quantification by culture and qPCR was positively 
correlated, there was a difference between the two methods at detecting low density 
carriage (Table 6.2). Including an enrichment step might decrease the number of culture 
negative, qPCR positive samples however, this would have to be performed after the initial 
quantification by culture and qPCR.   
8.3 Implications  
Although this experimental carriage model has been very successful in adults, it would be 
unsuitable for use in children because of the higher incidence of disease. It is also unknown 
if showing a decrease in carriage in adults after vaccination would be predictive of a similar 
decrease in children, the elderly, or the immunocompromised. Because the immune 
system and nasopharyngeal flora of every person differs, a level of variability is introduced 
into the model which requires careful consideration when screening volunteers and 
determining sample sizes.  
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8.3.1 Implications for testing novel vaccines and vaccine 
development  
Current pneumococcal conjugate vaccines have greatly decreased the incidence of IPD, 
more through herd protection than through a direct effect on immunized individuals. But 
this decrease has led to an increase in non-vaccine serotypes. Further serotype 
replacement, as well as high production cost and a lack of serotype diversity, makes global 
implementation of conjugate vaccines difficult. New vaccines are urgently needed to 
overcome the problems with conjugate vaccines. The safe and reproducible experimental 
carriage model presented here could be used to down-select candidate pneumococcal 
vaccines with carriage prevention as a surrogate of vaccine-induced immunity.  
For the first time, we have shown that asymptomatic URT viral infection is directly 
associated with increased pneumococcal colonization and increased mucosal FH levels in 
healthy adults. We suggest that FH binding to PspC in vivo masks the FH binding region, 
enabling FH to facilitate pneumococcal attachment to the epithelium during viral infection 
despite the presence of anti-PspC antibodies. A PspC vaccine that blocks the PspC-FH 
interaction with specific PspC antibodies at the mucosa could reduce pneumococcal 
colonization and may have enhanced protection in those with underlying viral infection. 
8.3.2 Implications for detection of pneumococcal carriage 
The suggestion that colonization is a good endpoint in vaccine trials is based on the idea 
that it is relatively easy to measure and is more common than disease, therefore requiring 
a much smaller sample size [282,284,333]. However, if the endpoint is a reduction in 
carriage density or duration, sensitive methods to accurately detect these changes will be 
important in estimating vaccine effects. We demonstrated that culture and qPCR were 
complementary in the detection of carriage density and duration. This will be important 
when novel vaccines are tested using experimental carriage and detection of carriage 
density or duration is crucial to the success of the trial.  
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8.4 Future work 
8.4.1 Novel vaccine testing  
We have developed a safe and reproducible model of experimental human pneumococcal 
carriage that could be used as a vaccine development tool. The first planned test of the 
model is a double-blind, randomized, controlled trial testing the protective effect of the 
current conjugate vaccine PCV13 (Prevenar) against colonization in healthy adult 
volunteers. Following that trial, we plan to test novel vaccine candidates for protection 
against acquisition of pneumococcus in healthy adults.  
8.4.2 Pneumococcal biology 
We have shown the experimental carriage model works well with a serotype 6B strain. To 
increase the scope of the model, a dose-response curve for a number of serotypes should 
be completed. Serotypes that cause carriage and are clinically relevant, as well as serotypes 
that have variable capsular expression should be included. We have shown that carriage 
differences might not be due to serotype alone so sequence type and genetic background 
should also be considered when choosing which serotypes to test.  
The role of specific genes and virulence factors in human carriage can be examined by 
challenging with auxotrophic mutants. There is a precedent for using genetically modified 
bacteria in human challenge studies; the role of the staphylococcal cell-wall protein 
clumping factor B in colonization was investigated by intra-nasally challenging human 
volunteers with a wild-type S. aureus strain and a single-locus knockout mutant [276].  
The idea of a microbiological bottleneck - in which disease is a monoclonal event [319] - is 
critical in pneumococcal transmission and, hence, vaccine escape. To try and answer this, 
healthy adults could be challenged with a mixed strain inoculum, containing similar and 
diverse strains, using sequencing to determine strain recovery. Mixed inoculation could 
also be used to investigate intraspecies competition, comparing different capsular and 
protein expressing strains.  
8.4.3 Host susceptibility to experimental carriage 
We have demonstrated successful experimental carriage in healthy adult volunteers 
however, healthy adults do not have high rates of carriage or disease and are not the target 
population of current vaccination strategies. The elderly, in comparison, have low carriage 
rates but high disease incidence. To better understand changes in susceptibility to carriage 
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associated with increasing age, an elderly cohort should be challenged with pneumococcus 
and the immunological response induced by carriage should be analysed.  
Because carriage rates and disease incidence also vary by geographic area, it is important 
to test the model in different locations, such as Africa. In these studies, the environment 
(such as exposure to smoke during cooking) and co-morbidities (such as HIV status) may 
alter the outcome of the model and need to be taken into consideration.  
Developing a successful experimental carriage model in these groups will allow novel 
vaccine candidates to be tested in some of the most-at-risk populations.    
8.5 Conclusion 
We have presented here a model of experimental human pneumococcal carriage that is 
safe and reproducible. In trying to determine what predicts experimental carriage, we have 
shown that mucosal innate factors are likely not involved, however the presence of virus 
increases the risk of becoming colonized. The model presented here could be used to test 
novel vaccines with experimental carriage as an endpoint, and to continue investigating the 
host and bacterial factors involved in establishing experimental human pneumococcal 
carriage.    
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Appendices 
 
Appendix A: Recipe for STGG medium 
Tryptone soya broth (Oxoid CM0129)   6 g 
Skim milk powder (Oxoid L31)    4 g 
Glucose      1 g 
Glycerol (Sigma G5516)     20 ml 
Distilled water      200 ml 
 
Mix together the tryptone soya broth, skim milk powder, glucose, and distilled water. 
Slowly add the glycerol. Autoclave at 15 lb/in2 and 121°C for 15 minutes. Store bottle at 
4°C. Before removing any media, vortex the bottle to resuspend the pellet that develops 
during storage.  
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Appendix B: Patient information sheet 
 
Experimental Human Pneumococcal Carriage  
Investigator  Designation  Contact telephone  
Professor Stephen Gordon  Principle Investigator  0151 705 3169  
Dr Andrea Collins  Research Registrar  0151 705 3712  
Angela Wright  Research Nurse  0151 706 4856  
David Shaw  Research Nurse  0151 706 4856  
Carole Hancock  Research Nurse  0151 706 3381  
 
Patient information sheet   
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully. Talk to others about the study if you wish.  
  
Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information. Take time 
to decide whether or not you wish to take part.  
PART 1  WHAT IS THE PURPOSE OF THE STUDY?  
We are interested in developing new and better ways to protect the body against a bug, or 
bacterium, called Streptococcus pneumoniae (also known as pneumococcus). In most 
people pneumococcus can occasionally be found harmlessly inhabiting the nose where it 
does not cause any problem (pneumococcal carriage). About 10% of adults carry 
pneumococcus at any one time, and almost all adults experience an episode of carriage at 
least once per year. Carriage acts as a natural vaccine, boosting immunity against 
pneumococcal infection in adults and children.  Disease in young adults is rare - less than 
10 cases per 100 000 people per year. When pneumococcus does cause problems, usually 
in young children or elderly people, it can be very serious as it is the bacterium responsible 
for diseases such as pneumonia, sepsis and meningitis, which kill millions of children 
around the world each year. There is already a vaccine against pneumococcus which helps 
prevent sepsis and meningitis but it is less effective against pneumonia than we would like.   
In order to develop an effective vaccine against pneumonia, we need to understand how 
pneumococcal carriage acts to boost immunity.  We need to demonstrate that we can 
reproduce carriage in healthy volunteers and then prevent it with new vaccines. Our aim in 
this study is to inoculate people with varied doses of pneumococcal bacteria to determine 
the optimum dose for carriage (dose-ranging study) and then reproduce these findings in 
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sufficient participants to be sure that we have a reproducible method (reproducibility 
study).   
  
What is involved?  
We will inoculate small doses of bacteria into the nostrils of volunteers known to have no 
current natural pneumococcal carriage. We will then collect samples from these people, 
some of whom will establish carriage for a period (days to weeks), in order to answer 
questions about immune defence and then use the information in our work to develop a 
better vaccine to protect against pneumonia.  We will offer antibiotics to clear carriage to 
all volunteers.  The samples we collect will include upper airway (nasal wash, throat swab 
and saliva), lower airway (bronchoscopy and lavage) and systemic (blood, urine) samples 
relevant to defence against infection. The number of samples that you will have depends 
on which part of the study you are in and is explained below –   
  
Study  Blood 
samples  
Urine 
samples   
Nasal wash 
samples  
Saliva 
samples  
Throat 
swabs  
Bronchoscopy  
Dose ranging  3  3  4  2  2  optional  
Reproducibility  7  7  7  2  2  optional  
Re-challenge  2  0  4  0  0  optional  
Enriched sampling (in 
addition to those above)  
5  0  0  0  0  optional  
 
Who may take part?  
You will be able to join the study if you are fit and healthy and not a current regular 
smoker.  
Who may NOT take part?  
 People who have/are:  
Current regular smokers (smoke on a daily basis)  
Significant smoking history defined as someone who has previously smoked more than 
20 cigarettes per day for 10 years (or the equivalent)  
Asthma/respiratory disease  
Pregnant  
Already involved in another clinical trial  
Allergic to penicillin/amoxicillin  
On medication that may affect the immune system in any way e.g steroids, steroid 
nasal spray Regular contact with ‘at-risk’ individuals – this means children, 
immunosuppressed adults, elderly or those with chronic ill health  
Do I have to take part?  
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No, you do not have to take part. It is entirely up to you to decide whether or not to take 
part in this study. If you do, you will be given this information sheet to keep and be asked 
to sign a consent form. You are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not affect 
the standard of care you receive at this hospital. You will be able to choose if samples and 
information collected up to that point may be used or should be destroyed.  
PART 2  WHAT DO I HAVE TO DO?   
Clinic  
After reading through the information if you decide you would like to take part we will 
arrange to see you in a clinic to discuss the trial further. During that appointment we will 
ask some routine questions about your medical health and we will want to listen to your 
heart and lungs. If you decide that you wish to take part we will ask you to sign a consent 
form. We will then ask your permission to take a wash from your nose, a sample of your 
saliva, throat swab, urine and a blood test. This will all be done to make sure you are fit to 
take part in the study, and to see if you are one of the 10% of people who already carry 
pneumococcus in their nose.   
Measurements of immune response in the nose   
The nasal wash is similar to a process used in yoga for nasal hygiene. Salty water is gently 
instilled in to the nose (sucked by breathing in yoga) and retained for a few seconds before 
being allowed to run out. As with a mouth wash, this process washes out some secretions 
and cells from the nose that can be used to measure immune responses. Inevitably, this 
process feels like having water up your nose, but warm saline is less likely to cause sneeze 
or irritation than cold water, and the process is safe.  
Nasal carriage of pneumococcus  
What we are now interested in is whether there is a change in your body's immune system 
when you have pneumococcus in your nose. We will invite you to the clinic where we will 
put a small amount of liquid in your nose that contains live pneumococcus in order to 
mimic natural pneumococcal carriage. We do not expect that this will cause you any 
symptoms as previous similar studies have not had any problems. As a precaution, 
however, we will provide you with an information sheet about warning symptoms or signs 
and there will be a doctor or nurse available by telephone day 24 hours a day in case you 
have any concerns. We will also provide you with a course of antibiotics to keep with you, 
in case you feel unwell. We will see you after the inoculation to repeat the nasal wash and 
see if pneumococcus is still present in your nose. Each day, we will ask you to contact the 
research team by phone or text to ensure that all is well.  
We will then follow you up once a week for a period (up to 4 weeks in the rechallenge and 
dose-ranging study; up to 8 weeks in the reproducibility study) for sample collection (nasal 
wash/saliva/throat swab/urine/blood) to monitor the presence or absence of 
pneumococci in your nose. If you are a carrier, we will ask you to take a 3 day course of 
antibiotics to be sure that the pneumococcus has been cleared at the end. One final visit 
will be arranged in the dose ranging and reproducibility study between 10 and 20 weeks 
after the start of the study.  
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In volunteers that successfully carry the bacteria, we will offer the chance to repeat this 
inoculation with the same strain or a different strain 2-18 months following carriage (this is 
called re-challenge). If you wish to participate in the re-challenge, you will be asked to 
complete a further consent form, your participation is optional.  
Volunteers that naturally carry the bacteria at their initial sampling, will be invited to 
return 2-18 months after for inoculation with 6B or 23F strain of pneumococcus, assuming 
they are no longer naturally carrying the bacteria. If you wish to participate, you will be 
asked to complete a further consent form, your participation is optional. The sampling is 
the same as for the re-challenge (see above table), lasting 14 days in total post inoculation.   
  
As part of the study, you will have the option of participating in extra 
sampling. This includes extra blood samples throughout the study and/or 
bronchoscopy at the end of the study.  
What does enriched sampling involve?  
Extra blood samples will be taken on five extra occasions during the study; this will involve 
extra visits to the hospital. This extra time and inconvenience is accounted for in the 
remuneration. 
What is a bronchoscopy and lavage?  
A bronchoscopy means a camera test to look inside the lungs and a lavage is washing of a 
small segment of the right lung.   The test is carried out as a day procedure in the hospital; 
to prepare for the test you must not eat or drink for 4 hours before arrival. In order 
to make the camera test comfortable and controlled, we first put local anaesthetic (both 
jelly and spray) inside your nose and mouth to numb the lining. We will also offer you 
some sedation to make you more relaxed if you would like. We do not do the test under a 
general anaesthetic. During the test we provide supplementary oxygen to all people, along 
with oxygen, pulse and blood pressure monitoring to ensure that you are safe.  
We pass the bronchoscope (a flexible tube of the same diameter as a ball-point pen) either 
through the nose or mouth to the back of the throat. Using a channel in the bronchoscope, 
we then put local anaesthetic on the voice box (this will make you splutter) and in the main 
airways. As a result of this anaesthetic, you will not feel the bronchoscope inside your 
lungs at all. When the bronchoscope is in the correct position, we wash a sub-segment of 
the right lung. We use 200mls of saline which is about the same as a cup of tea. The warm 
saline is introduced and withdrawn using gentle hand suction and as with the nasal wash, 
we collect some lung secretions and cells (bronchoalveolar lavage or BAL) in order to test 
immune function. It generally takes about 15-20 minutes to prepare a volunteer for 
bronchoscopy, including giving the anaesthetic and sedation, and 7 minutes to complete 
the bronchoscopy and lavage.  
After bronchoscopy, because you will have had medication to numb your throat and 
maybe even sedation, we will observe you for at least 2 hours. After this time, the 
medication will have worn off and you will be allowed to eat and drink again as normal 
before going home. Later in the evening after bronchoscopy, some people get a pain (mild 
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pleurisy) under their right arm which can last for the first 12-24hours. This is caused by 
inflammation in the area that lies above the part of the right lung where the lavage was 
done and is best alleviated using paracetamol.  
What laboratory investigations will be done on samples collected?  
All of your samples (blood, nasal wash, urine, saliva, throat swab and BAL) will be used to 
determine the organisms (bacteria and viruses) present and the immune responses that 
defend the body, particularly the lung, against infection. The tests on the samples will be 
done in the Liverpool School of Tropical Medicine and in collaborating laboratories 
including those at the Royal Liverpool University Hospital. All of your identifiable 
information will be removed from the samples; they will be given a unique number that 
does not reveal your identity.  
How much will I get paid?  
We do not want anybody to be persuaded to take part because of the money we offer. The 
money is to remunerate volunteers for the time, inconvenience, loss of income, risks and 
possible discomfort that taking part may cause.  
Activity  Approximate Time  Payment  
Screening appointments   (clinical exam, 
blood tests, nasal wash, throat swab and 
saliva sample)  
30min  £30 per visit  
  
Inoculation with pneumococcus (includes 
email/telephone contact and completion 
of daily symptom log)  
30 minutes  £50  
  
Weekly follow up visit (Review by 
researcher, blood, urine and nasal wash) 
15 minutes  £20 per visit  
      
Enriched sampling limb: blood sample  10 minutes  £10 per visit  
Bronchoscopy and BAL (including follow up 
visit)  
4 hours  £100  
 
What if I change my mind?  
You will be asked to sign a consent form at the beginning of the study, and a further form 
before bronchoscopy. You have the right to change your mind, or withdraw your consent, 
at any time during the study. This will have no effect on your future care within the NHS. 
Please note that should you decide to withdraw from the study, you will be paid for the 
amount completed up to that point.  
What are the benefits of taking part?  
It is unlikely that there will be any direct benefit to you as a result of taking part except 
that the nasal swabs may identify unexpected bacteria which could be treated. If this 
occurs, you will be referred for the appropriate treatment in either the Infectious Disease 
or Respiratory service in the Royal Liverpool University Hospital. In all cases, you will be a 
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valuable part of a research study that we hope will eventually lead to the development of a 
new vaccine against pneumonia.  
What are the risks?  
The risks that you should consider before participation in this study are:  
(i) Risks associated with nasal washing or bronchoscopy (ii) Risks associated with 
inoculation with live bacteria.  
  Risks associated with nasal washing  
Nasal washing carries minimal risk and is a part of common yoga as described above. The 
British Lung Foundation (BLF) describes bronchoscopy as a safe procedure which carries 
little risk (BLF patient information sheet available on request). Most people do not suffer 
any ill effects but of those that do, the common side effects are a sore throat and 
hoarseness for a few hours, or perhaps nasal discomfort and a minor nose bleed after the 
test. This is the reason we keep an eye on you in the hospital for a few hours after the test 
to make sure you are not experiencing any of these problems. It is possible that you will 
experience a drop in blood oxygen or breathlessness during the procedure and if these 
occur, we will stop immediately. As mentioned above, some people experience mild 
pleurisy (pain with fever) for some hours during the night following the procedure. This is 
best controlled by paracetamol.  
  Risks associated with inoculation with live bacteria  
Experimental studies of this type have never yet resulted in infection but the bacteria are 
live and so infection either of you or your close contacts is possible. We do however all 
commonly naturally carry this bacterium in our nose from time-to-time, especially as 
children. We do not expect that carrying the bacteria in your nose will cause any illness in 
you or your contacts but this is one of the reasons we want to make sure you are healthy 
(with a good immune system) before taking part and we will not recruit people in close 
contact with young children or vulnerable adults. The pneumococcus is a bacterium that 
can cause serious diseases such as pneumonia, sepsis and meningitis. It is therefore 
important that you are aware of this risk and clearly understand the safety information 
that you are given. In the event, should you feel unwell, you will have an emergency 
information leaflet to advise you on what to do and the precise symptoms to be concerned 
about including fever, drowsiness and ear-ache. You can speak to a doctor involved in the 
project at any time by telephone. You will also be given a course of antibiotics (that you 
will have at home and carry with you at all times) to take in the event that you develop any 
symptoms (as per emergency information leaflet) that may be related to the 
pneumococcal bacteria. If you carry the bacteria in your nose then at the end of 4 weeks, 
we will give you antibiotics to be absolutely sure that there are no bacteria left.  
What if there is a problem?  
You will have the contact numbers and email addresses for the Research Registrar and 
Nurse who will be available for contact to answer any questions. They will also be available 
24 hours a day in the unlikely event of an emergency. Any medical care needed will be 
provided in the Royal Liverpool University Hospital and this could include any test or 
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treatment needed up to and including hospital admission with CT scan, chest X-ray, lumbar 
puncture and intravenous antibiotics. Further, the study is sponsored (insured) by the 
Royal Liverpool University Hospital and the Liverpool School of Tropical Medicine. 
Compensation for any injury caused by taking part in this study will be in accordance with 
the guidelines of the Association of the British Pharmaceutical Industry (ABPI). Broadly 
speaking the ABPI guidelines recommend that 'the sponsor', without legal commitment, 
should compensate you without you having to prove that it is at fault. This applies in cases 
where it is likely that such injury results from giving any new drug or any other procedure 
carried out in accordance with the protocol for the study. 'The sponsor' will not 
compensate you where such injury results from any procedure carried out which is not in 
accordance with the protocol for the study. Your right at law to claim compensation for 
injury where you can prove negligence is not affected. Copies of these guidelines are 
available on request.  
 
Will my details be kept confidential?  
Yes. We need to collect information about your medical history and any relevant family 
history to make sure you are fit to take part in the study. We will also collect clinical data 
relating to the results of blood tests, swabs and bronchoscopies. It is important that the 
research doctors in charge of the study continue to have access to your personal 
information so you can be followed up properly, or contacted during/after the trial. One 
reason that we might need to contact you is if we find an important immune problem 
whilst testing your samples; this would mean that the Doctors would decode your specific 
volunteer identification number in order to contact you to inform you of the issue/defect. 
This ability to access personal information will be limited to Dr Stephen Gordon, Dr Andrea 
Collins and Sr Angela Wright. We will ask your permission to inform your GP that you are 
taking part in the trial as this may be relevant to your medical care outside the trial. Any 
information of value to your care will be conveyed to you and to your GP. All information 
we collect will be kept secure and confidential. Your research notes will be kept separate 
from your NHS notes. All data will be collected and stored within the Royal Liverpool 
University Hospital and the Liverpool School of Tropical Medicine. It will be stored for a 
period of 4 years after publication or longer if required by a publishing journal. No 
publication or presentation regarding this study will contain information that can be 
identified as from any particular volunteer.  
In the laboratory, all information that identifies you will be removed and replaced with a 
code so that laboratory staff will not know the individual identity of samples collected.  
 
What if I wish to complain about the way in which this study has been 
conducted?  
If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you and are not compromised in any way because 
you have taken part in a research study.  If you have any complaints or concerns please 
contact your study doctor (see below details).  
 
Further questions?  
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If you have any further questions about this trial please contact Prof Stephen Gordon 
(Principal Investigator) on 0151 705 3169, Dr Andrea Collins (Study Dr) on 0151 705 3712 
or Sr Angela Wright on 0151 706 4856 adwright@liverpool.ac.uk (Research Nurse) during 
normal working hours.   
In the event of an emergency please contact Professor Gordon via the Royal Liverpool 
University Hospital Switchboard (0151 706 2000).  
  
You will be given a copy of this information sheet and of your signed consent form to keep.  
  
Thank you.  
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Appendix C: Consent form 
 
 
 Appendices 
193 
 
 
Appendix D: Dose-Ranging study schedule with additional bloods 
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Appendix E: Reproducibility study schedule with additional bloods 
 
 
 
 
  
 
